SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,1,DB00006,__BIVALIRUDIN,5196404,Recruiting,NCT04046029,ACUTE CORONARY SYNDROME|PERCUTANEOUS CORONARY INTERVENTION|AGING|ANTICOAGULANTS AND BLEEDING DISORDERS,All,75 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The First Affiliated Hospital of Dalian Medical University, Dalian, China",C07K14/815,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.5591901271073,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.76,2180.2853,901.57,37.0,28.0,6.0,215.46,543.33,66.0,1.0,0.0,0.0,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,1,DB00006,__BIVALIRUDIN,5196404,Completed,NCT00759083,HEPARIN-INDUCED THROMBOCYTOPENIA|HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Duke Clinical Research Institute, Durham, North Carolina, United States",C07K14/815,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,32.5591901271073,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.76,2180.2853,901.57,37.0,28.0,6.0,215.46,543.33,66.0,1.0,0.0,0.0,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,LEIOMYOMAS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Not Yet Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Not yet recruiting,NCT04420585,"NOCTURNAL ENURESIS|ANEMIA, SICKLE CELL",All,"8 Years to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital at Montefiore, Bronx, New York, United States",C07K7/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Unknown status,NCT03343418,C.SURGICAL PROCEDURE; CARDIAC|BLOOD COAGULATION DISORDERS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Incor - Heart Institute - University of Sao Paulo, Sao Paulo, Brazil",C07K7/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,NCT01994330,ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO SEVERE AORTIC STENOSIS|HEYE´S SYNDROME|SEVERE AORTIC STENOSIS,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Clínico Universidad Católica de Chile, Santiago, Region Metropolitana, Chile",C07K7/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,,RENAL FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,,HEMOPHILIA A,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,LEIOMYOMAS,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00067,__VASOPRESSIN,9375478,Completed,,RENAL FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Recruiting,NCT02745717,SEVERE APLASTIC ANEMIA,All,"up to 60 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Not yet recruiting,NCT04470804,"PURE RED CELL APLASIA, ACQUIRED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, China",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00488436,MYELODYSPLASTIC SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Cabueñes, Asturias, Spain|Hospital germans Trias i Pujol, Badalona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Ntra Sra del Rossell, Cartagena, Spain|Hospital Materno Infantil de Las Palmas, Las Palmas de Gran Canaria, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital de Navarra, Pamplona, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital Clinico Universitario, Zaragoza, Spain",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00106,__ABARELIX,5843901,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.8242674387564,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,1416.09,424.98,16.0,13.0,6.0,149.31,373.91,38.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Active Not Recruiting,,CARDIOPULMONARY BYPASS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
N[C@@H](Cc1c[nH]cn1)C(=O)O,1,DB00117,__HISTIDINE,3943038,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N1/38,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,155.1546,92.0,4.0,3.0,1.0,14.67,38.06,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC(=O)C(=O)O,1,DB00119,__PYRUVIC_ACID,,Completed,,SICKLE CELL DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
N[C@@H](Cc1ccccc1)C(=O)O,1,DB00120,__PHENYLALANINE,3930948,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,19521.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,165.1891,63.32,3.0,2.0,1.0,17.03,45.12,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,1,DB00121,__BIOTIN,3946115,Unknown Status,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/158,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,244.31099999999998,78.43,3.0,3.0,2.0,24.92,60.05,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Recruiting,NCT03188445,IRON DEFICIENCY ANEMIA OF PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Copenhagen, Copenhagen, Sjaeland, Denmark",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Recruiting,NCT02225886,ANAEMIA RESPONSE TO THE TREATMENT|PERIPHERAL IRON INDICES|OXALEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","""Nefrolab"" Dialysis Center, Slatina, Romania",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT01768351,ANEMIA|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
NCC(=O)O,1,DB00145,__GLYCINE,,Completed,NCT02590224,IRON DEFICIENCY ANEMIA,Female,20 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Assiut university, Assiut, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,75.0666,63.32,3.0,2.0,0.0,6.65,16.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC(=O)O,1,DB00145,__GLYCINE,,Completed,NCT01913808,"POSTOPERATIVE ANEMIA|OSTEOARTHRITIS, KNEE",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital de la Esperanza (Parc de Salut MAR), Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,75.0666,63.32,3.0,2.0,0.0,6.65,16.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,"Active, not recruiting",NCT03621553,SARCOIDOSIS|VITAMIN D INSUFFICIENCY,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Withdrawn,NCT03073369,CKD|CHRONIC KIDNEY DISEASES|HEPCIDIN|ERGOCALCIFEROL|VITAMIN D|IRON-DEFICIENCY|ANEMIA,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Completed,NCT00680732,MALARIA|MALARIA IN PREGNANCY,Female,"15 Years to 44 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Centre Muraz, Bobo-Dioulasso, Burkina Faso",A61K9/1694,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Completed,NCT02675140,ANEMIA|WORM INFECTIONS,All,3 Years to 6 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,"Active, not recruiting",NCT03903133,SICKLE CELL DISEASE,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1ncc(CO)c(CO)c1O,1,DB00165,__PYRIDOXINE,6340695,Unknown status,NCT03372447,MEGALOBLASTIC ANEMIA NOS|PERNICIOUS ANEMIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr. Jose E Gonzalez UANL, Monterrey, Nuevo Leon, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,7.063800078030338,2814.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,169.1778,73.58,4.0,3.0,1.0,17.11,44.11,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT02214563,"KIDNEY FAILURE, CHRONIC|ANEMIA|VITAMIN D DEFICIENCY|BONE DISEASES, METABOLIC",All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan|Higashikouri hospital, Hirakata, Osaka, Japan|Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine, Suita, Osaka, Japan|Akebono clinic, Kumamoto, Japan|Obi clinic, Osaka, Japan|Nishi clinic, Osaka, Japan|Futaba clinic, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Terminated,NCT01817699,"KIDNEY TRANSPLANTATION|ANEMIA|VITAMIN D DEFICIENCY|RENAL INSUFFICIENCY, CHRONIC",All,"20 Years to 79 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CANDLE Trial Study Group, Suita, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00162955,NON-HODGKIN'S LYMPHOMA,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Graduate School of Medicine, Osaka City University, Osaka, Japan",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Suspended,NCT00701207,PULMONARY SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Unknown status,NCT02559154,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai General Hospital, Shanghai, China",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Recruiting,NCT03844360,HEMATOLOGICAL NEOPLASMS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China",C07K5/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Recruiting,NCT04348006,NEWLY DIAGNOSED MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baghdad Hematology center - Baghdad Medical City, Baghdad, Bab-Almuadham, Iraq",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Unknown status,NCT02844322,WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(C)(N)Cc1ccccc1,1,DB00191,__PHENTERMINE,6071537,Completed,,"OBESITY, CHILDHOOD",,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,35.4504199264872,1351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.32,149.2328,26.02,1.0,1.0,1.0,17.87,48.34,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Recruiting,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(O)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,1,DB00200,__HYDROXOCOBALAMIN,5834448,Unknown status,NCT03372447,MEGALOBLASTIC ANEMIA NOS|PERNICIOUS ANEMIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr. Jose E Gonzalez UANL, Monterrey, Nuevo Leon, Mexico",A61K9/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,23.8526458448838,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-14.0,1346.3551,437.23,14.0,10.0,12.0,135.56,340.03,16.0,1.0,0.0,0.0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Recruiting,NCT03402191,THALASSEMIA,All,"6 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Tanta, Egypt",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Unknown status,NCT00168948,MALARIA|ANEMIA,All,2 Months to 4 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,,6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Unknown status,NCT01469702,CAT-SCRATCH DISEASE|BARTONELLA INFECTIONS,All,"14 Years to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Infectious Disease Unit, Tel Aviv Medical Center, Tel Aviv, Israel",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Recruiting,NCT04319705,"ASTHMA|COPD|EXACERBATION COPD|ASTHMA; EOSINOPHILIC|BRONCHIAL DISEASES|LUNG DISEASES, OBSTRUCTIVE|LUNG DISEASES|IMMUNE SYSTEM DISEASES",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,1,DB00224,__INDINAVIR,5413999,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,24.049775149387003,1144.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.26,613.7895,118.03,7.0,4.0,5.0,68.63,175.89,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT01061697,CERVICAL SPONDYLOSIS|CERVICAL SPONDYLOTIC MYELOPATHY|CERVICAL SPONDYLOTIC RADICULOPATHY,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Outram Road, Singapore",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT02005653,FILARIAL; INFESTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vector Control Research Centre, Pondicherry, India",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00989742,LYMPHANGIOLEIOMYOMATOSIS|TUBEROUS SCLEROSIS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Nottingham University Hospitals, Nottingham, United Kingdom",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,1,DB00261,__ANAGRELIDE,4208521,Completed,NCT00202644,"THROMBOCYTHEMIA, HEMORRHAGIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven, Pleven, Bulgaria|University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology, Sofia, Bulgaria|University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic, Varna, Bulgaria|CHU Angers Services des Maladies du Sang, Angers, Cedex 09, France|Hopital Saint Louis - Centre d'Investigation Clinique, Paris, France|University of Debrecen Medical and Health Science Centre, Debrecen, Hungary|Petz Aladar County Teaching Hospital, Gyor, Hungary|Pandy Kalman Hospital of Bekes County, Gyula, Hungary|Kaposi Mor Teaching Hospital, Kaposvar, Hungary|Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin, Poland|Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej, Warsaw, Poland|Klinika Hematologii Instytut Hematologii i Transfuzjologi, Warsaw, Poland|Hospitals da Universidade de Coimbra, Coimbra, Portugal|Institute for Haematology of Clinical Centre of Serbia, Belgrade, Serbia",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,22.5713053656132,493.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,256.08799999999997,44.7,3.0,1.0,3.0,23.61,63.25,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Completed,,RESTLESS LEG SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,RESTLESS LEG SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,1,DB00278,__ARGATROBAN,5214052,Withdrawn,NCT00603824,HEPARIN-INDUCED THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.390439228731502,7.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.04,508.64,177.71,9.0,6.0,3.0,53.77,143.83,8.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,1,1,0
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,1,DB00278,__ARGATROBAN,5214052,Terminated,NCT00787332,SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Colorado Health Science Center, Aurora, Colorado, United States|Washington Regional Cardiac Surgery, Washington, DC, District of Columbia, United States|Florida Hospital Cardiovascular Research, Orlando, Florida, United States|University of South Florida, Tampa General Hospital, Tampa, Florida, United States|Emory University, Emory Crawford Long Hospital, Atlanta, Georgia, United States|Kaiser Permanente Medical Center, Honolulu, Hawaii, United States|Provena St. Joseph's Medical Center, Joliet, Illinois, United States|Mercy Medical Center, Sioux City, Iowa, United States|Maine Medical Center, Portland, Maine, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|St Mary's Hospital Rochester, Mayo Clinic, Rochester, Minnesota, United States|UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Montefiore Medical Center, Moses Division, Bronx, New York, United States|North Shore University Hospital, Manhasset, New York, United States|St Vincent's Hosptial -Manhattan, Manhattan, New York, United States|Mount Sinai Clinical & Translational Research Institute, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Forsyth Regional Medical Center, Winston-Salem, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Cardiothoracic Vascular Surgial Specialists, Columbus, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Methodist Hospital, Houston, Texas, United States|University of Utah Hospital, Salt Lake City, Utah, United States|Charleston Area Medical Center, Charleston, West Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,14.390439228731502,7.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.04,508.64,177.71,9.0,6.0,3.0,53.77,143.83,8.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,1,1,0
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,1,DB00278,__ARGATROBAN,5214052,Completed,NCT00039858,THROMBOCYTOPENIA|THROMBOSIS,All,up to 16 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mattel Children's Hospital at UCLA, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Children's Hospital, Chicago, Illinois, United States|Children's Hospital of Illinois, Peoria, Illinois, United States|Kosair Children's Hospital, University of Louisville, Louisville, Kentucky, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Michigan Congenital Heart Center, Ann Arbor, Michigan, United States|Rainbow Babies at Children's Hospital, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,14.390439228731502,7.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.04,508.64,177.71,9.0,6.0,3.0,53.77,143.83,8.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,1,1,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03630198,KELOID|ALOPECIA AREATA|ACNE|HYPERTROPHIC SCAR|EPIDERMAL INCLUSION CYST|FRONTAL FIBROSING ALOPECIA|LICHEN PLANO-PILARIS|KERATOACANTHOMA|PLAQUE PSORIASIS|LICHEN SIMPLEX CHRONICUS|PRURIGO NODULARIS|NUMMULAR ECZEMA|GRANULOMA ANNULARE|MORPHEA|LICHEN PLANUS,All,"12 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT04003012,LEUKEMIA-LYMPHOMA,All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"CAMC - Women and Children's Hospital, Charleston, West Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,1,DB00289,__ATOMOXETINE,5658590,Terminated,NCT00299234,ATTENTION DEFICIT HYPERACTIVITY DISORDER,All,"6 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Monarch Medical Research - Child and Adolescent Neurology, Norfolk, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,31.2449947637528,104.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.95,255.3547,21.26,2.0,1.0,2.0,29.79,79.44,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,1,DB00291,__CHLORAMBUCIL,4147767,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",A61K9/1658,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,18.070186246124106,5183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.81,304.212,40.54,3.0,1.0,1.0,31.98,79.68,9.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,1,DB00294,__ETONOGESTREL,5150718,"Active, not recruiting",NCT02594462,SICKLE CELL DISEASE,Female,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bahiana School of Medicne and Public Health, Salvador, Bahia, Brazil|University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,7.490913571120548,417.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,324.4565,37.3,2.0,1.0,4.0,37.77,96.35,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02222246,SICKLE CELL DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mount Sinai Hospital, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT03682211,PAIN|SICKLE CELL DISEASE,All,"1 Year to 21 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT00904709,MENORRHAGIA,Female,"15 Years to 50 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Unknown status,NCT03211286,HIP FRACTURES|ANEMIA,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Elda University Hospital, Elda, Alicante, Spain|Hospital Universitario de Elda, Elda, Alicante, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Unknown status,NCT03037515,"BLOOD LOSS, SURGICAL|BLOOD LOSS ANEMIA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT01067638,CORONARY ARTERY OCCLUSIVE DISEASE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,"Yonsei Univ., Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,1,DB00307,__BEXAROTENE,5780676,Completed,NCT01007448,REFRACTORY CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Florida Academic Dermatology Centers, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Tulane, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota Medical School, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University Health, Winston-Salem, North Carolina, United States|University Hospitals-Case Medical Center, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute At the University of Utah, Salt Lake City, Utah, United States",C07C65/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,37.22458366701571,808.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.86,348.4779,37.3,2.0,1.0,3.0,40.89,117.12,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00309,__VINDESINE,,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00309,__VINDESINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CCCC(CCC)C(=O)O,1,DB00313,__VALPROIC_ACID,6419953,Terminated,NCT00854581,LYMPHOMA|PRECANCEROUS/NONMALIGNANT CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT03541980,SICKLE CELL ANEMIA CRISIS,All,4 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Newark Beth Israel, Newark, New York, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Withdrawn,NCT00513864,SICKLE CELL DISEASE,All,"7 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Children's National Medical Center, Washington, District of Columbia, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Recruiting,NCT04233996,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Unknown status,NCT02463747,FEVER|FEBRILE NEUTROPENIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,NCT02222246,SICKLE CELL DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mount Sinai Hospital, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT02984475,BETA THALASSEMIA MAJOR ANEMIA,All,"11 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abo El Reesh Hospital, Cairo., Egypt|El Demerdash (Ain Shams Teaching Hospital)., Cairo., Egypt",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Withdrawn,NCT00475527,"ANEMIA, IRON-DEFICIENCY|HELICOBACTER PYLORI",All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Organization, Jerusalem, Israel",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT01822600,PEPTIC ULCER BLEEDING|HYPOALBUMINEMIA,All,"39 Years to 83 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cheng Kung University Hospital, Tainan, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Unknown status,NCT01795794,CDA TYPE I,All,"12 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
Nc1ccc(C(=O)NCC(=O)O)cc1,1,DB00345,__AMINOHIPPURIC_ACID,4292154,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N27/44747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,194.1873,92.42,4.0,3.0,1.0,19.13,50.82,3.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,1,DB00377,__PALONOSETRON,5202333,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00029224,BREAST CANCER|MULTIPLE MYELOMA|PROSTATE CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stockton Hematology Oncology Medical Group, Stockton, California, United States|Osceola Cancer Center, Kissimmee, Florida, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Hematology-Oncology Associates PC, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Hematology Oncology Associates, PC, Medforo, Oregon, United States|Virginia Physicians, Inc, Richmond, Virginia, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00334139,PROSTATE CANCER|BREAST CANCER|BONE METASTASIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Ulm, Germany",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00346242,THALASSEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,"Novartis Investigative Site, Athens, Greece",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Not yet recruiting,NCT02480634,NON-SMALL CELL LUNG CANCER|BONE METASTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT02286830,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Odense University Hospital, Odense C, Denmark",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01129336,FIRST OR SECOND LINE HER2-NEGATIVE BREAST CANCER|METASTATIC DISEASE WITHOUT BONE METASTASIS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|Kaiser Permanente Medical Group Kaiser Permanente - Hawaii, Anaheim, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States|Hematology and Medical Oncology, Waterbury, Connecticut, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|Lakeland Regional Cancer Center Dept. of Lakeland Regional, Lakeland, Florida, United States|Space Coast Medical Associates, Titusville, Florida, United States|Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Oncology Specialists, SC Lutheran General Cancer Instit, Park Ridge, Illinois, United States|Cancer Center of Kansas, Witchita, Kansas, United States|Park Nicollet Institute Dept. of Park Nicollet, St. Louis Park, Minnesota, United States|St. John's Mercy Medical Center St. John's Mercy Med Ctr, St. Louis, Missouri, United States|Hematology Oncology Centers of the Northern Rockies Hema Onc Ctr N. Rockies (4, Billings, Montana, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States|Reno Oncology Consultants, Reno, Nevada, United States|Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2), Winston-Salem, North Carolina, United States|Hematology Oncology Center, Inc., Elyria, Ohio, United States|Milton S Hershey Medical Center Hershey Medical Center (4), Hershey, Pennsylvania, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|East Texas Medical Center Cancer Institute Tyler Hem/Onc (3), Tyler, Texas, United States|Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA, Reston, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00434447,BONE NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Redcliffe, Queensland, Australia|Novartis Investigative Site, Townsville, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00241111,PROSTATE CANCER WITH BONE METASTASIS,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00237159,PROSTATE CANCER PATIENTS WITH BONE METASTASIS,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,RESTLESS LEG SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Completed,NCT00552799,CELLULITIS/ERYSIPELAS OF THE LEG,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","South Infirmary-Victoria University Hospital, Cork, Ireland|Queens Medical Centre, Nottingham, Nottinghamshire, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Amersham Hospital, Amersham, United Kingdom|Brighton General Hospital, Brighton, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Cumberland Infirmary, Carlisle, United Kingdom|Derbyshire Royal Infirmary, Derby, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Gloucestershire Royal Infirmary, Gloucester, United Kingdom|James Paget University Hospital, Great Yarmouth, United Kingdom|Princess Royal Hospital, Hull, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Queen Elizabeth Hospital, King's Lynn, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Broadgreen Hospital, Liverpool, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Hope Hospital, Salford, United Kingdom|King's Mill Hospital, Sutton in Ashfield, United Kingdom|Singleton Hospital, Swansea, United Kingdom|Watford General Hospital, Watford, United Kingdom|York Hospital, York, United Kingdom",C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,1,DB00419,__MIGLUSTAT,5472969,Recruiting,NCT03910621,"NIEMANN-PICK DISEASE, TYPE C",All,"4 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University first Hospital, Beijing, China|Xin Hua Hospital, Shanghai Jiao Tong University, Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,13.766196431138198,165.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.1,219.278,84.16,5.0,4.0,1.0,23.99,55.74,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",A61L15/585,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,NCT00576472,ACUTE LYMPHOBLASTIC LEUKEMIA|BRAIN TUMORS,All,"6 Years to 18 Years   (Child, Adult)",Other|NIH,"Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Duke University Medical Center, Durham, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States",A61L15/585,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O,1,DB00438,__CEFTAZIDIME,7112592,Completed,NCT04187755,"NEUTROPENIA, FEBRILE|LEUKEMIA|PEDIATRIC CANCER|ANTIBIOTIC REACTION",All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",C07D487/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,62.0957309184993,211.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,546.576,191.22,10.0,3.0,4.0,51.06,143.88,9.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Unknown status,NCT01501136,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Recruiting,NCT04040491,PERIPHERAL T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,Unknown status,NCT01765231,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Cancer Hospital & Institute, Beijing, Beijing, China|307 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|309 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|Aerospace Central Hospital, Beijing, Beijing, China|Air Force General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|First Hospital affiliated to General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|General Hospital of Chinese People's Liberation Army, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China",C07D239/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,Completed,NCT00926757,NON HODGKIN'S LYMPHOMA|HEPATITIS B,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei, Taiwan",C07D239/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00444,__TENIPOSIDE,4766149,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,2806.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,656.654,160.83,12.0,3.0,8.0,64.83,155.61,6.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,1,DB00445,__EPIRUBICIN,4950738,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",A61K41/0042,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Terminated,NCT00115336,"HEMATOLOGIC DISEASES|ANEMIA, SICKLE CELL",All,"6 Years to 18 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Not yet recruiting,NCT03805607,CESAREAN SECTION COMPLICATIONS|POSTOPERATIVE PAIN|COAGULATION DEFECT; POSTPARTUM|NONSTEROIDALS (NSAIDS)TOXICITY|POSTPARTUM HEMORRHAGE,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",,A61K9/0048,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,1,DB00468,__QUININE,3960559,Completed,NCT02092766,ANAEMIA,All,6 Months to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the",H01L23/291,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,1,DB00468,__QUININE,3960559,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",H01L23/291,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Completed,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT04038411,NK/T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,,NEWLY DIAGNOSED MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT04040491,PERIPHERAL T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",C07D411/04,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Terminated,NCT00854581,LYMPHOMA|PRECANCEROUS/NONMALIGNANT CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Completed,NCT00454272,INFECTION|FEBRILE NEUTROPENIA,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi aventis administrative office, Istanbul, Turkey",A61K9/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Unknown status,NCT02463747,FEVER|FEBRILE NEUTROPENIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Withdrawn,NCT00513864,SICKLE CELL DISEASE,All,"7 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Children's National Medical Center, Washington, District of Columbia, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Completed,NCT02005653,FILARIAL; INFESTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vector Control Research Centre, Pondicherry, India",C07D235/32,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Completed,NCT03036059,LYMPHATIC FILARIASIS|HELMINTH INFECTION,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Noguchi Memorial Institute for Medical Research, Legon-Accra, Ghana",C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Not yet recruiting,NCT04391998,ANEMIA OF PREGNANCY,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kasr Alainy medical school, Cairo, Egypt",C07D235/32,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Unknown status,NCT01459146,MALARIA|SCHISTOSOMIASIS|HELMINTHIASIS|ANEMIA|CHANGE IN SUSTAINED ATTENTION,All,6 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NHRC, Navrongo, Ghana",C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,1,DB00520,__CASPOFUNGIN,5378804,Terminated,NCT02895529,HEMATOLOGIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijign, China|Beijing, China|Changchun, China|Changzhou, China|Fuzhou, China|Guangzhou, China|Guiyang, China|Hefei, China|Shanghai, China|Suzhou, China|Tianjin, China|Zhengzhou, China",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,21.618513727181202,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,1093.3131,412.03,18.0,16.0,4.0,117.52,278.78,23.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0
O=C(O)P(=O)(O)O,1,DB00529,__FOSCARNET,,Recruiting,NCT03004261,CYTOMEGALOVIRUS INFECTIONS|HEMATOLOGICAL DISEASE,All,"14 Years to 60 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Jiao Tong University Affilated Shanghai General Hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,126.0053,94.83,5.0,3.0,0.0,7.89,19.07,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00526305,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Ntra. Sra. Sonsoles, Avila, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital vall d'Hebrón, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Hospital de Cruces, Bilbao, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Morales Meseguer, Murcia, Spain|Hospital General Universitario Morales Meseguer., Murcia, Spain|Hospital Santa María del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|H. Carlos Haya, Málaga, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital de Sagunto, Sagunto, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H.U. Virgen del Rocio, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital dr. Peset, Valencia, Spain|Hospital General Universitario, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT01995331,APLASTIC ANEMIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pediatrics,Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT01649635,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 007, Centro, Brazil|Investigational Site Number 004, Curitiba, Brazil|Investigational Site Number 006, Lajeado, Brazil|Investigational Site Number 005, Porto Alegre, Brazil|Investigational Site Number 001, Santo Andre, Brazil|Investigational Site Number 002, São Paulo, Brazil",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Unknown status,NCT02967341,CHILDHOOD CANCER|NEUTROPENIA,All,1 Month to 17 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitair Ziekenhuis Brussel, Brussels, Belgium",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT02816112,EARLY STAGE BREAST CANCER,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT02173262,BREAST CANCER,Female,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"The Ottawa Hospital, Ottawa, Ontario, Canada",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,,PERIPHERAL T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1,1,DB00545,__PYRIDOSTIGMINE,3931205,Recruiting,,MYASTHENIA GRAVIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
O=C(O)CCCCCCCC(=O)O,1,DB00548,__AZELAIC_ACID,6534070,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,30.8507361547465,3639.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.37,188.2209,74.6,4.0,2.0,0.0,20.5,46.54,8.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,1,DB00552,__PENTOSTATIN,4151347,Unknown Status,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/052,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.831906199305902,1542.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,268.2691,112.13,7.0,4.0,3.0,26.34,64.98,2.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
COc1c2occc2cc2ccc(=O)oc12,1,DB00553,__METHOXSALEN,4129575,Completed,NCT00221039,CUTANEOUS T CELL LYMPHOMA|MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush-Presbyterian Hospital, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospital of Cleveland/Case Western Reserve University, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.000657097681604,590.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,216.192,48.67,2.0,0.0,3.0,20.98,56.85,1.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1c2occc2cc2ccc(=O)oc12,1,DB00553,__METHOXSALEN,4129575,Terminated,,CUTANEOUS T-CELL LYMPHOMA (MYCOSIS FUNGOIDES),,,,,"FISABIO, Elche, Alicante, Spain",C07D493/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.000657097681604,590.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,216.192,48.67,2.0,0.0,3.0,20.98,56.85,1.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Terminated,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00029523,MENINGEAL NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barrow Neurological Institute, Phoenix, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of Southern California, Norris Cancer Center, Los Angeles, California, United States|University of Colorado Hospital, Anschutz Cancer Pavilion, Denver, Colorado, United States|Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory Clinic, Department of Neurosurgery, Atlanta, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Rush Cancer Institute, Chicago, Illinois, United States|Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center Dept. of Neurology, Boston, Massachusetts, United States|Park Nicollet Institute, Oncology Research Program, Minneapolis, Minnesota, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University Hospital of Cleveland, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Utah, Hunsman Cancer Institute, Salt lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02323659,"LYMPHOMA, T-CELL, CUTANEOUS|MYCOSIS FUNGOIDES",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz, Poland",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00153530,CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charite Campus Benjamin Franklin, Berlin, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Terminated,NCT00918554,SARCOID-ASSOCIATED UVEITIS|OCULAR SARCOIDOSIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hôpital Avicenne - Service de Médecine Interne, Bobigny, France|CHU Michallon de Grenoble, Grenoble, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,1,DB00569,__FONDAPARINUX,,Withdrawn,NCT00603824,HEPARIN-INDUCED THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,1508.263,805.48,44.0,19.0,5.0,122.56,255.85,27.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,1,DB00569,__FONDAPARINUX,,"Active, not recruiting",NCT01727401,MEDICAL PATIENT|THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Marcello Di Nisio, Chieti, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,1508.263,805.48,44.0,19.0,5.0,122.56,255.85,27.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00570,__VINBLASTINE,3932417,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,15409.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,810.9741,154.1,9.0,3.0,9.0,87.46,222.42,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,NCT03036059,LYMPHATIC FILARIASIS|HELMINTH INFECTION,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Noguchi Memorial Institute for Medical Research, Legon-Accra, Ghana",A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,NCT01593722,LOIASIS,All,20 Years to 60 Years   (Adult),NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Filariasis and other Tropical Diseases Research Center, Yaounde, Cameroon",A01N53/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,NCT03852303,EPILEPSY,All,"5 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,NCT03052998,IVERMECTIN|ONCHOCERCIASIS|EPILEPSY,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,,LYMPHATIC FILARIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A01N53/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Not Yet Recruiting,,LYMPHATIC FILARIASES,,,,,"FISABIO, Elche, Alicante, Spain",A01N53/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,,ABNORMAL UTERINE BLEEDING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Terminated,NCT00964691,MALARIA|MALARIA IN PREGNANCY,Female,"15 Years to 49 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Honiara City Council, Honiara, Solomon Islands",2,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT02389374,MALARIA,All,"12 Months and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Recruiting,NCT02876549,VIVAX MALARIA,All,"6 Months and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dr. Ghulam Rahim Awab MD, Jalalabad, Nangarha, Afghanistan",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Terminated,NCT03337152,"MALARIA, VIVAX|G6PD DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,NCT01651416,MALARIA|ANAEMIA,All,3 Months to 59 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ejisu-Juaben Municipality, Kumasi, Ashanti, Ghana",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,1,DB00614,__FURAZOLIDONE,3980434,Completed,,FUNCTIONAL DYSPEPSIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,13.5362122425511,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.15,225.1583,98.18,5.0,0.0,2.0,19.78,50.08,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,1,DB00618,__DEMECLOCYCLINE,3966922,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,NCT00845221,CHRONIC MYELOID LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"CHU Amiens, Amiens, France|Hôpital La Timone - CHU de Marseille, Marseille, France|Hôpital de Brabois - CHU de Nancy, Vendoeuvre les Nancy, France",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,NCT00171899,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Toronto, Canada",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Recruiting,NCT03844360,HEMATOLOGICAL NEOPLASMS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Recruiting,NCT02602314,CHRONYC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi G. Salesi, Ancona, Italy|Az.Ospedaliera S.G.Moscati, Avellino, Italy|UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy|Ematologia Torre 6 piano 4 - ASST Papa Giovanni XXIII, Bergamo, Italy|Istituto di Ematologia ""Lorenzo e A. Seragnoli"" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy|USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia, Brescia, Italy|ASL N.8 -Ospedale A. Businco, Cagliari, Italy|Università di Catania - Cattedra di Ematologia - Ospedale ""Ferrarotto"", Catania, Italy|U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile, Civitanova Marche, Italy|Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi, Cona, Italy|S.C. Ematologia ASO S. Croce e Carle, Cuneo, Italy|Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano, Firenze, Italy|IRCCS_AOU San Martino-IST.Clinica Ematologica, Genova, Italy|ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy|Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina, Messina, Italy|Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti ""Papardo Piemonte"", Messina, Italy|U.O. di Ematologia- Ospedale dell'Angelo - Mestre, Mestre, Italy|UO Ematologia - AOU Policlinico di Modena, Modena, Italy|Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Universitaria - Università degli Studi di Napoli ""Federico II"" - Facoltà di Medicina e Chirurgia, Napoli, Italy|Ospedale San Gennaro - ASL Napoli 1, Napoli, Italy|S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy|U.O. CTMO Ematologia - Osp. S. Francesco, Nuoro, Italy|Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2, Orbassano, Italy|Ospedali Riuniti ""Villa Sofia-Cervello"", Palermo, Italy|U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico ""Paolo Giaccone"", Palermo, Italy|Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore, Pesaro, Italy|Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto, Piacenza, Italy|Az.Ospedaliera S.G.Moscati, Potenza, Italy|Dipartimento Oncologico - Ospedale S.Maria delle Croci, Ravenna, Italy|Dipartimento Emato-Oncologia A.O.""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Az. Ospedaliera ""Sant' Andrea""-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia, Roma, Italy|Divisione Ematologia - Università Campus Bio-Medico, Roma, Italy|Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy|UOC Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma ""Sapienza"", Roma, Italy|U.O.C. Ematologia - Ospedale S. Eugenio, Rome, Italy|Unità Operativa di Oncologia Giovanni Paolo II ""Vito Fazzi"", Rossano, Italy|Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Ematologia - Dipartimento di Medicina Clinica e Sperimentale, Sassari, Italy|A.O. Santa Maria - Terni S.C Oncoematologia, Terni, Italy|Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine, Udine, Italy|Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, Verona, Italy|ULSS N.6 Osp. S. Bortolo, Vicenza, Italy",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Recruiting,NCT01491763,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,All,"up to 55 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|H. Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Canarias, Tenerife, Canarias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital General de Albacete, Albacete, Spain|Hospital de Alcorcón, Alcorcón, Spain|Hospital General de Alicante., Alicante, Spain|Hospital de Cabueñes, Asturias, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clinic y Provincial de Barcelona, Barcelona, Spain|Hospital Clínico y Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau., Barcelona, Spain|Hospital de la Santa Creu i Sant Pau., Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital de la santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Reina Sofía, Córdoba, Spain|Area Hospitalaria Juan Ramón Jimenez, Huelva, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital del SAS de Jerez de la Frontera, Jerez de la Frontera, Spain|Hospital general de Jerez de la Frontera, Jerez de la Frontera, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica La Concepción, Madrid, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre. Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital de Madrid, S.A.- Norte Hospital General, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Princcipe de Asturias, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Univeristario Morales Messeguer, Murcia, Spain|Hospital Sta. Maria del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital de Mérida, Mérida, Spain|Hospital del Río Carrión, Palencia, Spain|Hospital de Gran Canaria Doctor Negrín, Palma De Gran Canaria, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital de Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital de Donostia, San Sebastián, Spain|Hoaspital Marqués de Valdecilla, Santander, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain|Hospital Joan XIII de, Tarragona, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Clínico de Valencia., Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Xeral-Cies, Vigo, Spain|Hospital do Meixoeiro, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Unknown Status,,"LYMPHOMA, T-CELL, CUTANEOUS",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03829371,MULTIPLE MYELOMA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, TO, Italy",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04276233,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01356511,"PURPURA, THROMBOCYTOPENIC, IDIOPATHIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Shandong University, Jinan, Shandong, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01649635,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 007, Centro, Brazil|Investigational Site Number 004, Curitiba, Brazil|Investigational Site Number 006, Lajeado, Brazil|Investigational Site Number 005, Porto Alegre, Brazil|Investigational Site Number 001, Santo Andre, Brazil|Investigational Site Number 002, São Paulo, Brazil",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02703194,IMMUNOGLOBULIN G4 RELATED SCLEROSING DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese PLA General Hospital, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT01524536,EOSINOPHILIA|HYPEREOSINOPHILIC SYNDROME|LEUKOCYTE DISORDER|HEMATOLOGIC DISEASES,All,"7 Years to 100 Years   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03598725,HEMOPHILIA A WITH INHIBITOR,Male,1 Year to 14 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Children's Hospital, Beijing, Beijing, China",5,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT01210677,CARDIAC SARCOIDOSIS|SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,1,DB00650,__LEUCOVORIN,4148999,"Active, not recruiting",NCT01271582,STAGE IV COLORECTAL CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Hwasun Hospital, Chŏnam, Hwasun-gun, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Nowon-Gu, Korea, Republic of|Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Terminated,NCT01625455,SEZARY SYNDROME|PRURITUS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Terminated,NCT00386997,FUNGAL INFECTION,All,"55 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Gilead Sciences GmbH, Martinsried/Munich, Germany",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Terminated,NCT00190463,MALIGNANT HEMOPATHY|DURATION OF NEUTROPENIA FOLLOWING CHEMOTHERAPY > 10 DAYS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chu Henri Mondor, Paris, Ile de France, France",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Terminated,NCT00421187,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gilead Sciences, Athens, Greece",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Completed,,INVASIVE ASPERGILLOSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,NCT00964353,BLOOD COAGULATION DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Chicago, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Terminated,NCT00800137,HEMATOMA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Instituto de Cardiologia - Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil|University of Calgary, Calgary, Alberta, Canada|Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Winnipeg Health Sciences Centre, Winnipeg, Manitoba, Canada|St. John Regional Hospital, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Science Center, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|St. Mary's General Hospital, Kitchener, Ontario, Canada|London Health Sciences Center, London, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Rouge Valley Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Mike's Hospital, Toronto, Ontario, Canada|Cité-de-la-Santé Hospital, Laval, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Centre Hospitalier de L'Université de Montréal, Montréal, Quebec, Canada|Hôpital Sacré-Coeur de Montréal, Montréal, Quebec, Canada|Hôpital Laval, Québec, Quebec, Canada|Sherbrooke University Hospital Centre CHUS, Sherbrooke, Quebec, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Recruiting,NCT02238444,CIRRHOSIS|HYPERTENSION|VENOUS THROMBOSIS|STATUS; SPLENECTOMY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Active Not Recruiting,,ANTIPHOSPHOLIPID SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,NCT00257790,NEUTROPENIA|FEVER|CANCER,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Active Not Recruiting,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1278,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",C07D411/04,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
CCN(CC)C(=O)N1CCN(C)CC1,1,DB00711,__DIETHYLCARBAMAZINE,3956330,Completed,NCT02005653,FILARIAL; INFESTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vector Control Research Centre, Pondicherry, India",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,15.901763896589198,132.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.9,199.2932,26.79,2.0,0.0,1.0,22.89,58.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCN(CC)C(=O)N1CCN(C)CC1,1,DB00711,__DIETHYLCARBAMAZINE,3956330,Completed,NCT01593722,LOIASIS,All,20 Years to 60 Years   (Adult),NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Filariasis and other Tropical Diseases Research Center, Yaounde, Cameroon",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.901763896589198,132.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.9,199.2932,26.79,2.0,0.0,1.0,22.89,58.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,1,DB00746,__DEFEROXAMINE,3957435,Completed,NCT00733811,BETA-THALASSEMIA|THALASSEMIA MAJOR,All,"13 Years to 60 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ao V. Cervello, Palermo, Italy",G01N33/556,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,17.183104375859802,794.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,560.684,205.84,9.0,6.0,0.0,62.42,144.95,23.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,1,DB00746,__DEFEROXAMINE,3957435,Recruiting,NCT02041299,IRON OVERLOAD|SICKLE CELL DISEASE|OTHER ANEMIAS,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Oakland, Oakland, California, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Children's Hospital, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|The Children's Hospital of Philadephia, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Centro Infantil Boldrini, Campinas, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto Estadual de Hematologia, Rio de Janeiro, Brazil|Casa de Saúde Santa Marcelina, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil|Hospital for Sick Kids, Toronto, Ontario, Canada|Alexandria University, Alexandria, Egypt|Pediatric Department and Clinical Research Center, Faculty of Medicine, Alexandria, Egypt|Zagazig University, Alexandria, Egypt|Ains Shams University, Cairo, Egypt|Cairo University, Cairo, Egypt|Pediatric Hospital of Cairo University, Cairo, Egypt|Mansoura University Children's Hospital, Mansoura, Egypt|Tanta University Hospital, Tanta, Egypt|Hamad Medical Corporation National Center for Cancer Care and Research, Doha, Qatar|Asser Central Hospital, Abha, Saudi Arabia|King Abdulaziz University Hospital, Jeddah, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia|National Center for Bone Marrow Transplantation, Tunis, Bad Saadoun, Tunisia|Farhat Hached Hospital, Hematology Department, Sousse, Tunisia|Principal Military Hospital of Instruction of Tunis, Tunis, Tunisia|Cukurova University, Adana, Turkey|Hacettepe University, Ankara, Turkey|Istanbul University, Istanbul, Turkey|Barts and The London, London, United Kingdom|Evelina Children's Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|St. Mary's Hospital and Hammersmith Hospital, London, United Kingdom",G01N33/556,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,17.183104375859802,794.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,560.684,205.84,9.0,6.0,0.0,62.42,144.95,23.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,1,DB00746,__DEFEROXAMINE,3957435,Completed,NCT00800761,IRON OVERLOAD|CARDIOMYOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Adult Talassemic Center, Ospedale Microcitemico, Cagliari, Sardinia, Italy",G01N33/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,17.183104375859802,794.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,560.684,205.84,9.0,6.0,0.0,62.42,144.95,23.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,1,DB00746,__DEFEROXAMINE,3957435,Completed,NCT00749515,TRANSFUSION-DEPENDENT HEMACHROMATOSIS|THALASSEMIA MAJOR|SICKLE CELL DISEASE,All,"Child, Adult, Older Adult",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Boston, Boston, Massachusetts, United States",G01N33/556,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,17.183104375859802,794.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,560.684,205.84,9.0,6.0,0.0,62.42,144.95,23.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,1,DB00755,__TRETINOIN,5955109,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61Q19/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,75.1391198997925,9501.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.66,300.442,37.3,2.0,1.0,1.0,36.85,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Recruiting,NCT04088513,G6PD DEFICIENCY|STROKE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Jieyang Municipal People's Hospital, Jieyang, Guangdong, China|Meizhou City People's Hospital, Meizhou, Guangdong, China|Yue Bei People's Hospital, Shaoguan, Guangdong, China|Yunfu People's Hospital, Yunfu, Guangdong, China|The Forth Affiliated Hospital of Guangxi Medical Hospital, Liuzhou, Guangxi, China|The First Affiliated Hospital of Guangxi Medical Hospital, Nanning, Guangxi, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China|Ganzhou Municipal Hospital, Ganzhou, Jiangxi, China|The Forth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,FUNCTIONAL DYSPEPSIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Recruiting,NCT04233996,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,NCT02149329,FEBRILE NEUTROPENIA|HEMATOLOGICAL MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU university medical center, Amsterdam, Netherlands|HAGA ziekenhuis, The Hague, Netherlands",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Unknown status,NCT02463747,FEVER|FEBRILE NEUTROPENIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,1,DB00762,__IRINOTECAN,6403569,"Active, not recruiting",NCT01271582,STAGE IV COLORECTAL CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Hwasun Hospital, Chŏnam, Hwasun-gun, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Nowon-Gu, Korea, Republic of|Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT04038411,NK/T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT03707847,ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT04490590,NK/T-CELL LYMPHOMA,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Completed,,ACUTE LYMPHOBKASTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown Status,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00500578,HEMATOLOGICAL MALIGNANCY,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Unknown status,NCT00887081,HEMOGLOBINOPATHIES,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"AOVCervello, Palermo, Italy",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00475072,"HEPATITIS C, CHRONIC",Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mexico City, Mexico",7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00056862,HEPATITIS C INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00028093,CHRONIC HEPATITIS C,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Terminated,NCT02717949,LIVER DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00560274,ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Angers, France|Besancon, France|Caen, France|Chambray Les Tours, France|Clichy, France|Creteil, France|Creteil, France|Limoges, France|Lyon, France|Marseille, France|Marseille, France|Montpellier, France|Nice, France|Paris, France|Paris, France|Pessac, France|Rennes, France|Rouen, France|Saint Laurent Du Var, France|Strasbourg, France|Toulouse, France|Tourcoing, France|Vandoeuvre-les-nancy, France|Villejuif, France",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT03682211,PAIN|SICKLE CELL DISEASE,All,"1 Year to 21 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01482091,"ANEMIA, SICKLE CELL|PAIN",All,"3 Years to 21 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital at Montefiore, Bronx, New York, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02246023,LUNG CANCER|SARCOIDOSIS|INTERSTITIAL PNEUMONIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University Hospital Zurich, Zurich, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT00424970,HIGH ALTITUDE POLYCYTHEMIA,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Cayetano Heredia, Lima, Peru",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,1,DB00836,__LOPERAMIDE,6103260,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",8,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,36.9617445943448,375.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,477.038,43.78,3.0,1.0,4.0,52.67,139.32,7.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,1
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Suspended,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00632554,EOSINOPHILIC PNEUMONIA|CHRONIC DISEASE,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Not yet recruiting,NCT04276233,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00526409,ACUTE LYMPHOBLASTIC LEUKEMIA,All,up to 16 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital materno Infantil vall d'Hebrón, Barcelona, Spain|Hospital Niño Jesús, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Infantil Carlos Haya, Málaga, Spain",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT03265405,SARCOIDOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Postgraduate Institute of Medical Education and Research, Chandigarh, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,ADVANCED FOLLICULAR LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT04056962,"TACROLIMUS, KAPOSIFORM HEMANGIOENDOTHELIOMA, TUFTED ANGIOMA",All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital of Sichuan University, Chengdu, Sichuan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Unknown status,NCT03540472,PURE RED CELL APLASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT03918265,AUTOIMMUNE HEMOLYTIC ANEMIA|PURE RED CELL APLASIA|EVANS SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Not yet recruiting,NCT04470804,"PURE RED CELL APLASIA, ACQUIRED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Recruiting,NCT04077515,HEMANGIOMA|KAPOSIFORM HEMANGIOENDOTHELIOMA,All,up to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Recruiting,NCT04448873,KAPOSIFORM HEMANGIOENDOTHELIOMA|KASABACH-MERRITT SYNDROME,All,up to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,"Active, not recruiting",NCT03688191,CONNECTIVE TISSUE DISEASES|THROMBOCYTOPENIA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT03364764,PURE RED CELL APLASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Not yet recruiting,NCT03866681,PAROXYSMAL NOCTURNAL HEMOGLOBINURIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking union medical college hospital, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,1,DB00889,__GRANISETRON,5952340,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,39.7215548573892,477.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.64,312.4170000000001,50.16,3.0,1.0,4.0,35.57,101.83,2.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1,1,DB00900,__DIDANOSINE,5880106,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.183104375859802,2081.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.99,236.2273,88.74,6.0,2.0,3.0,22.9,58.59,2.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Recruiting,NCT02876211,ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Son Espases University Hospital, Palma de Mallorca, Islas Baleares, Spain",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01768351,ANEMIA|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federico II University, Naples, Italy",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,,RENAL FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C401/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Not yet recruiting,NCT04391998,ANEMIA OF PREGNANCY,Female,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kasr Alainy medical school, Cairo, Egypt",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Withdrawn,NCT00475527,"ANEMIA, IRON-DEFICIENCY|HELICOBACTER PYLORI",All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Organization, Jerusalem, Israel",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0078,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Unknown Status,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,1,DB00928,__AZACITIDINE,4058602,Terminated,NCT01011283,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States|Stanford University Cancer Center, Stanford, California, United States|Stockton Hematology Oncology, Stockton, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Gulf Coast Oncology, St. Petersburg, Florida, United States|University of Chicago, Chicago, Illinois, United States|Siouxland Haeatology - Oncology Associates, Sioux City, Iowa, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Sletten Cancer Institute, Great Falls, Montana, United States|Cornell Medical Center, New York, New York, United States|Carolinas Medical Center NorthEast NorthEast Oncology Associates, Concord, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology and Hematology Care, Cincinnati, Ohio, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Gunderson Clinic Ltd., La Crosse, Wisconsin, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,1,DB00928,__AZACITIDINE,4058602,Recruiting,,ACUTE MYELOID LEUKAEMIA; MYELODYSPLASTIC SYNDROMES;CHRONIC MYELOMONOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,1,DB00943,__ZALCITABINE,4704357,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",G01N33/5008,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,25.1011314400706,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,211.2178,88.15,5.0,2.0,2.0,20.86,52.24,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT04088513,G6PD DEFICIENCY|STROKE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|Jieyang Municipal People's Hospital, Jieyang, Guangdong, China|Meizhou City People's Hospital, Meizhou, Guangdong, China|Yue Bei People's Hospital, Shaoguan, Guangdong, China|Yunfu People's Hospital, Yunfu, Guangdong, China|The Forth Affiliated Hospital of Guangxi Medical Hospital, Liuzhou, Guangxi, China|The First Affiliated Hospital of Guangxi Medical Hospital, Nanning, Guangxi, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China|Ganzhou Municipal Hospital, Ganzhou, Jiangxi, China|The Forth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT02238444,CIRRHOSIS|HYPERTENSION|VENOUS THROMBOSIS|STATUS; SPLENECTOMY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT02986594,THROMBOPHILIA WITH RECURRENT PREGNANCY LOSS,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai first Maternity and Infant health hospital, Tong Ji University, Shanghai, China",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT04003844,KAWASAKI DISEASE,All,3 Months to 12 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|Kyung Hee University Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,1,DB00975,__DIPYRIDAMOLE,6015577,Recruiting,NCT02238444,CIRRHOSIS|HYPERTENSION|VENOUS THROMBOSIS|STATUS; SPLENECTOMY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,1101.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.52,504.6256,145.44,12.0,4.0,4.0,56.94,142.78,12.0,1.0,0.0,0.0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00029523,MENINGEAL NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barrow Neurological Institute, Phoenix, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of Southern California, Norris Cancer Center, Los Angeles, California, United States|University of Colorado Hospital, Anschutz Cancer Pavilion, Denver, Colorado, United States|Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory Clinic, Department of Neurosurgery, Atlanta, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Rush Cancer Institute, Chicago, Illinois, United States|Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center Dept. of Neurology, Boston, Massachusetts, United States|Park Nicollet Institute, Oncology Research Program, Minneapolis, Minnesota, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University Hospital of Cleveland, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Utah, Hunsman Cancer Institute, Salt lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada",A61K9/127,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00487448,MYELODYSPLASTIC SYNDROME|ACUTE MYELOBLASTIC LEUKEMIA,All,"up to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de la Ribera, Alzira, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Puerta del Mar, Cadiz, Spain|Hospital del SAS, Jerez de la Frontera, Spain|Hospital de Leon, Leon, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Dr. Pesset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",A61K9/127,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Active Not Recruiting,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/127,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,,ACUTE LYMPHOBKASTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/127,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Recruiting,,RESTLESS LEG SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Recruiting,NCT03164473,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07F9/5537,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,"Active, not recruiting",NCT02577783,MULTIPLE MYELOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,NCT00969462,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Departmetn of Medicine. Meir Medical Center, Kfar-Saba, Israel",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",C07F9/5537,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Not yet recruiting,NCT04276233,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,1,DB01003,__CROMOGLICIC_ACID,4145438,Completed,NCT02371941,EOSINOPHILIC ESOPHAGITIS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LeBonheur Children's Hospital, Memphis, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,1,DB01003,__CROMOGLICIC_ACID,4145438,Completed,,"OESOPHAGITIS, EOSINOPHILIC",,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,Recruiting,NCT03004261,CYTOMEGALOVIRUS INFECTIONS|HEMATOLOGICAL DISEASE,All,"14 Years to 60 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Jiao Tong University Affilated Shanghai General Hospital, Shanghai, Shanghai, China",A61K9/5073,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Completed,NCT00202644,"THROMBOCYTHEMIA, HEMORRHAGIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven, Pleven, Bulgaria|University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology, Sofia, Bulgaria|University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic, Varna, Bulgaria|CHU Angers Services des Maladies du Sang, Angers, Cedex 09, France|Hopital Saint Louis - Centre d'Investigation Clinique, Paris, France|University of Debrecen Medical and Health Science Centre, Debrecen, Hungary|Petz Aladar County Teaching Hospital, Gyor, Hungary|Pandy Kalman Hospital of Bekes County, Gyula, Hungary|Kaposi Mor Teaching Hospital, Kaposvar, Hungary|Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin, Poland|Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej, Warsaw, Poland|Klinika Hematologii Instytut Hematologii i Transfuzjologi, Warsaw, Poland|Hospitals da Universidade de Coimbra, Coimbra, Portugal|Institute for Haematology of Clinical Centre of Serbia, Belgrade, Serbia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,"Active, not recruiting",NCT02149537,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Ibadan College of Medicine, Ibadan, Oyo State, Nigeria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Unknown status,NCT02844673,SICKLE CELL ANAEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Active Not Recruiting,,SICKLE CELL ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Completed,,DREPANOCYTIC MEN TREATED BY HYDROXYUREA FOR THE FIRST TIME,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Unknown status,NCT01339988,ACUTE LEUKEMIAS|CHRONIC LEUKEMIAS|MYELODYSPLASTIC SYNDROME|JUVENILE MYELOMONOCYTIC LEUKEMIA,Male,"up to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Completed,NCT00361140,"MYELODYSPLASTIC SYNDROMES|MYELOPROLIFERATIVE DISORDERS|LEUKEMIA, LYMPHOCYTIC|MYELOMA|LYMPHOMA",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Recruiting,NCT02670564,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Hôpital Cantonal de Genève, Département de Pédiatrie, Geneva, Cansearch Laboratory, Switzerland|Universitäts-Kinderspital beider Basel (UKBB), Onkologie/Hämatologie, Basel, Switzerland|HUG Hôpitaux Universitaire de Genève, Unité d'onco-hématologie pédiatrique, Geneva, Switzerland|Universitäts-Kinderspital, Zurich, Switzerland",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Completed,,"LEUKEMIA, LYMPHOCYTIC",,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,NCT02257970,LYMPHEDEMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Stanford, California, United States",C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT00431496,ANEMIA|SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02559154,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai General Hospital, Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02844309,WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Terminated,NCT00314665,UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati Medical Center, Cincinnati, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,1,DB01042,__MELPHALAN,8410077,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Terminated,NCT00115336,"HEMATOLOGIC DISEASES|ANEMIA, SICKLE CELL",All,"6 Years to 18 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Terminated,NCT00880373,SICKLE CELL DISEASE,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","North West London Hospitals NHS Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,1,DB01058,__PRAZIQUANTEL,4283400,Unknown status,NCT01459146,MALARIA|SCHISTOSOMIASIS|HELMINTHIASIS|ANEMIA|CHANGE IN SUSTAINED ATTENTION,All,6 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NHRC, Navrongo, Ghana",A23K10/20,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,251.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.42,312.4061,40.62,2.0,0.0,4.0,34.84,88.79,1.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1
O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,1,DB01058,__PRAZIQUANTEL,4283400,Withdrawn,NCT02734186,SCHISTOSOMIASIS,All,"14 Years to 80 Years   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A23K10/20,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,23.0312737427873,251.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.42,312.4061,40.62,2.0,0.0,4.0,34.84,88.79,1.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03172676,IMMUNE THROMBOCYTOPENIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut Medical School, Assiut, Egypt",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00487448,MYELODYSPLASTIC SYNDROME|ACUTE MYELOBLASTIC LEUKEMIA,All,"up to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de la Ribera, Alzira, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Puerta del Mar, Cadiz, Spain|Hospital del SAS, Jerez de la Frontera, Spain|Hospital de Leon, Leon, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Dr. Pesset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00220311,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00361140,"MYELODYSPLASTIC SYNDROMES|MYELOPROLIFERATIVE DISORDERS|LEUKEMIA, LYMPHOCYTIC|MYELOMA|LYMPHOMA",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Recruiting,NCT03692754,"IMMUNE THROMBOCYTOPENIA|PURPURA, THROMBOCYTOPENIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu hospital, Shandong University, Jinan, Shandong, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(O)(P(=O)(O)O)P(=O)(O)O,1,DB01077,__ETIDRONIC_ACID,,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,206.0282,135.29,7.0,5.0,0.0,13.97,34.51,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,NCT02434952,"MALARIA, FALCIPARUM|G6PD DEFICIENCY",All,"1 Year and older   (Child, Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ratanakiri Provincial Hospital, Ratanakiri, Cambodia",G01N33/62,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,NCT02389374,MALARIA,All,"12 Months and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G01N33/62,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Recruiting,NCT02876549,VIVAX MALARIA,All,"6 Months and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dr. Ghulam Rahim Awab MD, Jalalabad, Nangarha, Afghanistan",G01N33/62,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Terminated,NCT03337152,"MALARIA, VIVAX|G6PD DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand",G01N33/62,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,,GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,NCT00403650,SARCOIDOSIS|PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati, Cincinnati, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Completed,NCT02703194,IMMUNOGLOBULIN G4 RELATED SCLEROSING DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese PLA General Hospital, Beijing, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)[O-])NC1=O)C(C)O,1,DB01111,__COLISTIMETHATE,,Completed,NCT02966457,HEMATOLOGICAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Republican Center of Hematology and Bone Marrow Transplantation, Minsk, Belarus",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,1634.87,706.71,33.0,18.0,1.0,161.9,370.19,44.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,1,DB01131,__PROGUANIL,5084449,"Active, not recruiting",NCT03178643,"MALARIA,FALCIPARUM",All,1 Year to 10 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Homa Bay County Referral Hospital, Homa Bay Town, Homa Bay County, Kenya",C07C317/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,13.7004866629704,658.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.29,253.731,83.79,5.0,5.0,1.0,26.75,91.65,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1,1,DB01141,__MICAFUNGIN,5376634,Completed,NCT01200355,ACUTE MYELOGENOUS LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.3499455840982,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.67,1270.274,510.14,22.0,16.0,7.0,128.22,303.07,18.0,1.0,0.0,0.0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1,1,DB01141,__MICAFUNGIN,5376634,Unknown status,NCT01135589,NEUTROPENIA|HEMATOPOIETIC STEM CELL TRANSPLANTATION|INVASIVE FUNGAL DISEASE,All,"up to 19 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Goyang, Korea, Republic of|Hwasun, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of",C07K7/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.3499455840982,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.67,1270.274,510.14,22.0,16.0,7.0,128.22,303.07,18.0,1.0,0.0,0.0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0
NCCCNCCSP(=O)(O)O,1,DB01143,__AMIFOSTINE,5424471,Completed,NCT00158041,HEAD AND NECK CANCER|LUNG CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Mt. Sinai Medical Center, Miami Beach, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Terminated,NCT02895529,HEMATOLOGIC NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijign, China|Beijing, China|Changchun, China|Changzhou, China|Fuzhou, China|Guangzhou, China|Guiyang, China|Hefei, China|Shanghai, China|Suzhou, China|Tianjin, China|Zhengzhou, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,NCT01198236,INVASIVE FUNGAL INFECTIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,,NEUTROPENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,,MYCOSES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K47/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Completed,NCT00487448,MYELODYSPLASTIC SYNDROME|ACUTE MYELOBLASTIC LEUKEMIA,All,"up to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de la Ribera, Alzira, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Puerta del Mar, Cadiz, Spain|Hospital del SAS, Jerez de la Frontera, Spain|Hospital de Leon, Leon, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Dr. Pesset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",A61K47/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Recruiting,NCT01366898,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",A61K47/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Unknown status,NCT01990807,"CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|PHILADELPHIA CHROMOSOME, PH^1^, ABSENT|B-CELL CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA",All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Scienses, Tianjin, Tianjin, China",A61K47/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",C12C3/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00199069,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C12C3/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Recruiting,NCT03172676,IMMUNE THROMBOCYTOPENIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut Medical School, Assiut, Egypt",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Not yet recruiting,NCT04005209,"ANEMIA; SICKLE-CELL, WITH CRISIS|ACUTE PAIN",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke Hospital, Durham, North Carolina, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Terminated,NCT00252122,SICKLE CELL DISEASE,All,"7 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Recruiting,NCT04330183,SICKLE CELL CRISIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02019758,EOSINOPHILIC ESOPHAGITIS,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT01501136,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04094805,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu hospital, Shandong University, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01356511,"PURPURA, THROMBOCYTOPENIC, IDIOPATHIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Shandong University, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Active Not Recruiting,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,1,DB01241,__GEMFIBROZIL,4126637,Withdrawn,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/235,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,1026.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,250.3334,46.53,3.0,1.0,1.0,28.9,71.82,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Recruiting,NCT03844360,HEMATOLOGICAL NEOPLASMS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China",C07D491/113,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Recruiting,NCT04155411,DASATINIB|BCR-ABL|CHRONIC MYELOID LEUKEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xin Du, Shenzhen, Guangdong, China",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Unknown status,NCT03216070,CHRONIC MYELOGENOUS LEUKEMIA,Female,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico",C07D491/113,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Completed,NCT01660906,CHRONIC PHASE CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Cancer Medical Center, Anaheim, California, United States|Cancer Center Of Central Connecticut, Southington, Connecticut, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Local Institution, Creteil Cedex, France|Local Institution, Lille CEDEX, France|Local Institution, Pierre Benite cedex, France|Local Institution, Pringy Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Jena, Germany|Local Institution, Koln, Germany|Local Institution, Lubeck, Germany|Local Institution, Mannheim, Germany|Local Institution, Rostock, Germany|Local Institution, Catania, Italy|Local Institution, Firenze, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Seoul, Korea, Republic of",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT02013102,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University General Hospital, Tianjin, Tianjin, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT01806116,HIGHER-RISK MYELODYSPLASTIC SYNDROME|RELAPSED /REFRACTORY ACUTE MYELOID LEUKEMIA,All,"8 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT03558412,T-LYMPHOBLASTIC LYMPHOMA,All,"14 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT03579082,DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT01200355,ACUTE MYELOGENOUS LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT02805946,ALLOGENEIC STEM CELL TRANSPLANT|ACUTE GRAFT VERSUS HOST DISEASE|ACUTE MYELOID LEUCAEMIA|MYELO DYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Radboudumc, Nijmegen, Netherlands",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT00686543,FUNGAL INFECTION|ACUTE MYELOGENOUS LEUKEMIA|NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT02875743,"APLASTIC ANEMIA|LEUKEMIA, MYELOID, ACUTE|MYELODYSPLASTIC SYNDROMES|BONE MARROW TRANSPLANTATION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"King's College Hospital NHS Foundation Trust, London, United Kingdom",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT02372357,HEMATOLOGICAL MALIGNANCY,All,2 Years to 13 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Catholic University Leuven - Department of Pharmaceutical and Pharmacological Sciences, Leuven, Vlaams-Brabant, Belgium|Institutul Clinic Fundeni, Bucharest, Sector 2, Romania",C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,Completed,NCT00167843,MALARIA,All,up to 5 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Medical Research Unit of the Albert Schweitzer Hospital, Lambaréné, Moyen Ogooué, Gabon",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,Completed,NCT00206739,MALARIA|ANEMIA,All,2 Months to 4 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ashanti Region, Ghana",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,"Active, not recruiting",NCT03178643,"MALARIA,FALCIPARUM",All,1 Year to 10 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Homa Bay County Referral Hospital, Homa Bay Town, Homa Bay County, Kenya",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01171365,ASTHMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,1,DB01413,__CEFEPIME,5409898,Recruiting,NCT04233996,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,11.9591778065258,178.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.37,480.561,150.04,8.0,2.0,4.0,47.53,141.98,7.0,0.0,1.0,0.0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,1,DB01413,__CEFEPIME,5409898,Completed,NCT04187755,"NEUTROPENIA, FEBRILE|LEUKEMIA|PEDIATRIC CANCER|ANTIBIOTIC REACTION",All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,11.9591778065258,178.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.37,480.561,150.04,8.0,2.0,4.0,47.53,141.98,7.0,0.0,1.0,0.0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1
CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,1,DB01418,__ACENOCOUMAROL,4334020,Completed,NCT00966290,BLOOD COAGULATION DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Brest, France|Louis Pasteur Hospital, Dole, France|University Hospital, Lille, France|Dupuytren University Hospital, Limoges, France|Bellevue University Hospital, Saint-Etienne, France|University Hospital, Strasbourg, France|Rangueil University Hospital, Toulouse, France",C12R1/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,24.049775149387003,46.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,353.3255,109.42,5.0,1.0,3.0,34.35,94.18,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Recruiting,,NEPHROTIC SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown Status,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB01452,__DIAMORPHINE,3955926,Terminated,NCT00880373,SICKLE CELL DISEASE,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","North West London Hospitals NHS Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",G01N31/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,38.900182755292704,2392.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,369.411,65.07,4.0,0.0,5.0,38.19,98.43,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB01586,__URSODEOXYCHOLIC_ACID,3969503,Terminated,NCT02472509,HEMOLYTIC DISORDERS|GALLSTONES,All,"4 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Shaare Zedek Medical Center, Jerusalem, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,9.363641963900688,359.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,392.57199999999995,77.76,4.0,3.0,4.0,46.33,109.27,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,"Active, not recruiting",NCT03525834,RENAL ANGIOMYOLIPOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,1,DB01597,__CILASTATIN,8487093,Completed,,FEBRILE NEUTROPENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,358.45300000000015,129.72,6.0,4.0,1.0,38.28,92.85,11.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,NCT02213783,PATIENTS WITH FEBRILE NEUTROPENIA,All,"20 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,NCT02149329,FEBRILE NEUTROPENIA|HEMATOLOGICAL MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU university medical center, Amsterdam, Netherlands|HAGA ziekenhuis, The Hague, Netherlands",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,FEBRILE NEUTROPENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Unknown Status,,INTRACRANIAL HEMORRHAGES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00749515,TRANSFUSION-DEPENDENT HEMACHROMATOSIS|THALASSEMIA MAJOR|SICKLE CELL DISEASE,All,"Child, Adult, Older Adult",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Boston, Boston, Massachusetts, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Withdrawn,NCT02069886,THALASSEMIA (TRANSFUSION DELENDENT),All,"2 Years to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Withdrawn,NCT01724138,Β-THALASSEMIA MAJOR,All,"2 Years to 71 Years   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT01709838,NON-TRANSFUSION DEPENDENT THALASSEMIA,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Nanning, Guangxi, China|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Cagliari, CA, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Hazmiyeh, Beirut, Lebanon|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Tunis, Tunisia|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, London, United Kingdom",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT01250951,MYELODYSPLASTIC SYNDROME|THALASSEMIA,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00171301,BETA-THALASSEMIA MAJOR|HEMOSIDEROSIS|IRON OVERLOAD|RARE ANEMIA,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Damascus, Syrian Arab Republic",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00673608,HEMOGLOBINOPATHIES|MYELODYSPLASTIC SYNDROMES|OTHER INHERITED OR ACQUIRED ANAEMIA|MPD SYNDROME|DIAMOND-BLACKFAN ANEMIA|OTHER RARE ANAEMIAS|TRANSFUSIONAL IRON OVERLOAD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novarts Investigative Site, Adelaide, Australia|Novarts Investigative Site, Brisbane, Australia|Novarts Investigative Site, Melbourne, Australia|Novarts Investigative Site, Sydney, Australia",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Terminated,NCT01326845,MYELODYSPLASTIC SYNDROME|TRANSFUSIONAL IRON OVERLOAD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Caen, Cedex, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Alessandria, AL, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Madrid, Spain",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00901199,THALASSEMIA|IRON OVERLOAD,All,"8 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHRCO, Oakland, California, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00564941,MYELODYSPLASTIC SYNDROMES|BETA-THALASSEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,,BETA-THALASSEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,,IRON OVERLOAD AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH BETA-THALASSEMIA MAJOR,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,,MYELODYSPLASTIC SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Withdrawn,NCT00361933,GIANT LYMPH NODE HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Completed,NCT01255644,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Vienna, Austria",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Completed,,HEART TRANSPLANT RECIPIENTS,,,,,"FISABIO, Elche, Alicante, Spain",C07D473/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Not yet recruiting,NCT04316494,ANCA ASSOCIATED VASCULITIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|WEGENER GRANULOMATOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Unknown status,NCT01830959,SARCOIDOSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(O)/C=C/c1ccc(O)c(O)c1,1,DB01880,"__3,4-DIHYDROXYCINNAMIC_ACID",3965033,Completed,NCT02556814,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Qilu Hospital, Shandong University, Jinan, Shandong, China",A61K9/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,28.68231380521161,3049.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.67,180.1574,77.76,4.0,3.0,1.0,17.34,47.02,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Suspended,NCT00593619,IRON DEFICIENCY ANEMIA|PERIOPERATIVE BLOOD CONSERVATION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","London Health Sciences Centre, London, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00224055,"ANEMIA, IRON-DEFICIENCY|KIDNEY FAILURE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tucson, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|Hines, Illinois, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Birmingham, New York, United States|Bronx, New York, United States|Mineola, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Charlotte, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Fairfax, Virginia, United States|San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT03117192,THALASSEMIA|SPLENECTOMY; STATUS|IMMUNOSUPPRESSION,All,"12 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT03095326,THALASSEMIA|PNEUMOCOCCAL INFECTION,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT03317210,ANEMIA,Female,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Unknown status,NCT02707757,ANAEMIA|HAEMODIALYSIS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Imperial Renal and Transplant Centre, London, United Kingdom|Imperial NHS Healthcare Trust, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00660933,ANEMIA|PUERPERAL DISORDERS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Clínic of Barcelona, Barcelona, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT02198495,ANEMIA OF CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Division of Nephrology and Dialysis, Vienna, Austria|Wiener Dialysezentrum GmbH, Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Unknown status,NCT01084122,HIP FRACTURE|SURGICAL INTERVENTION,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Servicio de Cirugía Ortopédica y Traumatología. Hospital Clinic., Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT01227616,IRON DEFICIENCY ANEMIA TREATMENT|CHRONIC KIDNEY DISEASE(CKD),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pine Bluff, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Azusa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lynwood, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Paramount, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Gabriel, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Simi Valley, California, United States|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Middlebury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Framingham, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pontiac, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Roseville, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Farmington, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ridgewood, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bethlehem, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Edinburg, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Canada|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00802139,IRON DEFICIENCY ANEMIA,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chonnam National Universitiy Hospital, KwangJu, Korea, Republic of|Asan Hospital, Seoul, Korea, Republic of|Catholic University of Korea Kangnam St. Mary's Hospital, Seoul, Korea, Republic of",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Unknown status,NCT00199277,COLORECTAL NEOPLASM|IRON DEFICIENCY ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Comarcal Sant Jaume de Calella., Calella, Barcelona, Spain|Fundació Hospital Asil de Granollers, Granollers, Barcelona, Spain|Consorci Sanitari del Maresme, Mataró, Barcelona, Spain|Hospital Miguel Servet, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT04225728,CHRONIC HEART FAILURE (CHF)|IRON DEFICIENCY,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, Cardiology department, Yaoundé, Cameroon",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00354692,"KIDNEY FAILURE, CHRONIC|ANEMIA, IRON-DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Glendale, California, United States|Shreveport, Louisiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT02392910,IRON DEFICIENCY|HEART FAILURE|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Aleman, Buenos Aires, Caba, Argentina",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT01067547,IRON DEFICIENCY|INFLAMMATORY BOWEL DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alberta, Edmonton, Alberta, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00239642,ANEMIA|CHRONIC KIDNEY DISEASE,All,"2 Years to 21 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Luitpold Pharmaceutials, Norristown, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00308490,ANEMIA IN CHRONIC RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Papageorgiou General Hospital, Thessaloniki, Greece",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT03658876,RENAL FAILURE CHRONIC|ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Unknown status,NCT00204256,"KIDNEY FAILURE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Muenster, Muenster, Westphalia, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Not yet recruiting,NCT03805607,CESAREAN SECTION COMPLICATIONS|POSTOPERATIVE PAIN|COAGULATION DEFECT; POSTPARTUM|NONSTEROIDALS (NSAIDS)TOXICITY|POSTPARTUM HEMORRHAGE,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",,,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,1,DB04572,__THIOTEPA,4766149,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,1,DB04703,__HESPERIDIN,4078137,"Active, not recruiting",NCT04360889,LOWER EXTREMITY LYMPHEDEMA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ryazan State Medical University, Ryazan', Russian Federation",C07H17/07,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,22.012772336187602,842.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,610.5606,234.29,15.0,8.0,5.0,58.76,140.77,7.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,1
CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,1,DB04846,__CELIPROLOL,4767784,Completed,NCT00190411,"EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT|CHROMOSOME 2Q31.2 DELETION SYNDROME",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,21.059980697755602,352.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.29,379.501,90.9,5.0,3.0,1.0,43.18,108.25,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,1,DB04847,__ROXADUSTAT,WO-2004108681-A1,Recruiting,NCT04454879,RENAL ANEMIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University First Hospital, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.7488,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.13,352.346,108.75,5.0,3.0,3.0,35.7,92.85,5.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,1,DB04847,__ROXADUSTAT,WO-2004108681-A1,Recruiting,NCT04134026,ANEMIA IN INCIDENT DIALYSIS PATIENTS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.7488,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.13,352.346,108.75,5.0,3.0,3.0,35.7,92.85,5.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Recruiting,NCT02602314,CHRONYC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi G. Salesi, Ancona, Italy|Az.Ospedaliera S.G.Moscati, Avellino, Italy|UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy|Ematologia Torre 6 piano 4 - ASST Papa Giovanni XXIII, Bergamo, Italy|Istituto di Ematologia ""Lorenzo e A. Seragnoli"" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy|USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia, Brescia, Italy|ASL N.8 -Ospedale A. Businco, Cagliari, Italy|Università di Catania - Cattedra di Ematologia - Ospedale ""Ferrarotto"", Catania, Italy|U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile, Civitanova Marche, Italy|Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi, Cona, Italy|S.C. Ematologia ASO S. Croce e Carle, Cuneo, Italy|Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano, Firenze, Italy|IRCCS_AOU San Martino-IST.Clinica Ematologica, Genova, Italy|ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy|Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina, Messina, Italy|Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti ""Papardo Piemonte"", Messina, Italy|U.O. di Ematologia- Ospedale dell'Angelo - Mestre, Mestre, Italy|UO Ematologia - AOU Policlinico di Modena, Modena, Italy|Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Universitaria - Università degli Studi di Napoli ""Federico II"" - Facoltà di Medicina e Chirurgia, Napoli, Italy|Ospedale San Gennaro - ASL Napoli 1, Napoli, Italy|S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy|U.O. CTMO Ematologia - Osp. S. Francesco, Nuoro, Italy|Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2, Orbassano, Italy|Ospedali Riuniti ""Villa Sofia-Cervello"", Palermo, Italy|U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico ""Paolo Giaccone"", Palermo, Italy|Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore, Pesaro, Italy|Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto, Piacenza, Italy|Az.Ospedaliera S.G.Moscati, Potenza, Italy|Dipartimento Oncologico - Ospedale S.Maria delle Croci, Ravenna, Italy|Dipartimento Emato-Oncologia A.O.""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Az. Ospedaliera ""Sant' Andrea""-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia, Roma, Italy|Divisione Ematologia - Università Campus Bio-Medico, Roma, Italy|Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy|UOC Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma ""Sapienza"", Roma, Italy|U.O.C. Ematologia - Ospedale S. Eugenio, Rome, Italy|Unità Operativa di Oncologia Giovanni Paolo II ""Vito Fazzi"", Rossano, Italy|Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Ematologia - Dipartimento di Medicina Clinica e Sperimentale, Sassari, Italy|A.O. Santa Maria - Terni S.C Oncoematologia, Terni, Italy|Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine, Udine, Italy|Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, Verona, Italy|ULSS N.6 Osp. S. Bortolo, Vicenza, Italy",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT03332511,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT01227577,CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer, Burbank, California, United States|Bay Area Cancer Research Dept.ofBayAreaCancerResearch, Concord, California, United States|St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda, California, United States|Sarah Cannon Research Institute SCRI, Jacksonville, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Pasco Hernando Oncology, New Port Richey, Florida, United States|Georgia Regents University MedCollege of GA Cancer Ctr 2, Augusta, Georgia, United States|Stroger Cook County Hospital Division of Hematology & Onc, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|Indiana Blood and Marrow Institute, Beach Grove, Indiana, United States|Cancer Center of Kansas, Witchita, Kansas, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3), New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Louis University Cancer Center, St. Louis, Missouri, United States|University of Nebraska Medical Center University of Nebraska Med Ctr, Omaha, Nebraska, United States|Hackensack University Medical Center Dept.of HackensackUniv.MedCtr., Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Ct James P Wilmot Cancer Ctr, Rochester, New York, United States|Duke University Medical Center Duke University Med Ctr, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Cancer Centers of the Carolinas Cancer Center, Greenville, South Carolina, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States|The Jones Clinic, Germantown, Tennessee, United States|Tennessee Oncology Sarah Cannon Research Inst., Nashville, Tennessee, United States|Baylor Research Institute Baylor Research Institute (17), Dallas, Texas, United States|Oncology Consultants Oncology Consultants, P.A., Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT00980018,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Hematology Oncology Services of Arkansas SC, Little Rock, Arkansas, United States|USC Norris Cancer Center LAC & USC Medical Center, Los Angeles, California, United States|Southwest Cancer Care Murrieta, Poway, California, United States|Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4, Ocoee, Florida, United States|Stroger Cook County Hospital John H. Stroger Hospital, Chicago, Illinois, United States|St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn, Beech Grove, Indiana, United States|St. Agnes Hospital, Baltimore, Maryland, United States|St. Louis University Cancer Center, St. Louis, Missouri, United States|Northwest Cancer Specialists Salmon Creek Office, Portland, Oregon, United States|Oregon Health Sciences University, Portland, Oregon, United States|The Jones Clinic, Germantown, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States|Texas Oncology Texas Oncology - Sugar Land, Dallas, Texas, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,"Active, not recruiting",NCT02546674,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Mergentheim, Germany|Novartis Investigative Site, Bad Reichenhall, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bad Soden, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Biberach, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Donauwoerth, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Georgsmarienhuette, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Goslar, Germany|Novartis Investigative Site, Göppingen, Germany|Novartis Investigative Site, Halberstadt, Germany|Novartis Investigative Site, Halle S, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Memmingen, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Moers, Germany|Novartis Investigative Site, Muelheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Mutlangen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Paderborn, Germany|Novartis Investigative Site, Passau, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Rotenburg, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Schorndorf, Germany|Novartis Investigative Site, Schweinfurt, Germany|Novartis Investigative Site, Schwäbisch-Hall, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Westerstede, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Wilhelmshaven, Germany|Novartis Investigative Site, Wolfsburg, Germany|Novartis Investigative Site, Worms, Germany|Novartis Investigative Site, Wuerzburg, Germany",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Unknown status,NCT02389920,"LEUKEMIA, CHRONIC MYELOID",All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Terminated,NCT02086487,"MYELOID LEUKEMIA, CHRONIC",All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Guard Hospital, Riyadh, Central, Saudi Arabia|King Fahad specialist Hospital, Dammam, Eastern, Saudi Arabia",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Terminated,NCT01131325,CML|PHILADELPHIA CHROMOSOME POSITIVE (PH+)|CHRONIC MYELOGENOUS LEUKEMIA CHRONIC PHASE(CML-CP) PATIENTS WITH LOW IMATINIB TROUGH LEVELS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas, Nevada, United States|Cancer Center of the High Plains, Amarillo, Texas, United States|Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2), Dallas, Texas, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT01043874,PHILADELPHIA CHROMOSOME POSITIVE|CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Kitakyushu, Fukuoka, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Aomori, Japan|Novartis Investigative Site, Gifu, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Saga, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT00644878,CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Cancer Center Jane Anne Nohl, Los Angeles, California, United States|Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch, Miami Shores, Florida, United States|Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States|Kootenai Medical Center Dept.ofKootenai Med.Ctr., Coeur d'Alene, Idaho, United States|Indiana Blood and Marrow Institute, Beach Grove, Indiana, United States|University of Iowa Hospitals & Clinics Univ of Iowa Hosp & Clinic, Iowa City, Iowa, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans, Louisiana, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Montefiore Medical Center Medical Center, Bronx, New York, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Westchester Medical Center Munger Pavillion (2), Valhalla, New York, United States|Wake Forest University Baptist Medical Center Hematology and Oncology, Winston-Salem, North Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|University of Tennessee Cancer Institute Cancer Institute, Memphis, Tennessee, United States|South Texas Institute of Cancer S. Tex Inst.- Corpus Christi, Corpus Christi, Texas, United States|Baylor College of Medicine - Breast Care Dan L Duncan Cancer Ctr, Houston, Texas, United States|Central Utah Clinic Central Utah Clinic (7), Provo, Utah, United States|Froedert Memorial Lutheran Hospital Dept.ofFroedert Memorial, Milwaukee, Wisconsin, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT01061177,CML IN CHRONIC PHASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Luxembourg, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Olomouc, CZE, Czech Republic|Novartis Investigative Site, Brno - Bohunice, Czech Republic|Novartis Investigative Site, Hradec Kralove, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Aarhus C, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, HUS Helsinki, Finland|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Bayonne, Bayonne cedex, France|Novartis Investigative Site, Paris Cedex 10, Cedex 10, France|Novartis Investigative Site, Saint Denis, FRANCE / La Reunion, France|Novartis Investigative Site, Monte-Carlo, Principauté de Monaco, France|Novartis Investigative Site, Aix en Provence Cedex 1, France|Novartis Investigative Site, Amiens cedex1, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Argenteuil Cedex, France|Novartis Investigative Site, Avignon cedex 9, France|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Blois Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Chalon sur Saône, France|Novartis Investigative Site, Chambéry cedex, France|Novartis Investigative Site, Clermont-Ferrand cedex 1, France|Novartis Investigative Site, Compiègne cedex, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Dunkerque, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Coudray, France|Novartis Investigative Site, Le Mans Cedex 09, France|Novartis Investigative Site, Lens Cedex, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz Cedex 01, France|Novartis Investigative Site, Montfermeil, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Mulhouse cedex, France|Novartis Investigative Site, Mâcon Cedex, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pau, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Pringy cedex, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Roubaix, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint Brieuc cedex 1, France|Novartis Investigative Site, Saint Priest en Jarez Cedex, France|Novartis Investigative Site, St Quentin Cedex, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Tours Cedex 9, France|Novartis Investigative Site, Troyes, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Duisburg, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Eschweiler, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Oder, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Goslar, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hagen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamm, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Herrsching, Germany|Novartis Investigative Site, Hildesheim, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koblenz, Germany|Novartis Investigative Site, Landshut, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Lemgo, Germany|Novartis Investigative Site, Luebeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Moers, Germany|Novartis Investigative Site, Muelheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Mutlangen, Germany|Novartis Investigative Site, Mönchengladbach, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Neunkirchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Offenburg, Germany|Novartis Investigative Site, Paderborn, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Schorndorf, Germany|Novartis Investigative Site, Schwäbisch-Hall, Germany|Novartis Investigative Site, Sindelfingen, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Traunstein, Germany|Novartis Investigative Site, Triberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Viersen, Germany|Novartis Investigative Site, Weilheim, Germany|Novartis Investigative Site, Wendlingen, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Zella-Mehlis, Germany|Novartis Investigative Site, Alexandroupolis, Evros, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Cagliari, CA, Italy|Novartis Investigative Site, Cagliari, CA, Italy|Novartis Investigative Site, Cuneo, CN, Italy|Novartis Investigative Site, Rossano, CS, Italy|Novartis Investigative Site, Catanzaro, CZ, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pesaro, PU, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Potenza, PZ, Italy|Novartis Investigative Site, Ravenna, RA, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nocera Inferiore, SA, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Taranto, TA, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Treviso, TV, Italy|Novartis Investigative Site, Ronciglione, VT, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Perugia, Italy|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tromsoe, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucharest, District 2, Romania|Novartis Investigative Site, Iasi, Jud. Iasi, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Celje, Slovenia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Toledo, Castilla la Mancha, Spain|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Tarragona, Catalunya, Spain|Novartis Investigative Site, Terrassa, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Orense, Galicia, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas de G.C, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Uxbridge, London, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Dudley, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,NCT01206088,CML|NILOTINIB|IMATINIB RESISTANT|IMATINIB INTOLERANT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Mary hospital, Catholic medical center, Seoul, Korea, Republic of",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,1,DB04868,__NILOTINIB,7169791,Completed,,CML,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Unknown status,NCT03260556,"SARCOIDOSIS, PULMONARY",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,1,DB05271,__ROTIGOTINE,6884434,Completed,,RESTLESS LEG SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,73.29924639109629,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.01,315.48,23.47,2.0,1.0,3.0,36.56,94.56,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Withdrawn,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Unknown status,NCT00247507,ANEMIA|ATHEROSCLEROSIS|END-STAGE RENAL DISEASE|OXIDATIVE STRESS|PRO-INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Far Eastern Memorial Hospital, Pan-Chiao, Taipei, Taiwan",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,1,DB06204,__TAPENTADOL,6071970,Terminated,,PERIPHERAL NEUROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,185.0,59.9930183371321,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.47,221.3385,23.47,2.0,1.0,1.0,26.58,69.56,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Completed,NCT01098487,"PURPURA, THROMBOCYTOPAENIC, IDIOPATHIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Caen cedex 9, France|GSK Investigational Site, Créteil, France|GSK Investigational Site, Pessac Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Shatin, New Territories, Hong Kong|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Vicenza, Veneto, Italy|GSK Investigational Site, Seongnam-si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, St Petersburg, Russian Federation",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,NCT03844360,HEMATOLOGICAL NEOPLASMS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Withdrawn,NCT01055600,THROMBOCYTOPAENIA,All,up to 26 Weeks   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"GSK Investigational Site, Research Triangle Park, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,NCT03243656,ELTROMBOPAG,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Facility of medicine, Assiut, Egypt",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,NCT04518475,PRIMARY IMMUNE THROMBOCYTOPENIA,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Not yet recruiting,NCT04102033,IMMUNE THROMBOCYTOPENIA,All,1 Year to 17 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Completed,NCT00888901,IDIOPATHIC THROMBOCYTOPENIC PURPURA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,,APLASTIC ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,NCT01401010,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sparrow Hospital, Lansing, Michigan, United States",C07C307/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Not yet recruiting,NCT04278651,"PREGNANCY RELATED|ANEMIA, IRON DEFICIENCY|ANEMIA OF PREGNANCY",Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Not yet recruiting,NCT04205266,"ANEMIA, IRON DEFICIENCY|HEAVY MENSTRUAL BLEEDING",Female,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",B82Y5/00,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Completed,NCT01227616,IRON DEFICIENCY ANEMIA TREATMENT|CHRONIC KIDNEY DISEASE(CKD),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pine Bluff, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Azusa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lynwood, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Paramount, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Gabriel, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Simi Valley, California, United States|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Middlebury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Framingham, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pontiac, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Roseville, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Farmington, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ridgewood, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bethlehem, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Edinburg, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Canada|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Completed,NCT01148745,IRON DEFICIENCY ANEMIA,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Dialysis Clinic, Inc., North Brunswick, New Jersey, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Completed,NCT01942460,IRON-DEFICIENCY ANEMIA|INFLAMMATION|OXIDATIVE STRESS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,NCT04080908,ANEMIA,All,"19 Years to 110 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Langone Health, New York, New York, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,OSTEONECROSIS,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,ANEMIA OF PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB06287,__TEMSIROLIMUS,5362718,Completed,NCT01180049,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mercy Research Institute, Miami, Florida, United States|Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111), East Orange, New Jersey, United States|Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City-Oncology Infusion, Oklahoma City, Oklahoma, United States|Amy Shen, RPh, Seattle, Washington, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|St George Hospital, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czech Republic, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|CHU de Nancy, Vandoeuvre les Nancy, France|Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV, Aachen, Germany|Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Presidio Ferrarotto - A.O.U. - PoliclinicoVittorio Emanuele, Catania, Italy|Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Modena, Italy|Struttura Complessa di Ematologia, Dipartimento di Oncologia ed Ematologia-, Torino, Italy|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Institutul Clinic Fundeni Bucuresti, Sectia II Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania|Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania|Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|GBOU VPO ""First Saint-Petersburg State Medical University n.a. I.P.Pavlov"", Saint-Petersburg, Russian Federation|Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva, Saint-Petersburg, Russian Federation|Clinical Centre of Serbia,Clinic for Hematology, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,NK/T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,NK/T-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,PERIPHERAL T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1,DB06480,__PRUCALOPRIDE,6413988,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,8.18086613688166,98.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,367.87,76.82,5.0,2.0,3.0,39.08,100.67,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,1,DB06603,__PANOBINOSTAT,6552065,Recruiting,NCT02386800,PRIMARY MYELOFIBROSIS|CHRONIC IDIOPATHIC MYELOFIBROSIS|POST POLYCYTHEMIA VERA MYELOFIBROSIS|POST ESSENTIAL THROMBOCYTHAEMIA MYELOFIBROSIS|STEROID REFRACTORY GRAFT VERSUS HOST DISEASE,All,"1 Month and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Cape Town, Western Province, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Bangkok, Bangkoknoi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",C07D471/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Not yet recruiting,NCT04128254,FOOT ANKLE INJURIES|ANTICOAGULANTS AND BLEEDING DISORDERS|VENOUS THROMBOEMBOLISM,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Completed,NCT02958969,VENOUS THROMBOEMBOLISM|MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,1,DB06616,__BOSUTINIB,6002008,"Active, not recruiting",NCT02228382,PREVIOUSLY TREATED PH + CML,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Keck Hospital of USC - Norris Healthcare Center (HC3), Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|Indiana Blood and Marrow Transplantation-Administrative Offices, Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation-Clinic, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medizinische Universitaet Innsbruck, Innsbruck, Austria|Ordensklinikum Linz Gmbh Barmherzige Schwestern, Linz, Austria|CHU Nice-Hopital Archet I, Nice cedex 3, Alpes Maritimes, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse Cedex 9, Cedex 9, France|Institut Bergonie, Bordeaux Cedex 09, France|Centre Hospitalier de Versailles (CHV) - Hopital Andre Mignot, Le Chesnay Cedex, France|Centre Regional De Lutte Contre Le Cancer, Marseille, France|CHU Brabois, Vandoeuvre-les-Nancy cedex, France|Universitaetsklinikum Koeln (AoeR), Koeln, Koln, Germany|RWTH Uniklinik Aachen, Aachen, Germany|Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK), Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Jena, Jena, Germany|III. Medizinische Klinik, Mannheim, Germany|AOU Policlinico Consorziale di Bari - UO Ematologia con Trapianto, Bari, BA, Italy|A.O.U. Policlinico S. Orsola-Malpighi, Bologna, BO, Italy|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|AOU Policlinico Vittorio Emanuele - P.O. Ferrarotto - UOC Ematologia, Catania, CT, Italy|Azienda Socio Sanitaria Territoriale - ASST Monza, Monza, MB, Italy|Ospedale S. Eugenio - UOC Ematologia, Rome, RM, Italy|AOU San Luigi Gonzaga SCDU Medicina Interna II ad indirizzo Ematologico, Orbassano, TO, Italy|SOD Ematologia, Firenze, Italy|A.O. Ospedale Niguarda Ca Granda - SC Ematologia, Milano, Italy|Haukeland Universitetssjukehus, Bergen, Norway|St Olav Hospital, Trondheim, Norway|Hospital Universitario Quiron de Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic De Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitari i Politecnic La Fe de Valencia - Instituto de Investigacion Sanitaria La Fe, Valencia, Spain|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|Hospital Quiron de Zaragoza Servicio de Hematologia, Zaragoza, Spain|Hematologiskt centrum, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Withdrawn,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Completed,,VENOUS THROMBOEMBOLISM,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT01651416,MALARIA|ANAEMIA,All,3 Months to 59 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ejisu-Juaben Municipality, Kumasi, Ashanti, Ghana",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT02389374,MALARIA,All,"12 Months and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Unknown status,NCT01459146,MALARIA|SCHISTOSOMIASIS|HELMINTHIASIS|ANEMIA|CHANGE IN SUSTAINED ATTENTION,All,6 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NHRC, Navrongo, Ghana",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Suspended,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,1,DB06730,__GESTODENE,4081537,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,C07J51/00,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,17.7416374052855,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,310.4299,37.3,2.0,1.0,4.0,35.94,92.99,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,1,DB06769,__BENDAMUSTINE,8436190,Completed,NCT01056510,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pori, Finland|Vantaa, Finland|Argenteuil, France|Avignon, France|Blois, France|Bordeaux, France|Brest, France|La Roche Sur Yon, France|La Tronche, France|Le Mans, France|Lens, France|Limoges, France|Lyon, France|Marseille, France|Mulhouse, France|Nice, France|Nimes, France|Paris, France|Paris, France|Perpignan, France|Pierre Benite, France|Salouel, France|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vitoria, Alava, Spain|Elche, Alicante, Spain|Jerez de La Frontera, Cadiz, Spain|Torrelavega, Cantabria, Spain|La Coruna, La Coruña, Spain|Alcorcon, Madrid, Spain|Cartagena, Murcia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Huelva, Spain|Leon, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Tarragona, Spain|Valencia, Spain|Zaragoza, Spain|Falun, Sweden|Kristianstad, Sweden|Luleå, Sweden|Sundsvall, Sweden|Uddevalla, Sweden|Umea, Sweden|Uppsala, Sweden|Tunis, Tunisia|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Bursa, Turkey|Edirne, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Samsun, Turkey|Blackpool, United Kingdom|Bournemouth, United Kingdom|Edinburgh, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Manchester, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Somerset, United Kingdom|Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,1,DB06769,__BENDAMUSTINE,8436190,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Completed,NCT01649635,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 007, Centro, Brazil|Investigational Site Number 004, Curitiba, Brazil|Investigational Site Number 006, Lajeado, Brazil|Investigational Site Number 005, Porto Alegre, Brazil|Investigational Site Number 001, Santo Andre, Brazil|Investigational Site Number 002, São Paulo, Brazil",3,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,1,DB06800,__METHYLNALTREXONE,6559158,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,43.0,31.2778496478367,15.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.59,356.441,66.76,4.0,2.0,6.0,38.04,107.42,2.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,1,DB06809,__PLERIXAFOR,RE42152,Completed,NCT01164475,NON-HODGKIN'S LYMPHOMA,All,"18 Years to 78 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Samsung Medical Center, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",C07D401/14 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB06813,__PRALATREXATE,6028071,Recruiting,NCT03150602,"PERIPHERAL T CELL LYMPHOMA|PROGRESSION, DISEASE",All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ntional Taiwan University Hospital, Taipei, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,11.5320643134355,86.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.1,477.4726,207.3,11.0,5.0,3.0,47.31,126.82,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
Cc1c(O)c(=O)ccn1C,1,DB08826,__DEFERIPRONE,7049328,Completed,NCT00733811,BETA-THALASSEMIA|THALASSEMIA MAJOR,All,"13 Years to 60 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ao V. Cervello, Palermo, Italy",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cc1c(O)c(=O)ccn1C,1,DB08826,__DEFERIPRONE,7049328,Unknown status,NCT00103753,BETA-THALASSEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Ospedale Microcitemico, Via Jenner, Cagliari, Sardinia, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cc1c(O)c(=O)ccn1C,1,DB08826,__DEFERIPRONE,7049328,Enrolling by invitation,NCT02443545,IRON OVERLOAD|SICKLE CELL DISEASE|OTHER ANEMIAS,All,"3 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|The Children's Hospital of Philadephia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Hospital for Sick Kids, Toronto, Ontario, Canada|Zagazig University, Alexandria, Egypt|Ain Shams University, Cairo, Egypt|Cairo University, Cairo, Egypt|Pediatric Hospital of Cairo University, Cairo, Egypt|Asser Central Hospital, Abha, Saudi Arabia|Barts and The London, London, United Kingdom|Evelina Children's Hospital, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cc1c(O)c(=O)ccn1C,1,DB08826,__DEFERIPRONE,7049328,"Active, not recruiting",NCT03591575,BETA THALASSEMIA MAJOR ANEMIA|IRON OVERLOAD,All,6 Months to 9 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ain Shams University, Cairo, Egypt|Cairo University, Cairo, Egypt|Pediatric Hospital of Cairo University, Cairo, Egypt|Cipto Mangunkusumo National Hospital, Jakarta, Indonesia",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cc1c(O)c(=O)ccn1C,1,DB08826,__DEFERIPRONE,7049328,Completed,NCT00800761,IRON OVERLOAD|CARDIOMYOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Adult Talassemic Center, Ospedale Microcitemico, Cagliari, Sardinia, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Recruiting,NCT03707847,ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Withdrawn,NCT02487316,SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weiping Liu, Beijing, Beijing, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Recruiting,NCT03672643,ALK OR ROS1-POSITIVE NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fujian Province Oncology Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Nanjing Bayi Hospital of PLA, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Internal Department, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,1,DB08877,__RUXOLITINIB,7598257,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,1,DB08877,__RUXOLITINIB,7598257,Recruiting,NCT02386800,PRIMARY MYELOFIBROSIS|CHRONIC IDIOPATHIC MYELOFIBROSIS|POST POLYCYTHEMIA VERA MYELOFIBROSIS|POST ESSENTIAL THROMBOCYTHAEMIA MYELOFIBROSIS|STEROID REFRACTORY GRAFT VERSUS HOST DISEASE,All,"1 Month and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Cape Town, Western Province, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Bangkok, Bangkoknoi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",C07K5/0812,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07K5/0812,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0812,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,1,DB08911,__TRAMETINIB,7378423,Recruiting,NCT03975829,"DIFFUSE ASTROCYTOMA|ANAPLASTIC ASTROCYTOMA|ASTROCYTOMA|OLIGODENDROGLIOMA, CHILDHOOD|ANAPLASTIC OLIGODENDROGLIOMA|GLIOBLASTOMA|PILOCYTIC ASTROCYTOMA|GIANT CELL ASTROCYTOMA|PLEOMORPHIC XANTHOASTROCYTOMA|ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA|ANGIOCENTRIC GLIOMA|CHORDOID GLIOMA OF THIRD VENTRICLE|GANGLIOCYTOMA|GANGLIOGLIOMA|ANAPLASTIC GANGLIOGLIOMA|DYSPLASTIC GANGLIOCYTOMA OF CEREBRELLUM|DESMOPLASTIC INFANTILE ASTROCYTOMA AND GANGLIOGLIOMA|PAPILLARY GLIONEURONAL TUMOR|ROSETTE-FORMING GLIONEURONA TUMOR|CENTRAL NEUROCYTOMA|EXTRAVENTRICULAR NEUROCYTOMA|CEREBELLAR LIPONEUROCYTOMA|NEUROFIBROMATOSIS TYPE 1",All,"1 Year and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Childrens Hospital, Phoenix, Arizona, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Novartis Investigative Site, Rennes, Bretagne, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom",C07C275/50,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,1,DB08912,__DABRAFENIB,7994185,Recruiting,NCT03975829,"DIFFUSE ASTROCYTOMA|ANAPLASTIC ASTROCYTOMA|ASTROCYTOMA|OLIGODENDROGLIOMA, CHILDHOOD|ANAPLASTIC OLIGODENDROGLIOMA|GLIOBLASTOMA|PILOCYTIC ASTROCYTOMA|GIANT CELL ASTROCYTOMA|PLEOMORPHIC XANTHOASTROCYTOMA|ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA|ANGIOCENTRIC GLIOMA|CHORDOID GLIOMA OF THIRD VENTRICLE|GANGLIOCYTOMA|GANGLIOGLIOMA|ANAPLASTIC GANGLIOGLIOMA|DYSPLASTIC GANGLIOCYTOMA OF CEREBRELLUM|DESMOPLASTIC INFANTILE ASTROCYTOMA AND GANGLIOGLIOMA|PAPILLARY GLIONEURONAL TUMOR|ROSETTE-FORMING GLIONEURONA TUMOR|CENTRAL NEUROCYTOMA|EXTRAVENTRICULAR NEUROCYTOMA|CEREBELLAR LIPONEUROCYTOMA|NEUROFIBROMATOSIS TYPE 1",All,"1 Year and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Childrens Hospital, Phoenix, Arizona, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Novartis Investigative Site, Rennes, Bretagne, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Unknown status,NCT02625558,SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Terminated,NCT02717949,LIVER DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT03961828,BETA-THALASSEMIA|HEPATITIS C,All,"12 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pediatric Hematology Unit, Faculty of Medicine, Tanta University, Tanta, Gharbia Governorate, Egypt",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT03032666,THALASSEMIA|HEPATITIS C,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"American University of Beirut Medical Center, Beirut, Lebanon",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,,BETA-THALASSEMIA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,1,DB09027,__LEDIPASVIR,7964580,Completed,NCT03961828,BETA-THALASSEMIA|HEPATITIS C,All,"12 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pediatric Hematology Unit, Faculty of Medicine, Tanta University, Tanta, Gharbia Governorate, Egypt",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,17.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.98,888.9999,174.64,6.0,4.0,10.0,97.49,235.47,12.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Recruiting,NCT04042376,WALDENSTROM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First Hospital of Jilin University, Changchun, China|Peking Union Medical College Hospital, Dongcheng, China|Fujian Meidical University Union Hospital, Fuzhou, China|Guangdong Provincial People's Hospital, Guangzhou, China|First affiliated Hospital of Zhejiang University, Hangzhou, China|The People's Hospital of Jiangsu Province, Nanjing, China|Institute of Hematology & Blood Diseases Hospital, Tianjin, China|Wuhan Union Hospital, Wuhan, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Henan Cancer Hospital, Zhengzhou, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Enrolling by invitation,NCT03229200,"LYMPHOMA, B-CELL|LYMPHOMA, NON-HODGKIN|LEUKEMIA, B-CELL|GRAFT VS HOST DISEASE|SOLID TUMOR",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, United States|City Of Hope National Medical Center, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Medical Plaza II, 3991 Dutchmans Lane, Louisville, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|TRIO - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack UMC, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Northwell Health, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center, Columbus, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Texas Oncology, Tyler, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Northwest Cancer Specialists, Compass Oncology, Vancouver, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Concord Repatriation General Hospital - Haematology Clinical Trials, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent Hospital, Fitzroy, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|UZ Leuven, Leuven, Belgium|AZ Turnhout, Turnhout, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|QEII Health Science Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|University Hospital Hradec Kralove, Hradec Králové, Kralovehradecky Kraj, Czechia|Hematology and Oncology Masaryk University Hospital Brno, Brno, Czechia|University Hospital Pilsen, Pilsen, Czechia|Charles University Hospital, Prague, Prague, Czechia|IHK FNKV Praha, Praha, Czechia|CHU Hotel Dieu, Nantes, Loire Atlantique, France|Centre Henri Becquerel, Rouen Cedex, France|Centre Hospitalier Saint Brieuc, Saint-Brieuc, France|General Hospital of Athens ""Laiko"", Athens, Attica, Greece|Hadassah Medical Center, Jerusalem, Israel|Rabin Dedical Center, Petach Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Italy|Azienda Sanitaria Universitaria Integrata Udine, Udine, Italy|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital, Auckland, New Zealand|Szpital Specjalistyczny w Brzozowie, Oddział Hematologii Onkologicznej z Klinicznym Oddziałem Przeszczepiania Szpiku, Brzozów, Podkarpackie, Poland|Klinika Hematologii i Transplantologii, Gdańsk, Pomorskie, Poland|SPZOZ ZSM w Chorzowie, Chorzów, Silesia, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Łódź, Poland|Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Nizhegorodskaya, Russian Federation|SBI of Ryazan region ""Regional Clinical Hospital"", Ryazan', Ryazan Region, Russian Federation|Russian Scientific and Research Institute of Hematology and Transfusiology of Federal Medical Biological Agency, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|ICO - Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Sanata Creus i Sant Pau, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|University Hospital of Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sunderby hospital, Luleå, Norrbotten, Sweden|Södra Älvsborg Hospital Borås, Borås, Sweden|Karolinska University Hospital, Solna, Sweden|Pamukkale University Medical Faculty, Denizli, Pamukkale, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Gazi University, Ankara, Turkey|VKV American Hospital, Istanbul, Turkey|Dokuz Eylul University, İzmir, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Recruiting,NCT03190330,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL|LYMPHOMA, MANTLE-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Vedanta Institute of Medical Science, Ahmedabad, India|Avron Hospitals Pvt. Ltd, Ahmedabad, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India|Cytecare Hospitals Pvt. Ltd, Karnataka, India|Apollo Gleneagles Hospital, Kolkata, India|Tata Medical Center, Kolkata, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, India|Noble Hospital Pvt Ltd, Pune, India|Regional Cancer Centre, Thiruvananthapuram, India|Christian Medical College, Vellore, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,1,DB09075,__EDOXABAN,7365205,Completed,NCT03666650,BLOOD COAGULATION DISORDER,Male,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Turku University Hospital, Turku, Varsinais-Suomi, Finland",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1
O=C(OOC(=O)c1ccccc1)c1ccccc1,1,DB09096,__BENZOYL_PEROXIDE,7820186,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,94.096388016181,5475.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.75,242.2268,52.6,2.0,0.0,2.0,24.16,64.77,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
[Mg+2].[OH-].[OH-],1,DB09104,__MAGNESIUM_HYDROXIDE,5989588,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",A61K33/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,58.32,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)(O)CCS,1,DB09110,__COENZYME_M,,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,1,DB09110,__COENZYME_M,,Unknown Status,,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Suspended,NCT00593619,IRON DEFICIENCY ANEMIA|PERIOPERATIVE BLOOD CONSERVATION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","London Health Sciences Centre, London, Ontario, Canada",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT03317210,ANEMIA,Female,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A23L5/273,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Unknown status,NCT02707757,ANAEMIA|HAEMODIALYSIS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Imperial Renal and Transplant Centre, London, United Kingdom|Imperial NHS Healthcare Trust, London, United Kingdom",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT00660933,ANEMIA|PUERPERAL DISORDERS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Clínic of Barcelona, Barcelona, Spain",A23L5/273,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT02198495,ANEMIA OF CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Division of Nephrology and Dialysis, Vienna, Austria|Wiener Dialysezentrum GmbH, Vienna, Austria",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Unknown status,NCT01084122,HIP FRACTURE|SURGICAL INTERVENTION,All,65 Years and older   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Servicio de Cirugía Ortopédica y Traumatología. Hospital Clinic., Barcelona, Spain",A23L5/273,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT01227616,IRON DEFICIENCY ANEMIA TREATMENT|CHRONIC KIDNEY DISEASE(CKD),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pine Bluff, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Azusa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lynwood, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Paramount, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Gabriel, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Simi Valley, California, United States|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Whittier, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Middlebury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Framingham, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pontiac, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Roseville, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Farmington, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ridgewood, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bethlehem, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Edinburg, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Canada|For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Unknown status,NCT00199277,COLORECTAL NEOPLASM|IRON DEFICIENCY ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Comarcal Sant Jaume de Calella., Calella, Barcelona, Spain|Fundació Hospital Asil de Granollers, Granollers, Barcelona, Spain|Consorci Sanitari del Maresme, Mataró, Barcelona, Spain|Hospital Miguel Servet, Zaragoza, Spain",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Withdrawn,NCT01151592,IRON DEFICIENCY ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT04225728,CHRONIC HEART FAILURE (CHF)|IRON DEFICIENCY,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yaounde Central Hospital, Cardiology department, Yaoundé, Cameroon",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT00354692,"KIDNEY FAILURE, CHRONIC|ANEMIA, IRON-DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Glendale, California, United States|Shreveport, Louisiana, United States",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT02392910,IRON DEFICIENCY|HEART FAILURE|CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Aleman, Buenos Aires, Caba, Argentina",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT01067547,IRON DEFICIENCY|INFLAMMATORY BOWEL DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alberta, Edmonton, Alberta, Canada",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT00308490,ANEMIA IN CHRONIC RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Papageorgiou General Hospital, Thessaloniki, Greece",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Completed,NCT03658876,RENAL FAILURE CHRONIC|ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Unknown status,NCT00204256,"KIDNEY FAILURE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Muenster, Muenster, Westphalia, Germany",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,"Active, not recruiting",NCT03388385,RENAL ANEMIA|IRON TOXICITY|OXIDATIVE STRESS|ENDOTHELIAL DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Dr. Carol Davila"" Teaching Hospital of Nephrology, Bucharest, Romania",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Unknown status,NCT03305705,FATIGUE|IRON-DEFICIENCY,Female,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","University Hospital Zurich, Zürich, Switzerland",7,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Terminated,NCT03191201,"IRON-DEFICIENCY|IRON TOXICITY|GLUCOSE METABOLISM DISORDERS (INCLUDING DIABETES MELLITUS)|METABOLIC SIDE EFFECTS OF DRUGS|METABOLIC DISORDER, GLUCOSE|SAFETY ISSUES",Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Policlinique Médicale Universitaire, Lausanne, Vaud, Switzerland",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1.[Cl-],1,DB09241,__METHYLENE_BLUE,3933788,Recruiting,NCT03395223,ACQUIRED METHAEMOGLOBINAEMIA,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Lariboisière, Paris, France",C12P21/005,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,30.817881270662603,2914.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,319.85,19.37,3.0,0.0,3.0,33.1,86.98,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,NCT02092766,ANAEMIA,All,6 Months to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1,1,DB09282,__MOLSIDOMINE,4731241,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,12.222016879196598,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,242.235,77.91,5.0,0.0,2.0,23.94,76.99,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
O=S(=O)([O-])[O-].[Zn+2],1,DB09322,__ZINC_SULFATE,,Completed,NCT03117192,THALASSEMIA|SPLENECTOMY; STATUS|IMMUNOSUPPRESSION,All,"12 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,161.472,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Enrolling by invitation,NCT03584633,LYMPHEDEMA,Female,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Iowa, Iowa City, Iowa, United States",A61B5/0261,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CC(=O)[O-].[Na+],1,DB09395,__SODIUM_ACETATE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.2,82.0338,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=P([O-])(O)O.[Na+],1,DB09449,"__SODIUM_PHOSPHATE,_MONOBASIC",7084130,Completed,,SICKLE CELL DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,119.977,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Na+].[O-2].[O-2].[O-2],1,DB09517,__SODIUM_FERRIC_GLUCONATE_COMPLEX,,Completed,NCT00224055,"ANEMIA, IRON-DEFICIENCY|KIDNEY FAILURE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tucson, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|Hines, Illinois, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Birmingham, New York, United States|Bronx, New York, United States|Mineola, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Charlotte, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Fairfax, Virginia, United States|San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,2089.3089999999997,189.53,11.0,8.0,10.0,30.86,68.77,30.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Na+].[O-2].[O-2].[O-2],1,DB09517,__SODIUM_FERRIC_GLUCONATE_COMPLEX,,Completed,NCT00224003,ANEMIA,All,2 Years to 16 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Los Angeles, California, United States|San Diego, California, United States|Stanford, California, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|Kansas City, Missouri, United States|Bronx, New York, United States|Dallas, Texas, United States|Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,2089.3089999999997,189.53,11.0,8.0,10.0,30.86,68.77,30.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Na+].[O-2].[O-2].[O-2],1,DB09517,__SODIUM_FERRIC_GLUCONATE_COMPLEX,,Not yet recruiting,NCT04063033,HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,2089.3089999999997,189.53,11.0,8.0,10.0,30.86,68.77,30.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,1,DB09570,__IXAZOMIB,7442830,Recruiting,NCT04217967,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PekingUMCH, Beijing, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,1,DB09570,__IXAZOMIB,7442830,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
O=[N+]([O-])[O-].[Ag+],1,DB11080,__SILVER_NITRATE,,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.027999999999999997,169.8731,68.88,3.0,0.0,0.0,3.24,9.85,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,1,DB11089,__DOCUSATE,4156715,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/466,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.9716215938725,95.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,422.577,106.97,5.0,1.0,0.0,46.82,107.35,18.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,"Active, not recruiting",NCT03621553,SARCOIDOSIS|VITAMIN D INSUFFICIENCY,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Active Not Recruiting,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Terminated,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
NCC(=O)[O-].NCC(=O)[O-].[Fe+2],1,DB11210,__FERROUS_BISGLYCINATE,,"Active, not recruiting",NCT04017598,"ANEMIA, IRON DEFICIENCY|ANEMIA|INTESTINAL INFLAMMATION|INFLAMMATION|INTESTINE; COMPLAINTS",Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Prey Kuy, Srayov and Tboung Krapeu Health Centres, Kampong Thom, Cambodia",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,203.963,66.15,3.0,1.0,0.0,6.25,26.84,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB11256,__LEVOMEFOLIC_ACID,5798338,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,459.4558,198.48,12.0,7.0,3.0,46.56,126.68,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Unknown Status,,ORAL MUCOSITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=C(O)c1cc(O)c2c(c1)C(C1c3cc(C(=O)O)cc(O)c3C(=O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc31)c1cccc(OC3OC(CO)C(O)C(O)C3O)c1C2=O,1,DB11365,__SENNOSIDES,,Completed,,CONSTIPATION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.94,862.7460000000003,347.96,20.0,12.0,8.0,81.49,205.44,9.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,1,DB11376,__AZAPERONE,4508715,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,35.64754923099029,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.73,327.403,36.44,4.0,0.0,3.0,36.19,94.27,6.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1
CC(C)(O)C(Cl)(Cl)Cl,1,DB11386,__CHLOROBUTANOL,3975515,Completed,,ORAL MUCOSITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61Q19/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,22.5713053656132,797.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,177.45,20.23,1.0,1.0,0.0,14.75,37.27,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C,1,DB11574,__ELBASVIR,7973040,Completed,,RENAL FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.6,882.035,188.8,7.0,4.0,9.0,100.15,241.52,13.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,1
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,1,DB11575,__GRAZOPREVIR,7973040,Completed,,RENAL FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.26,766.903,195.22,10.0,3.0,7.0,79.37,193.61,7.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,1,DB11616,__PIRARUBICIN,4818818,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07H15/252,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,29.14228218238561,628.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,627.643,204.3,13.0,5.0,6.0,64.85,157.38,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB11636,__NOMEGESTROL,4544555,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,C07J7/0045,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,36.1403724922483,186.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,328.452,54.37,3.0,1.0,4.0,37.69,95.03,1.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,1,DB11793,__NIRAPARIB,8859562,Recruiting,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,1,DB11817,__BARICITINIB,8158616,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,1,DB11904,__FLUMATINIB,EP-1840122-A1,Not Yet Recruiting,,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,92.05938520298149,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,562.601,99.17,8.0,2.0,5.0,57.44,152.3,8.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,1,DB11995,__AVATROMBOPAG,7638536,Not Yet Recruiting,,IMMUNE THROMBOCYTOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,83.4514055730097,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.97,649.65,101.9,8.0,2.0,6.0,69.95,169.16,7.0,0.0,1.0,0.0,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,1,DB12130,__LORLATINIB,8680111,Not yet recruiting,NCT04362072,CARCINOMA|NON-SMALL-CELL LUNG,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Cancer & Blood Center, Llc, Athens, Georgia, United States|Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna, Lublin, Poland|Elkardia Lubelskie Centrum Kardiologii, Lublin, Poland|Centrum Medyczne Luxmed Sp. z o.o., Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Centrum Medyczne EVOMED, Szczecin, Poland|Dom Lekarski Centrum Medyczne Outlet Park, Szczecin, Poland|Dom Lekarski S.A., Szczecin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Tadeusza Sokolowskiego Pomorskiego UM, Szczecin, Poland|Hospital Teresa Herrera (C.H.U.A.C), A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain",C07D498/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,1,DB12160,__BUCILLAMINE,4241086,Unknown Status,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,14.6204234173186,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.52,223.31,66.4,3.0,4.0,0.0,22.09,54.7,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Completed,,"PERIPHERAL ARTERY DISEASE, PAD",,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Recruiting,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[O+][O-],1,DB12510,__OZONE,,Unknown Status,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,1,DB12808,__TRIFAROTENE,7807708,Enrolling by Invitation,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C233/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,39.360151132466704,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.12,459.586,70.0,5.0,2.0,4.0,53.11,136.98,8.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1c2ccccc2C(=O)C1c1ccc(F)cc1,1,DB13136,__FLUINDIONE,WO-2002062322-A2,Completed,NCT00966290,BLOOD COAGULATION DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Brest, France|Louis Pasteur Hospital, Dole, France|University Hospital, Lille, France|Dupuytren University Hospital, Limoges, France|Bellevue University Hospital, Saint-Etienne, France|University Hospital, Strasbourg, France|Rangueil University Hospital, Toulouse, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,32.7488,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.09,240.233,34.14,2.0,0.0,3.0,23.35,65.45,1.0,0.0,1.0,0.0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Enrolling by invitation,NCT03229954,POST GASTRECTOMY ANEMIA,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT03438227,IRON DEFICIENCY ANEMIA OF PREGNANCY|IRON MALABSORPTION,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indiana University School of Medicine, Indianapolis, Indiana, United States|Center for Outpatient Health, Washington University in St. Louis, Saint Louis, Missouri, United States",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT00224068,ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bakersfield, California, United States|Chula Vista, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Norwich, Connecticut, United States|Port St Lucie, Florida, United States|Zephyrhills, Florida, United States|Columbus, Georgia, United States|Coeur d'Alene, Idaho, United States|Hutchinson, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Southfield, Michigan, United States|St Joseph, Michigan, United States|Duluth, Minnesota, United States|Greenwood, Mississippi, United States|Cherry Hill, New Jersey, United States|Denville, New Jersey, United States|Manhasset, New York, United States|Bismarck, North Dakota, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Chester, Pennsylvania, United States|Columbia, South Carolina, United States|Laredo, Texas, United States|Richmond, Virginia, United States|Salem, Virginia, United States|Walla Walla, Washington, United States|Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT04435574,"ANEMIA, IRON DEFICIENCY",All,6 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Primary care center, Giza, Egypt",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Not yet recruiting,NCT04278651,"PREGNANCY RELATED|ANEMIA, IRON DEFICIENCY|ANEMIA OF PREGNANCY",Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Recruiting,NCT03359447,ANEMIA|IRON-DEFICIENCY,All,3 Months to 3 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri, La Plata, Buenos Aires, Argentina",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,"Active, not recruiting",NCT04017598,"ANEMIA, IRON DEFICIENCY|ANEMIA|INTESTINAL INFLAMMATION|INFLAMMATION|INTESTINE; COMPLAINTS",Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Prey Kuy, Srayov and Tboung Krapeu Health Centres, Kampong Thom, Cambodia",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT00224055,"ANEMIA, IRON-DEFICIENCY|KIDNEY FAILURE, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tucson, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|Hines, Illinois, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Birmingham, New York, United States|Bronx, New York, United States|Mineola, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Charlotte, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Fairfax, Virginia, United States|San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT01481766,NON-ANEMIC IRON DEFICIENCY,All,12 Months to 40 Months   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Michael's Hospital, Toronto, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT04267653,IRON DEFICIENCY ANEMIA TREATMENT,All,2 Years to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"AssuitU, Assiut, Egypt",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Recruiting,NCT03524651,IRON DEFICIENCY ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","General Hospital of Athens G. Gennimatas, Athens, Greece|Attikon University Hospital, Haidari/Athens, Greece|Amalia Fleming Prefecture General Hospital of Melissia, Melíssia, Greece",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Not yet recruiting,NCT04205266,"ANEMIA, IRON DEFICIENCY|HEAVY MENSTRUAL BLEEDING",Female,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,NCT02086968,IRON DEFICIENCY ANEMIA SECONDARY TO IBD OR GASTRIC BYPASS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Unknown status,NCT02086968,IRON DEFICIENCY ANEMIA (IDA) SECONDARY TO INFLAMMATORY BOWEL DISEASE (IBD) OR GASTRIC BYPASS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Terminated,NCT00830037,CHRONIC KIDNEY DISEASE|IRON-DEFICIENCY ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA Medical Center, Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Recruiting,NCT03991169,CHRONIC KIDNEY INSUFFICIENCY|CHRONIC KIDNEY DISEASES,All,"1 Year to 21 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,IRON DEFICIENCY ANEMIA OF PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=CC1=C(C)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C)c5CCC(=O)O)C(CCC(=O)O)=C4C)c(C)c3C=C.[Fe+3].[OH-],1,DB13387,__HEMATIN,,Completed,NCT02086838,TREATMENT OF IRON DEFICIENCY ANEMIA IN PREGNANCY,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maternity Hospital, Faculty of Madicine, AinShams University, Cairo, Egypt",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,633.506,126.16,8.0,2.0,5.0,65.11,165.03,8.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
[Fe+3].[OH-].[OH-].[OH-],1,DB13423,__FERRIC_HYDROXIDE,,Recruiting,NCT03748043,IRON-DEFICIENCY,All,3 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Valley University, Qinā, Egypt",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,106.866,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+3].[OH-].[OH-].[OH-],1,DB13423,__FERRIC_HYDROXIDE,,Recruiting,,IRON DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,106.866,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.[Al+3].[Al+3].[O-2].[O-2].[O-2],1,DB13654,__MONTMORILLONITE,,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.66,360.30699999999996,34.14,2.0,0.0,0.0,3.28,2.89,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,1,DB13679,__DEXCHLORPHENIRAMINE,4619934,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.6717797080022,310.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.74,274.79,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[68Ga+3],1,DB13925,__DOTATATE_GALLIUM_GA-68,9375498,Completed,,CARDIAC SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07B59/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,46.5882256309164,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.99,1500.54,505.95,24.0,14.0,6.0,144.31,397.34,26.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,NCT01651416,MALARIA|ANAEMIA,All,3 Months to 59 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ejisu-Juaben Municipality, Kumasi, Ashanti, Ghana",3,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,NCT02434952,"MALARIA, FALCIPARUM|G6PD DEFICIENCY",All,"1 Year and older   (Child, Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ratanakiri Provincial Hospital, Ratanakiri, Cambodia",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,,GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Recruiting,,HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB13981,__NOMEGESTROL_ACETATE,4544555,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,C07J7/0045,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,36.1403724922483,86.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.46,370.48900000000003,60.44,3.0,0.0,4.0,41.78,104.18,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
O=[N+]([O-])[O-],1,DB14049,__NITRATE,,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.84,62.0049,66.2,3.0,0.0,0.0,3.28,8.35,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,1,DB14104,__LINOLEIC_ACID,3932476,Completed,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C07C231/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Unknown status,NCT02585947,"NON-HODGKIN'S LYMPHOMA, BURKITT'S",All,"19 Years to 81 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National University, Seoul, Korea, Republic of",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)C1CC[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@]12C,1,DB14152,__GINSENOSIDES,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.39,444.744,40.46,2.0,2.0,4.0,55.91,135.64,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Fe+2],1,DB14488,__FERROUS_GLUCONATE,,Unknown status,NCT00248716,IRON DEFICIENCY|ANEMIA,All,9 Months to 18 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Primary Pediatric Care Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,446.139,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Fe+2],1,DB14488,__FERROUS_GLUCONATE,,Completed,NCT02271997,IRON DEFICIENCY,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OLVG West/ Sint Lucas Andreas Ziekenhuis, Amsterdam, Noord-Holland, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Rose Kruis Ziekenhuis, Beverwijk, Netherlands",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,446.139,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
O=C([O-])CCC(=O)[O-].[Fe+2],1,DB14489,__FERROUS_SUCCINATE,,Completed,NCT02631668,"ANEMIA, IRON-DEFICIENCY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hushan Hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,171.917,80.26,4.0,0.0,0.0,9.33,45.21,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Recruiting,NCT03188445,IRON DEFICIENCY ANEMIA OF PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Copenhagen, Copenhagen, Sjaeland, Denmark",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Completed,NCT02271997,IRON DEFICIENCY,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OLVG West/ Sint Lucas Andreas Ziekenhuis, Amsterdam, Noord-Holland, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Rose Kruis Ziekenhuis, Beverwijk, Netherlands",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Recruiting,NCT03830034,IRON DEFICIENCY ANEMIA,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Ain shams university maternity hospital, Cairo, Egypt",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Recruiting,NCT03295851,ANEMIA|MAJOR ABDOMINAL SURGERY|PRE-OPERATIVE,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Unknown status,NCT01975272,POSTOPERATIVE ANAEMIA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Maastricht University Medical Centre, Maastricht, Limburg, Netherlands|Orbis Medical Centre, Sittard, Limburg, Netherlands",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Completed,NCT01078818,ANAEMIA,All,"18 Years to 78 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario de Canarias, Tenerife, Santa Cruz de Tenerife, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,Unknown status,NCT02243735,ANEMIA|COLORECTAL CARCINOMA|SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medisch Centrum Alkmaar, Alkmaar, Netherlands|Flevoziekenhuis, Almere, Netherlands|Meander Ziekenhuis, Amersfoort, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands|Spaarne ziekenhuis, Amsterdam, Netherlands|VU medical center, Amsterdam, Netherlands|Amsterdam, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Albert Schweizer Ziekenhuis, Dordrecht, Netherlands|Tergooi ziekenhuis, Hilversum, Netherlands|Haga Ziekenhuis, The Hague, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])/C=C/C(=O)[O-].[Fe+2],1,DB14491,__FERROUS_FUMARATE,6667050,"Active, not recruiting",NCT01953107,OVARIAN CANCER|CERVICAL CANCER|UTERINE CANCER|ANEMIA,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Odette Cancer Centre, Toronto, Ontario, Canada",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,30.357912893488496,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.83,169.90099999999995,80.26,4.0,0.0,0.0,8.65,46.28,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Terminated,NCT03531437,CONTRACEPTION|HYPERCOAGULABILITY,Female,19 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,,,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14540,__HYDROCORTISONE_BUTYRATE,4137311,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,16.263167621511702,582.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,47.56,115.78,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,1,DB14541,__HYDROCORTISONE_CYPIONATE,4304765,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.53,486.649,100.9,5.0,2.0,5.0,54.76,132.33,7.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Unknown status,NCT03631862,NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Completed,NCT03376958,RELAPSED AND REFRACTORY|DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB14936,__MENAQUINONE_6,6190695,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,24.37832399022561,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.01,580.8821,34.14,2.0,0.0,2.0,74.54,193.11,17.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,1,DB14975,__VOXELOTOR,9018210,Not yet recruiting,NCT04400487,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,All,"12 Years to 55 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,27.95950635536661,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.02,337.379,77.24,5.0,1.0,3.0,35.37,106.25,6.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,1,DB14975,__VOXELOTOR,9018210,Not Yet Recruiting,,SICKLE CELL ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,27.95950635536661,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.02,337.379,77.24,5.0,1.0,3.0,35.37,106.25,6.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0
Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Fe+3],1,DB15598,__FERRIC_MALTOL,9248148,Terminated,NCT03774615,"HEART FAILURE, LEFT SIDED|ANEMIA, IRON DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie (HTTG), Hannover, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,80.6587404258814,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.62,431.154,49.36,3.0,0.0,3.0,11.25,44.27,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=S(=O)([O-])CCS.[Na+],1,,_MESNA,,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00526305,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Ntra. Sra. Sonsoles, Avila, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital vall d'Hebrón, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Hospital de Cruces, Bilbao, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Morales Meseguer, Murcia, Spain|Hospital General Universitario Morales Meseguer., Murcia, Spain|Hospital Santa María del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|H. Carlos Haya, Málaga, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital de Sagunto, Sagunto, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H.U. Virgen del Rocio, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital dr. Peset, Valencia, Spain|Hospital General Universitario, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT01995331,APLASTIC ANEMIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pediatrics,Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,1,,_VEDOTIN,,Completed,NCT01990534,HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Praha, Prague, Czechia|Brno, Czechia|Heidelberg, Baden Wuerttemberg, Germany|Koeln, Germany|Georgetown, Penang, Malaysia|Ampang, Selangor, Malaysia|Kuala Lumpur, Malaysia|Gdansk, Poland|Krakow, Poland|Warszawa, Poland|Pamplona, Navarra, Spain|Madrid, Spain|Bangkoknoi, Bangkok, Thailand|Patumwan, Bangkok, Thailand|Ratchathewi, Bangkok, Thailand|Izmir, Bornova, Turkey|Ankara, Turkey|Izmir, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,1,,_VEDOTIN,,"Active, not recruiting",NCT01909934,ANAPLASTIC LARGE-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio, Porto, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal|Policlinica de Diagnostic Rapid SA, Brasov, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania|ICO lHospitalet Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Ankara University Medical Faculty, Ankara, Turkey|Pamukkale Uni. Med. Fac., Denizli, Turkey|Istanbul Bilim University Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Faculty of Medicine, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|The Christie, Manchester, Greater Manchester, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Unknown status,NCT02585947,"NON-HODGKIN'S LYMPHOMA, BURKITT'S",All,"19 Years to 81 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National University, Seoul, Korea, Republic of",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT04056962,"TACROLIMUS, KAPOSIFORM HEMANGIOENDOTHELIOMA, TUFTED ANGIOMA",All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital of Sichuan University, Chengdu, Sichuan, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Unknown status,NCT03540472,PURE RED CELL APLASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT03918265,AUTOIMMUNE HEMOLYTIC ANEMIA|PURE RED CELL APLASIA|EVANS SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT04009525,THALASSEMIA MAJOR,All,"2 Years to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],1,,_INDOCYANINE_GREEN,3959455,Enrolling by invitation,NCT03584633,LYMPHEDEMA,Female,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Iowa, Iowa City, Iowa, United States",A61K51/0485,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO,1,,_ELTROMBOPAG_OLAMINE,,Completed,NCT01098487,"PURPURA, THROMBOCYTOPAENIC, IDIOPATHIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Caen cedex 9, France|GSK Investigational Site, Créteil, France|GSK Investigational Site, Pessac Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Shatin, New Territories, Hong Kong|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Vicenza, Veneto, Italy|GSK Investigational Site, Seongnam-si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, St Petersburg, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],1,,_FONDAPARINUX,,Withdrawn,NCT00603824,HEPARIN-INDUCED THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],1,,_FONDAPARINUX,,"Active, not recruiting",NCT01727401,MEDICAL PATIENT|THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Marcello Di Nisio, Chieti, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Enrolling by invitation,NCT03229954,POST GASTRECTOMY ANEMIA,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,"Active, not recruiting",NCT02905539,"ANEMIA, IRON-DEFICIENCY",Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Recruiting,NCT03188445,IRON DEFICIENCY ANEMIA OF PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Copenhagen, Copenhagen, Sjaeland, Denmark",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Recruiting,NCT04505514,POST PARTUM HEMORRHAGE|ANEMIA,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Petaling Jaya, Wilayah Persekutuan Kuala Lumpur, Malaysia",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Unknown status,NCT02999217,"ANEMIA, IRON-DEFICIENCY|INTRAVENOUS DRUG USAGE|COLORECTAL NEOPLASMS|COLORECTAL SURGERY",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anaesthesiology, Lithuanian University of Health Sciences, Kaunas, Lithuania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Unknown status,NCT01927328,ANEMIA|ESOPHAGEAL CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nottingham Univeristy Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Recruiting,NCT03466983,IBD,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pharmacosmos Investigational Site, Silkeborg, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ISOMALT,,Suspended,NCT02642562,HEART FAILURE|IRON DEFICIENCY|LEFT VENTRICULAR SYSTOLIC DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Monklands Hospital, Airdrie, United Kingdom|Antrim Area Hospital, Antrim, United Kingdom|Wansbeck General Hospital, Ashington, United Kingdom|University Hospital Ayr, Ayr, United Kingdom|Barnet Hospital, Barnet, United Kingdom|Basildon University Hospital, Basildon, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|Blackpool Hospital, Blackpool, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Princess of Wales Hospital, Bridgend, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Chesterfield Royal Hospital, Chesterfield, United Kingdom|St Richard's Hospital, Chichester, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Croydon University Hospital, Croydon, United Kingdom|County Durham and Darlington NHS Foundation Trust, Darlington, United Kingdom|Doncaster Royal Infirmary, Doncaster, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Ulster Hospital, Dundonald, United Kingdom|Eastbourne District General Hospital, Eastbourne, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Golden Jubilee National Hospital, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom|Wycombe General Hospital, High Wycombe, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|West Middlesex University Hospital, Isleworth, United Kingdom|University Hospital Crosshouse, Kilmarnock, United Kingdom|Kingston Hospital, Kingston upon Thames, United Kingdom|Victoria Hospital, Kirkcaldy, United Kingdom|Forth Valley Royal Hospital, Larbert, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, United Kingdom|Llandough Hospital, Llandough, United Kingdom|Royal Glamorgan Hospital, Llantrisant, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Hammersmith Hospital (Imperial College), London, United Kingdom|King's College Hospital, London, United Kingdom|North Middlesex University Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Royal Gwent Hospital, Newport, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|Royal Oldham Hospital, Oldham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Alexandra Hospital, Paisley, United Kingdom|Poole Hospital, Poole, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom|Salford Royal Hospital, Salford, United Kingdom|Salisbury District Hospital, Salisbury, United Kingdom|Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, United Kingdom|University Hospital Southampton, Southampton, United Kingdom|Southend University Hospital, Southend, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|City Hospitals Sunderland, Sunderland, United Kingdom|Morriston Hospital, Swansea, United Kingdom|Great Western Hospital, Swindon, United Kingdom|St George's Hospital, Tooting, United Kingdom|Torbay Hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Watford General Hospital, Watford, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINDESINE,4208414,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,13.1419536335448,1292.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINDESINE,4208414,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,13.1419536335448,1292.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT02005653,FILARIAL; INFESTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vector Control Research Centre, Pondicherry, India",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00989742,LYMPHANGIOLEIOMYOMATOSIS|TUBEROUS SCLEROSIS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Nottingham University Hospitals, Nottingham, United Kingdom",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,1,,_DIDANOSINE,,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,1,,_INDINAVIR_SULFATE,6248363,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",4,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O,1,,_ZICONOTIDE,,Withdrawn,NCT01992562,PAINFUL MYELOPATHY|PAINFUL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The Ohio State University Department of Neurology, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,1,1,0,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,1,,_MORPHINE_SULFATE,4083982,Completed,NCT02222246,SICKLE CELL DISEASE,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mount Sinai Hospital, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
Nc1cc[nH]c(=O)n1,1,,_CYTOSINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,1,,_GRANISETRON,4845092,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,17.478798332614602,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,1,,_LEUCOVORIN,4148999,"Active, not recruiting",NCT01271582,STAGE IV COLORECTAL CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Hwasun Hospital, Chŏnam, Hwasun-gun, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Nowon-Gu, Korea, Republic of|Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,1,,_OXYTOCIN,3943246,Withdrawn,NCT03361124,BLOOD LOSS ANEMIA|UTERINE ATONY WITH HEMORRHAGE,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,A61K38/095,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,1,,_OXYTOCIN,3943246,Completed,NCT02101567,BLEEDING|ANEMIA,Female,20 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nesreen Abdel Fattah Abdullah Shehata, Cairo, Egypt",A61K38/095,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,1,,_VINBLASTINE_SULFATE,4303584,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,19.975769522988106,398.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Unknown status,NCT02731378,CHEMOTHERAPY-INDUCED ANAEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai East Hospital Home Branch, Shanghai, Shanghai, China|Shanghai East Hospital South Branch, Shanghai, Shanghai, China|Shanghai First People's Hospital, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital Lingang Branch, Shanghai, Shanghai, China|The First Affiliated Hospital, The Second Military Medical University, Shanghai, Shanghai, China|Shanghai East Hospital Jian Branch, Jian, Zhejiang, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Suspended,NCT00593619,IRON DEFICIENCY ANEMIA|PERIOPERATIVE BLOOD CONSERVATION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","London Health Sciences Centre, London, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT02086838,TREATMENT OF IRON DEFICIENCY ANEMIA IN PREGNANCY,Female,20 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maternity Hospital, Faculty of Madicine, AinShams University, Cairo, Egypt",7,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT03438227,IRON DEFICIENCY ANEMIA OF PREGNANCY|IRON MALABSORPTION,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indiana University School of Medicine, Indianapolis, Indiana, United States|Center for Outpatient Health, Washington University in St. Louis, Saint Louis, Missouri, United States",7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,1,,_DOXORUBICIN_HYDROCHLORIDE,4003996,"Active, not recruiting",NCT02577783,MULTIPLE MYELOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,1,,_ETOPOSIDE_PHOSPHATE,,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@H]2CCCCO2)[C@H](C)O1,1,,_PIRARUBICIN,,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Withdrawn,NCT00475527,"ANEMIA, IRON-DEFICIENCY|HELICOBACTER PYLORI",All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Organization, Jerusalem, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT01822600,PEPTIC ULCER BLEEDING|HYPOALBUMINEMIA,All,"39 Years to 83 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cheng Kung University Hospital, Tainan, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Unknown status,NCT01795794,CDA TYPE I,All,"12 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Unknown status,NCT03631862,NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Completed,NCT03376958,RELAPSED AND REFRACTORY|DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
COc1cnnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,,_SULPHADOXINE,,Completed,NCT01651416,MALARIA|ANAEMIA,All,3 Months to 59 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ejisu-Juaben Municipality, Kumasi, Ashanti, Ghana",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,1
COc1cnnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,,_SULPHADOXINE,,Terminated,NCT00964691,MALARIA|MALARIA IN PREGNANCY,Female,"15 Years to 49 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Honiara City Council, Honiara, Solomon Islands",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,1
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Not yet recruiting,NCT03805607,CESAREAN SECTION COMPLICATIONS|POSTOPERATIVE PAIN|COAGULATION DEFECT; POSTPARTUM|NONSTEROIDALS (NSAIDS)TOXICITY|POSTPARTUM HEMORRHAGE,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",,4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,,_IMATINIB_MESYLATE,WO-2002018368-A1,Completed,NCT00845221,CHRONIC MYELOID LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"CHU Amiens, Amiens, France|Hôpital La Timone - CHU de Marseille, Marseille, France|Hôpital de Brabois - CHU de Nancy, Vendoeuvre les Nancy, France",A61P35/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,,_IMATINIB_MESYLATE,WO-2002018368-A1,Completed,NCT00171899,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Toronto, Canada",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,,_DESMOPRESSIN,4613500,Not yet recruiting,NCT04420585,"NOCTURNAL ENURESIS|ANEMIA, SICKLE CELL",All,"8 Years to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital at Montefiore, Bronx, New York, United States",A61K9/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,30.489332429824,674.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,,_DESMOPRESSIN,4613500,Unknown status,NCT03343418,C.SURGICAL PROCEDURE; CARDIAC|BLOOD COAGULATION DISORDERS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Incor - Heart Institute - University of Sao Paulo, Sao Paulo, Brazil",A61K9/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,30.489332429824,674.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,,_DESMOPRESSIN,4613500,Completed,NCT01994330,ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO SEVERE AORTIC STENOSIS|HEYE´S SYNDROME|SEVERE AORTIC STENOSIS,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Clínico Universidad Católica de Chile, Santiago, Region Metropolitana, Chile",A61K9/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,30.489332429824,674.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Completed,NCT03036059,LYMPHATIC FILARIASIS|HELMINTH INFECTION,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Noguchi Memorial Institute for Medical Research, Legon-Accra, Ghana",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Completed,NCT01593722,LOIASIS,All,20 Years to 60 Years   (Adult),NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Filariasis and other Tropical Diseases Research Center, Yaounde, Cameroon",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Completed,NCT03852303,EPILEPSY,All,"5 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Completed,NCT03052998,IVERMECTIN|ONCHOCERCIASIS|EPILEPSY,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CCC(C)CCCCC(=O)N(CS(=O)(=O)O)[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@@H](CN[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(=O)(=O)O)NC1=O)[C@@H](C)O,1,,_COLISTIMETHATE,,Completed,NCT02966457,HEMATOLOGICAL INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Republican Center of Hematology and Bone Marrow Transplantation, Minsk, Belarus",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,0
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,1,,_TEICOPLANIN,,Completed,NCT00454272,INFECTION|FEBRILE NEUTROPENIA,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi aventis administrative office, Istanbul, Turkey",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,1,,_VALGANCICLOVIR,,Withdrawn,NCT00361933,GIANT LYMPH NODE HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,1,,_VALGANCICLOVIR,,Completed,NCT01255644,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,1,,_FLUDARABINE_PHOSPHATE,4357324,Completed,NCT00220311,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
Nc1nc(O)c2ncn(COC(CO)CO)c2n1,1,,_GANCICLOVIR,,Recruiting,NCT03004261,CYTOMEGALOVIRUS INFECTIONS|HEMATOLOGICAL DISEASE,All,"14 Years to 60 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Jiao Tong University Affilated Shanghai General Hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Completed,NCT02213783,PATIENTS WITH FEBRILE NEUTROPENIA,All,"20 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand",C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Completed,NCT02149329,FEBRILE NEUTROPENIA|HEMATOLOGICAL MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU university medical center, Amsterdam, Netherlands|HAGA ziekenhuis, The Hague, Netherlands",C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00162955,NON-HODGKIN'S LYMPHOMA,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Graduate School of Medicine, Osaka City University, Osaka, Japan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Cc1occc(=O)c1O,1,,_MALTOL,3940499,Terminated,NCT03774615,"HEART FAILURE, LEFT SIDED|ANEMIA, IRON DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie (HTTG), Hannover, Germany",A23G4/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,17.183104375859802,881.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-],1,,_METHYLENE_BLUE,,Recruiting,NCT03395223,ACQUIRED METHAEMOGLOBINAEMIA,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Lariboisière, Paris, France",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_FENTANYL_CITRATE,4486423,Completed,NCT03682211,PAIN|SICKLE CELL DISEASE,All,"1 Year to 21 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_FENTANYL_CITRATE,4486423,Completed,NCT01482091,"ANEMIA, SICKLE CELL|PAIN",All,"3 Years to 21 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital at Montefiore, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+],1,,_CROMOLYN_SODIUM,4161516,Completed,NCT02371941,EOSINOPHILIC ESOPHAGITIS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LeBonheur Children's Hospital, Memphis, Tennessee, United States",A61K9/1688,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,30.0293640526499,1596.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,Unknown status,NCT01765231,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Cancer Hospital & Institute, Beijing, Beijing, China|307 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|309 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|Aerospace Central Hospital, Beijing, Beijing, China|Air Force General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|First Hospital affiliated to General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China|General Hospital of Chinese People's Liberation Army, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,Completed,NCT00926757,NON HODGKIN'S LYMPHOMA|HEPATITIS B,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
CC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO,1,,_CHONDROITIN_SULFATE,,Completed,NCT00298441,CHRONIC RENAL FAILURE|HEMODIALYSIS|RENAL ANEMIA|IRON DEFICIENCY ANEMIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Midorigaoka Clinic, Arao, Kumamoto, Japan|Kumamoto University Hospital, Kumamoto, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT01086878,"ACQUIRED IMMUNODEFICIENCY SYNDROME|INFANT, NEWBORN|ANEMIA|NEUTROPENIA|HIV INFECTIONS",All,"Child, Adult, Older Adult",Other|NIH|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Scottish Livingstone Hospital, Molepolole, Kweneng, Botswana|Princess Marina Hospital, Gaborone, Botswana",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,0,DB00080,__DAPTOMYCIN,6468967,Terminated,NCT01216241,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Rochester Medical Center, Rochester, New York, United States",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,0,DB00080,__DAPTOMYCIN,6468967,Withdrawn,NCT00296049,"INFECTION|NEUTROPENIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",A61K38/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
C[N+](C)(C)CCO,0,DB00122,__CHOLINE,,Terminated,NCT01009931,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0
N=C(N)NCCC[C@H](N)C(=O)O,0,DB00125,__ARGININE,4271152,Suspended,NCT02447874,SICKLE CELL DISEASE,All,"7 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Healthcare fo Atlanta at Hughes Spalding, Atlanta, Georgia, United States|Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States",C07K14/672,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,0,DB00125,__ARGININE,4271152,Terminated,NCT00917826,EBV LYMPHOMAS|LYMPHO-PROLIFERATIVE DISEASES,All,"3 Years and older   (Child, Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hackensack University Medical Center, Hackensack, New Jersey, United States",C07K14/672,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT02589145,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT00131508,"ANEMIA, SICKLE CELL",All,"5 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT01783522,CHEMOTHERAPEUTIC AGENT TOXICITY|MULTIPLE MYELOMA|PERIPHERAL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT00586209,SICKLE CELL ANEMIA|THALASSEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LA Biomed at Harbor-UCLA Medical Center, Torrance, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Withdrawn,NCT02114502,MYELOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Terminated,NCT00504205,"LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea, Scottsdale, Arizona, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Terminated,NCT02730195,"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE",All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
NC(=O)NCCC[C@H](N)C(=O)O,0,DB00155,__CITRULLINE,3950513,Withdrawn,NCT02659644,SICKLE CELL DISEASE,All,"10 Years to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Mississippi Medical Center, Jackson, Mississippi, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,78.7860120331013,1323.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,175.1857,118.44,4.0,4.0,0.0,17.35,41.33,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,0,DB00175,__PRAVASTATIN,5622985,Terminated,NCT01342887,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|RECURRENT ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,0,DB00175,__PRAVASTATIN,5622985,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,0,DB00175,__PRAVASTATIN,5622985,Withdrawn,NCT00305201,KAWASAKI DISEASE,All,"8 Years to 25 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pontificia Universidad Catolica de Chile, School of Medicine, Santiago, Región Metropolitana, Chile",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,0,DB00179,__MASOPROCOL,3995632,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",B01J4/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,26.2510523830058,271.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,302.3649,80.92,4.0,4.0,2.0,33.63,86.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,0,DB00196,__FLUCONAZOLE,4404216,Withdrawn,NCT02532192,LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,0,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00062231,"CHRONIC MYELOPROLIFERATIVE DISORDERS|FEVER, SWEATS, AND HOT FLASHES|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUTROPENIA|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,"Hopital Universitaire Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Institut Bergonie, Bordeaux, France|Institut Curie Hopital, Paris, France|Charite - Campus Charite Mitte, Berlin, Germany|Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Klinikum der Albert - Ludwigs - Universitaet Freiburg, Freiburg, Germany|Ruprecht - Karls - Universitaet Heidelberg, Heidelberg, Germany|Klinikum der Stadt Mannheim, Mannheim, Germany|Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt, Rostock, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Wolfson Medical Center, Holon, Israel|Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Universita Degli Studi di Udine, Udine, Italy|National Cancer Institute - Bratislava, Bratislava, Slovakia|St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Hopital D'Yverdon, Yverdon, Switzerland|Hacettepe University - Faculty of Medicine, Ankara, Turkey|Ibn-i Sina Hospital, Ankara, Turkey|Marmara University Hospital, Istanbul, Turkey",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,0,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00324324,BREAST CANCER|CHRONIC MYELOPROLIFERATIVE DISORDERS|GESTATIONAL TROPHOBLASTIC TUMOR|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUROBLASTOMA|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT02080416,NON-HODGKIN LYMPHOMA|HODGKIN LYMPHOMA|KAPOSI SARCOMA|GASTRIC CANCER|NASOPHARYNGEAL CANCER|EBV|CASTLEMAN DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT00385450,CARDIOPULMONARY BYPASS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Mayo Clinic, Rochester, Minnesota, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Withdrawn,NCT03422874,NEOPLASMS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Nc1ccc(O)c(C(=O)O)c1,0,DB00244,__MESALAZINE,5541170,Withdrawn,NCT00514982,HERMANSKI-PUDLAK SYNDROME|COLITIS|CYTOKINES|LYMPHOCYTES|DRUG EVALUATION,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",A61K9/2846,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,16.690281114601902,1899.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.75,153.1354,83.55,4.0,3.0,1.0,14.26,40.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,0,DB00252,__PHENYTOIN,3962430,Terminated,NCT00801931,LEUKEMIA|LYMPHOMA|NEUROBLASTOMA|IMMUNODEFICIENCIES|ANEMIA,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia Presbyterian Medical Center, New York, New York, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00281879,CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNUSUAL CANCERS OF CHILDHOOD,All,"up to 60 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00005987,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00632827,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University, Saint Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00482053,"LYMPHOMA, B-CELL|LYMPHOMA, NON-HODGKIN|DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)|MALIGNANT LYMPHOMA, NON-HODGKIN",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT02366663,RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01653418,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01500161,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|HODGKINS DISEASE|NON-HODGKINS LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELODYSPLASTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Oncology, Amarillo, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01220297,HEMATOLOGIC DISEASES|ACUTE-GRAFT-VERSUS-HOST DISEASE|LEUKEMIA|NON-HODGKIN LYMPHOMA (NHL)|HODGKIN LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00003567,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00003613,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA,All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT01769911,ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|AIDS-RELATED DIFFUSE LARGE CELL LYMPHOMA|AIDS-RELATED DIFFUSE MIXED CELL LYMPHOMA|AIDS-RELATED DIFFUSE SMALL CLEAVED CELL LYMPHOMA|AIDS-RELATED IMMUNOBLASTIC LARGE CELL LYMPHOMA|AIDS-RELATED LYMPHOBLASTIC LYMPHOMA|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|AIDS-RELATED SMALL NONCLEAVED CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|HEPATOSPLENIC T-CELL LYMPHOMA|HIV-ASSOCIATED HODGKIN LYMPHOMA|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I AIDS-RELATED LYMPHOMA|STAGE II AIDS-RELATED LYMPHOMA|STAGE III AIDS-RELATED LYMPHOMA|STAGE IV AIDS-RELATED LYMPHOMA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 66 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT03579927,CD19 POSITIVE|MANTLE CELL LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT FOLLICULAR LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY FOLLICULAR LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT02343666,HUMAN IMMUNODEFICIENCY VIRUS 1 POSITIVE|STAGE I ADULT HODGKIN LYMPHOMA|STAGE I ADULT NON-HODGKIN LYMPHOMA|STAGE II ADULT HODGKIN LYMPHOMA|STAGE II ADULT NON-HODGKIN LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT NON-HODGKIN LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT NON-HODGKIN LYMPHOMA,All,"18 Years to 66 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00135499,"LYMPHOMA, LARGE-CELL, DIFFUSE",All,"60 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT01659099,DIFFUSE LARGE B CELL LYMPHOMA CD20 POSITIVE,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|RHMS Baudour, Baudour, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Hôpital Erasme, Bruxelles, Belgium|Clinique universitaire Saint LUC, Bruxelles, Belgium|CHU de Charleroi, Charleroi, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Ch Jolimont, Haine Saint Paul, Belgium|AZ GROENINGE - Oncology Centre - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liège, Belgium|CHU de Liège - Clinique Saint Joseph, Liège, Belgium|CHU de Liège -Domaine Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Saint Joseph -Hôpital de Warquignies, Mons, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|Centre Hospitalier de Wallonie Picarde - CHwapi, Tournai, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CHU d'Amiens - Hôpital Sud, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|Hôpital de Bayonne - CHU de la Côte Basque, Bayonne, France|CH de Beauvais, Beauvais, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CH de Blois, Blois, France|APHP - Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH Dr Duchenne, Boulogne sur Mer, France|CH Fleyriat, Bourg en Bresse, France|CHU de Brest - Hôpital de Morvan, Brest, France|CH Brive la Gaillarde, Brive la Gaillarde, France|CHU de Caen, Caen, France|Centre François Baclesse, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau Le Lez, France|CH de Chambéry, Chambéry, France|CHU de Châlon sur Saône, Châlon sur Saône, France|APHP - Hôpital Antoine Béclère, Clamart, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU d'Estaing, Clermont Ferrand, France|Pôle Santé Publique, Clermont Ferrand, France|CH de Compiègne, Compiègne, France|CH Sud Francilien, Corbeil Essonnes, France|APHP - Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH de Dunkerque, Dunkerque, France|Institut Daniel Hollard, Grenoble, France|CHU de Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|CH La Rochelle, La Rochelle, France|APHP - Hôpital Bicêtre, Le Kremlin Bicêtre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CH de Lens, Lens, France|CH Saint Vincent de Paul, Lille, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Dupruytren - Limoges, Limoges, France|CH Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|CH Mantes La Jolie, Mantes La Jolie, France|Hôpital de la Conception, Marseille, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CH Marc Jacquet, Melun, France|Hôpital Notre Dame Bon Secours, Metz, France|CHI de Meulan, Meulan en Yvelines, France|CHU de Montpellier - Saint Eloi, Montpellier, France|Centre Val d'Aurélie - Paul Lamarque, Montpellier, France|Centre Auréen de Cancérologie, Mougins, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Centre Catherine de Sienne, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Clinique Valdegour, Nîmes, France|CHR d'Orléans, Orléans, France|APHP - Hôpital Saint Louis, Paris Cedex 10, France|APHP - Hôpital Saint Antoine, Paris Cedex 12, France|Institut Curie, Paris, France|APHP - Hôpital de la Pitié Salpetrière, Paris, France|Hôpital Cochin, Paris, France|APHP - Hôpital Necker, Paris, France|CH Saint Jean, Perpignan, France|CHU de Haut Lévèque, Pessac, France|Hospices Civils de Lyon - CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH d'Annecy, Pringy, France|CHU Robert Debré, Reims, France|Institut du Cancer de Courlancy, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Clinique Mathilde, Rouen, France|CH Yves Le Foll - St Brieuc, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|CHI de Poissy St Germain, Saint germain en laye, France|CHU de Saint Malo, Saint Malo, France|CH de Saint Quentin, Saint Quentin, France|Institut de Cancérologie, St Priest en Jarez, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Hopital Saint Husse, Toulon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU de Tours, Tours, France|CHU de Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CHU de Brabois, Vandœuvre-lès-Nancy, France|CH Bretagne Atlantique, Vannes, France|CH de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif, France",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,0,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Withdrawn,NCT01528865,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1,0,DB00362,__ANIDULAFUNGIN,5965525,Terminated,NCT00806351,FUNGEMIA|NEUTROPENIA|CANDIDIASIS,All,"16 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, GRENOBLE Cedex 09, France|Pfizer Investigational Site, Strasbourg Cedex, France|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Kosice, Slovakia",C07K7/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,52.633524302347,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1140.2369,377.42,17.0,14.0,7.0,122.78,292.29,14.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1,0,DB00362,__ANIDULAFUNGIN,5965525,Terminated,NCT01053884,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Elisabethinen hospital, Linz, Upper Austria, Austria",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,52.633524302347,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1140.2369,377.42,17.0,14.0,7.0,122.78,292.29,14.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00928200,RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA|ALLERGY TO PEG E.COLI ASPARAGINASE|ALLERGY TO NATIVE E.COLI ASPARAGINASE,All,"1 Year to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00165087,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Lewiston, Maine, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|McMaster University, Hamilton, Ontario, Canada|Laval University, Montreal, Quebec, Canada|Sainte Justine Hosptial, Montreal, Quebec, Canada|San Jorge Children's Hospital, Santurce, Puerto Rico",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,0,DB00390,__DIGOXIN,3933997,Terminated,NCT03113071,ACUTE MYELOID LEUKEMIA|MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Jeans Hospital, Philadelphia, Pennsylvania, United States",G01N31/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00687674,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT01159301,"ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00510289,"MYELODYSPLASTIC SYNDROMES|LEUKEMIA, MYELOMONOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT01510756,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSD Medical Center, La Jolla, California, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00303966,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,0,DB00434,__CYPROHEPTADINE,3968115,Terminated,NCT00949117,"LEUKEMIA|LYMPHOMA|MALNUTRITION|MYELODYSPLASTIC SYNDROMES|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC|WEIGHT CHANGES",All,2 Years to 17 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.719645167251905,797.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,287.3981,3.24,1.0,0.0,4.0,34.17,105.17,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,0,DB00434,__CYPROHEPTADINE,3968115,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.719645167251905,797.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,287.3981,3.24,1.0,0.0,4.0,34.17,105.17,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
Oc1ncnc2[nH]ncc12,0,DB00437,__ALLOPURINOL,8084483,Terminated,NCT00899431,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,0,DB00437,__ALLOPURINOL,8084483,Terminated,NCT01564277,ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|DE NOVO MYELODYSPLASTIC SYNDROMES|NONCONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|STAGE I ADULT BURKITT LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,0,DB00437,__ALLOPURINOL,8084483,Terminated,NCT00607152,HYPERURICEMIA,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Shanghai, China",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,0,DB00440,__TRIMETHOPRIM,5763449,Withdrawn,NCT01101412,"CHRONIC MYELOPROLIFERATIVE DISORDERS|INFECTION|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,0,DB00455,__LORATADINE,6132758,Terminated,NCT02392039,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,0,DB00482,__CELECOXIB,5972986,Terminated,NCT01143545,LUNG CANCER|ESOPHAGEAL CANCER|MALIGNANT PLEURAL MESOTHELIOMA|SARCOMA|THYMIC CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,0,DB00482,__CELECOXIB,5972986,Withdrawn,NCT00093678,"CACHEXIA|LYMPHOMA|MELANOMA (SKIN)|OVARIAN CANCER|PAIN|SARCOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,0,DB00497,__OXYCODONE,5508042,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,0,DB00503,__RITONAVIR,5541206,Withdrawn,NCT01165645,HODGKIN LYMPHOMA|STAGE I ADULT HODGKIN LYMPHOMA|STAGE II ADULT HODGKIN LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT01038856,POLYCYTHEMIA VERA,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Withdrawn,NCT00570375,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati, Cincinnati, Ohio, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Withdrawn,NCT02355431,SOLID TUMORS AND HEMATOLOGIC MALIGNANCY|NSCLC (NON-SMALL CELL LUNG CARCINOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ogden, Utah, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,0,DB00549,__ZAFIRLUKAST,4859692,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
CC(C)NCC(O)COc1cccc2ccccc12,0,DB00571,__PROPRANOLOL,6500454,Terminated,NCT02012777,SICKLE CELL DISEASE,All,10 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,DB00582,__VORICONAZOLE,5116844,Terminated,NCT03327727,INVASIVE ASPERGILLOSIS|INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States|Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|DMC Harper University Hospital, Detroit, Michigan, United States|University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Infectious Disease, Saint Louis, Missouri, United States|The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium|General Hospital Saint-Jan, Department of Hematology, Brugge, Belgium|Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium|UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir, Belgium|Hamilton Health Sciences, Infectious Disease Research, Hamilton, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Division of Infectios Diseases, Montréal, Quebec, Canada|Grenoble University Hospital Center, Department of Hematology, Grenoble, France|South Lyon Hospital Center, Pierre-Bénite, France|Hautepierre Hospital, Strasbourg, France|University Hospital Jena, Jena, Germany|Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich, Germany|Chonnam National University, Hwasun, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",C07D233/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,DB00582,__VORICONAZOLE,5116844,Terminated,NCT01148160,INVASIVE FUNGAL INFECTIONS,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",C07D233/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,0,DB00584,__ENALAPRIL,8568747,Terminated,NCT01096121,SICKLE CELL DISEASE,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Trousseau Hospital, Nephro-pediatric unit, Paris, France",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.7291936179387,1303.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.19,376.4467,95.94,5.0,2.0,2.0,40.41,99.57,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,0,DB00601,__LINEZOLID,5688792,Terminated,NCT02732327,NEOPLASMS|FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MD Anderson Cancer Center, Houston, Texas, United States",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
C[C@H](N)[C@H](O)c1cccc(O)c1,0,DB00610,__METARAMINOL,4275219,Withdrawn,,PREECLAMPSIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/63,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,20.961416045504,260.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.59,167.205,66.48,3.0,3.0,1.0,17.84,46.89,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Withdrawn,NCT02047552,FUNCTIONAL IRON DEFICIENCY|TRAUMA|ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Denver Health Medical Center, Denver, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01621477,"ACUTE LYMPHOBLASTIC LEUKEMIA|ACUTE MYELOCYTIC LEUKEMIA|CHRONIC MYELOCYTIC LEUKEMIA|JUVENILE MYELOMONOCYTIC LEUKEMIA|MYELODYSPLASTIC SYNDROME|HODGKIN OR NON-HODGKIN LYMPHOMA|SARCOMA, MYELOID",All,"up to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01629511,ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT|CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00814164,LEUKEMIA,All,"60 Years to 120 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00503880,MYELODYSPLASTIC SYNDROME,All,"19 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00593645,MYELODYSPLASTIC SYNDROMES|ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ravi Vij, M.D., St. Louis, Missouri, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01500161,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|HODGKINS DISEASE|NON-HODGKINS LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELODYSPLASTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Oncology, Amarillo, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT02518750,"ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN'S|LEUKEMIA, T-CELL|LEUKEMIA, B-CELL",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01158885,"MINIMAL RESIDUAL DISEASE|LEUKEMIA, LYMPHOBLASTIC, ACUTE|LEUKEMIA, MYELOGENOUS, ACUTE",All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Carolina-Levine Children's Hospital, Charlotte, North Carolina, United States|Seattle Children's Hospital, Seattle, Washington, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00852709,MYELODYSPLASTIC SYNDROME|ACUTE MYELOID LEUKEMIA|MYELOPROLIFERATIVE DISORDERS|ACUTE LYMPHOCYTIC LEUKEMIA|ACUTE PROMYELOCYTIC LEUKEMIA|ACUTE LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|MYELOFIBROSIS|CHRONIC MYELOMONOCYTIC LEUKEMIA|JUVENILE MYELOMONOCYTIC LEUKEMIA,All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Colorado Health Sciences Center and The Children's Hospital, Aurora, Colorado, United States|Pediatrix Hematology/Oncology University of Florida College of Medicine, Gainesville, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|M.D. Anderson Comprehensive Cancer Center, Houston, Texas, United States|Southern Alberta Children's Cancer Program, Calgary, Alberta, Canada",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT02349178,"LEUKEMIA, ACUTE LYMPHOBLASTIC|ACUTE MYELOID LEUKEMIA",All,"up to 39 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nationwide Children's Hospital, Columbus, Ohio, United States|American Family Children's Hospital, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01596699,MYELOID MALIGNANCY|BONE MARROW FAILURE SYNDROME|TRANSFUSION-DEPENDENT RED BLOOD CELL (RBC) DEFECT|CONGENITAL IMMUNODEFICIENCY|METABOLIC DISEASE|SEVERE IMMUNE DYSREGULATION,All,"3 Months to 30 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00708721,CANCER|CHRONIC MYELOMONOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00241371,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00617929,CANCER,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00691652,LYMPHOMA,All,"18 Years to 89 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00081887,CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00983528,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|UCSD Medical Center, San Diego, California, United States|Rady Children's Hospital, San Diego, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT01677949,ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT01796405,LANGERHANS CELL HISTIOCYTOSIS,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT00800566,LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Terminated,NCT01772719,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James Graham Brown Cancer Center, Louisville, Kentucky, United States",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Terminated,NCT00575965,WALDENSTROM'S MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Terminated,NCT00746603,CAROTID ARTERY DISEASE,All,18 Years to 35 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Columbia Univeristy Medical Center, New York, New York, United States",C07D205/08 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Withdrawn,NCT02971410,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Withdrawn,NCT01332617,MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00641,__SIMVASTATIN,RE42461,Withdrawn,NCT00503763,SMOLDERING MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00369629,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT01445392,MESOTHELIOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Withdrawn,NCT00712062,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,0,DB00678,__LOSARTAN,5210079,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,0,DB00695,__FUROSEMIDE,3939713,Withdrawn,NCT01705470,ANEMIA TREATMENT AMONG PATIENTS SUFFERING FROM LEFT VENTRICULAR SYSTOLIC DYSFUNCTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G01N30/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,0,DB00710,__IBANDRONATE,4927814,Terminated,NCT02739594,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ansbach, Germany|Aschaffenburg, Germany|Augsburg, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Duisburg, Germany|Duisburg, Germany|Erlangen, Germany|Essen, Germany|Esslingen, Germany|Frankfurt Am Main, Germany|Frankfurt Am Main, Germany|Greifswald, Germany|Göttingen, Germany|Güstrow, Germany|Gütersloh, Germany|Halle, Germany|Hamburg, Germany|Hamburg, Germany|Hamm, Germany|Hannover, Germany|Hannover, Germany|Herne, Germany|Hof, Germany|Jena, Germany|Karlsruhe, Germany|Kassel, Germany|Kassel, Germany|Koblenz, Germany|Krefeld, Germany|Köln, Germany|Köln, Germany|Leer, Germany|Leipzig, Germany|Ludwigshafen, Germany|Lübeck, Germany|Magedburg, Germany|Minden, Germany|Moers, Germany|Muenster, Germany|Mülheim, Germany|München, Germany|Neumünster, Germany|Offenbach, Germany|Offenburg, Germany|Oldenburg, Germany|Oldenburg, Germany|Stuttgart, Germany|Stuttgart, Germany|Tübingen, Germany|Weiden, Germany|Wiesbaden, Germany|Würzburg, Germany|Zwickau, Germany",C07F9/405,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,0,DB00717,__NORETHISTERONE,6036976,Terminated,NCT00580424,WOMEN'S HEALTH|BLOOD COAGULATION DISORDERS,Female,18 Years to 52 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Vermont, Burlington, Vermont, United States",A61K9/1647,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.905911825704802,1272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.72,298.4192,37.3,2.0,1.0,4.0,34.59,87.42,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
CC(C)Cn1cnc2c(N)nc3ccccc3c21,0,DB00724,__IMIQUIMOD,4689338,Terminated,NCT00596336,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Royal Bournemouth hospital, Bournemouth, Dorset, United Kingdom",C07D471/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,0,DB00736,__ESOMEPRAZOLE,5900424,Withdrawn,NCT00567658,LARYNX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,0,DB00738,__PENTAMIDINE,4399151,Suspended,NCT03730363,HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,27.170989137353892,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.32,340.4195,118.2,6.0,4.0,2.0,38.85,120.53,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC(c1cc2ccccc2s1)N(O)C(N)=O,0,DB00744,__ZILEUTON,4873259,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D307/81,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,20.961416045504,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,236.29,66.56,2.0,2.0,2.0,24.14,61.96,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0
CC(c1cc2ccccc2s1)N(O)C(N)=O,0,DB00744,__ZILEUTON,4873259,Terminated,NCT02047149,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",C07D307/81,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,20.961416045504,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,236.29,66.56,2.0,2.0,2.0,24.14,61.96,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0
C[C@](N)(Cc1ccc(O)cc1)C(=O)O,0,DB00765,__METYROSINE,4117161,Terminated,NCT01127503,VELO-CARDIO-FACIAL SYNDROME|PSYCHOSIS,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCFS International Center, Syracuse, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,16.3617322737633,105.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.9,195.2151,83.55,4.0,3.0,1.0,19.9,51.81,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB00806,__PENTOXIFYLLINE,4189469,Terminated,NCT01102218,END STAGE RENAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fresenius Medical Care North America, Chicago, Illinois, United States|Fresenius Medical Care North America, Kalamazoo, Michigan, United States|Fresenius Medical Care North America, Brookhaven, Mississippi, United States|Fresenius Medical Care North America, Tupelo, Mississippi, United States|Fresenius Medical Care North America, St. Ann, Missouri, United States|Fresenius Medical Care North America, St. Peters, Missouri, United States|Fresenius Medical Care North America, Las Vegas, Nevada, United States|Fresenius Medical Care North America, Columbia, Tennessee, United States|Fresenius Medical Care North America, Irving, Texas, United States|Fresenius Medical Care North America, Tyler, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,0,DB00820,__TADALAFIL,5859006,Terminated,NCT01374217,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,0,DB00820,__TADALAFIL,5859006,Withdrawn,NCT00538564,SICKLE CELL ANEMIA|PRIAPISM,Male,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Johns Hopkins Outpatient Center; Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",C07D471/14,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN(C)/N=N/c1[nH]cnc1C(N)=O,0,DB00851,__DACARBAZINE,4722834,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,22.965563974619602,1554.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.32,182.187,99.73,5.0,2.0,1.0,17.78,49.71,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00248534,LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00471653,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|THROMBOCYTOPENIA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Other|Time Perspective: Prospective,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00003567,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT02113007,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale School of Medicine, New Haven, Connecticut, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT01235793,B-CELL LYMPHOMA ORIGINATING IN THE CNS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cedars Sinai Medical Center, Los Angeles, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00005812,BRAIN TUMORS|CENTRAL NERVOUS SYSTEM TUMORS|LEPTOMENINGEAL METASTASES,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norris Cotton Cancer Center, Lebanon, New Hampshire, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,0,DB00863,__RANITIDINE,5098715,Terminated,NCT00527878,JOB'S SYNDROME|HYPER-IGE RECURRENT INFECTION SYNDROME|IMMUNE DEFICIENCY,All,"2 Years and older   (Child, Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",A61K9/2806,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,0,DB00863,__RANITIDINE,5098715,Terminated,NCT02999633,T-CELL TYPE ACUTE LEUKEMIA-PRECURSOR|T-LYMPHOBLASTIC LYMPHOMA/LEUKAEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400002, Atlanta, Georgia, United States|Investigational Site Number 8400003, Hackensack, New Jersey, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 2460001, Helsinki, Finland|Investigational Site Number 2500005, Nantes Cedex 01, France|Investigational Site Number 2500001, Paris Cedex 10, France|Investigational Site Number 2500004, Pessac, France|Investigational Site Number 2500002, Pierre Benite, France|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480002, Debrecen, Hungary|Investigational Site Number 3800001, Bergamo, Italy|Investigational Site Number 3800004, Brescia, Italy|Investigational Site Number 4400001, Vilnius, Lithuania|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation",A61K9/2806,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CN(CCCl)CCCl,0,DB00888,__MECHLORETHAMINE,7872050,Withdrawn,NCT03288818,MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,58.4159839011068,3535.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.31,156.054,3.24,1.0,0.0,0.0,15.84,38.67,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,0,DB00904,__ONDANSETRON,5344658,Withdrawn,NCT00499668,MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|NAUSEA AND VOMITING|SOLID TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC(COc1ccccc1)N(CCCl)Cc1ccccc1,0,DB00925,__PHENOXYBENZAMINE,4022893,Terminated,,CARDIOPULMONARY BYPASS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,27.4995379781925,540.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.26,303.82599999999996,12.47,2.0,0.0,2.0,34.09,88.92,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Withdrawn,NCT00378781,CANCER,All,"Child, Adult, Older Adult",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CC(C[N+](C)(C)C)OC(N)=O,0,DB01019,__BETHANECHOL,4474751,Terminated,NCT02058537,EOSINOPHILIC ESOPHAGITIS (EOE),All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.8,161.2221,52.32,1.0,1.0,0.0,17.73,54.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,0,DB01039,__FENOFIBRATE,5145684,Terminated,NCT01965834,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,0,DB01045,__RIFAMPICIN,3963705,Withdrawn,NCT01969682,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Site Reference ID/Investigator# 101416, Hackensack, New Jersey, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT03169790,NON HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,0,DB01118,__AMIODARONE,5134127,Terminated,NCT01511263,PRIMARY AMYLOIDOSIS OF LIGHT CHAIN TYPE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,645.3116,42.68,3.0,0.0,3.0,56.78,145.05,11.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,0,DB01124,__TOLBUTAMIDE,3977404,Terminated,NCT01185548,LYMPHOMA|ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Trent, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",A61F6/144,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,11.7620485020226,1153.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,270.348,75.27,3.0,2.0,1.0,29.1,70.27,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1
CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,0,DB01128,__BICALUTAMIDE,4636505,Terminated,NCT02582749,PROSTATE CANCER|BONE METASTASES|PROSTATE NEOPLASMS,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix, Arizona, United States|Illinois CancerCare, P. C., Peoria, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|University of Iowa Hopital and Clinics, Iowa City, Iowa, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Metro Health Cancer Center, Wyoming, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Integrated Medical Professionals, PLLC, Lake Success, New York, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States",C07D333/62,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,41.988541859175704,633.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.7,430.37300000000016,107.26,5.0,2.0,2.0,36.68,96.59,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,0,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT02730195,"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE",All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,0,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT03080480,CHRONIC GRANULOMATOUS DISEASE,All,"1 Month to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",C07D213/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,0,DB01136,__CARVEDILOL,6022562,Withdrawn,NCT01568645,PULMONARY HYPERTENSION,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,0,DB01137,__LEVOFLOXACIN,5053407,Terminated,NCT00250718,NON-HODGKIN'S LYMPHOMA|CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of New Mexico Cancer Center, Albuquerque, New Mexico, United States",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,0,DB01137,__LEVOFLOXACIN,5053407,Terminated,NCT03003273,"NEUTROPENIA, FEBRILE|PEDIATRIC CANCER",All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Oncology, AIIMS, New Delhi, India",C07D413/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CN(C)CCC=C1c2ccccc2COc2ccccc21,0,DB01142,__DOXEPIN,6211229,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
CNNCc1ccc(C(=O)NC(C)C)cc1,0,DB01168,__PROCARBAZINE,3993072,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",A61M31/002,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
CNNCc1ccc(C(=O)NC(C)C)cc1,0,DB01168,__PROCARBAZINE,3993072,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M31/002,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00227682,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00005786,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Medical Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT01397734,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00234000,LEUKEMIA|MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT01014546,ESSENTIAL THROMBOCYTHEMIA|POLYCYTHEMIA VERA|PRIMARY MYELOFIBROSIS,All,"19 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00590603,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00006220,LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"15 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Washington University Barnard Cancer Center, Saint Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00251511,MYELODYSPLASTIC SYNDROME,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Veeda Oncology, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00225992,MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Comprehensive Cancer Institute, Decatur, Alabama, United States|Comprehensive Cancer Institute, Huntsville, Alabama, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00104806,LEUKEMIA|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,All,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00006092,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00005595,LYMPHOMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Withdrawn,NCT00112879,STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Withdrawn,NCT01835288,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|RECURRENT ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Withdrawn,NCT00085345,STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Palo Verde Hematology Oncology, Glendale, Arizona, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Southbay Oncology / Hematology Medical Group, Campbell, California, United States|Fountain Valley, California, United States|Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States|Hematology Oncology Medical Group of Orange County, Incorporated, Orange, California, United States|Cancer Care Associates Medical Group - Redondo Beach, Redondo Beach, California, United States|Redwood Regional Oncology Center - Sotoyome, Santa Rosa, California, United States|Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital, Soquel, California, United States|San Diego Cancer Center - Vista, Vista, California, United States|Oncotherapeutics, West Hollywood, California, United States|Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center, Miami Beach, Florida, United States|Atlanta Cancer Care - Roswell, Roswell, Georgia, United States|Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Center for Cancer and Blood Disorders at Suburban Hospital, Bethesda, Maryland, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,0,DB01192,__OXYMORPHONE,5662933,Withdrawn,NCT01206907,CHRONIC PAIN,All,2 Years to 6 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,21.979917452103706,1154.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.26,301.3371,70.0,5.0,2.0,5.0,30.77,79.56,0.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC[C@@H](C(N)=O)N1CCCC1=O,0,DB01202,__LEVETIRACETAM,6471992,Terminated,NCT00489281,SICKLE CELL DISEASE,All,"2 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",A61K9/2072,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,56.2475615515718,30.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.64,170.21200000000005,63.4,2.0,1.0,1.0,17.79,44.08,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
O=NN(CCCl)C(=O)NC1CCCCC1,0,DB01206,__LOMUSTINE,4631289,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D233/91,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,42.9084786135238,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.62,233.695,61.77,2.0,1.0,1.0,23.61,58.65,4.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,0,DB01216,__FINASTERIDE,6046183,Withdrawn,NCT02548117,ERYTHROCYTOSIS,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,25.4296802809092,1662.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,372.5441,58.2,2.0,2.0,4.0,43.93,108.2,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Withdrawn,NCT00041171,ADULT SOLID TUMOR|BREAST CANCER|HEAD AND NECK CANCER|KIDNEY AND URINARY CANCER|MALE REPRODUCTIVE CANCER|THORAX AND RESPIRATORY CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00387426,"ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA|ACUTE UNDIFFERENTIATED LEUKEMIA|ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOMONOCYTIC LEUKEMIA|CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|MAST CELL LEUKEMIA|MENINGEAL CHRONIC MYELOGENOUS LEUKEMIA|PRIMARY MYELOFIBROSIS|PROGRESSIVE HAIRY CELL LEUKEMIA, INITIAL TREATMENT|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA|UNTREATED HAIRY CELL LEUKEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT02518750,"ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN'S|LEUKEMIA, T-CELL|LEUKEMIA, B-CELL",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00981799,RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA|RELAPSED T-CELL LYMPHOBLASTIC LYMPHOMA,All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Orange County, Orange, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|New York University Medical Center, New York, New York, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Rainbow Babies, Cleveland, Ohio, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Jude, Memphis, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Hospital, Fort Worth, Texas, United States|Primary Children's, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Melbourne, Victoria, Australia|Sydney Children's Hospital, Sydney, Australia|St. Anna Children's Hospital, Vienna, Austria|Hospital for Sick Kids, Toronto, Ontario, Canada|Sainte Justine University Hospital, Montreal, Quebec, Canada|British Columbia Children's Hospital, Vancouver, Canada|CHU Lille, Lille, France|Bambino Gesù Hospital, Rome, Italy|Erasmus MC - Sophia, Rotterdam, Netherlands",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00005982,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"16 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00005950,ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,0,DB01399,__SALSALATE,3954533,Terminated,NCT01506726,ANEMIA,All,65 Years and older   (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lakeview Medical Research, Summerfield, Florida, United States|St Joseph's/Candler Health System, Savannah, Georgia, United States|University of Illinois, Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Central Kentucky Research Associates, Lexington, Kentucky, United States|Johns Hopkins University Geriatrics Center, Baltimore, Maryland, United States|Case Western Reserve University Medical Center, Cleveland, Ohio, United States|Clinical Research Solutions, Columbia, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Clinical Research Solutions, Smyrna, Tennessee, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Institute for Advanced Studies in Aging (IASIA), Falls Church, Virginia, United States",C06B23/007,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.[Mg+2],0,DB01401,__CHOLINE_MAGNESIUM_TRISALICYLATE,,Terminated,NCT01009931,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,539.814,60.36,3.0,1.0,3.0,12.38,46.13,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,0,DB01406,__DANAZOL,4055562,Terminated,NCT01001598,FANCONI ANEMIA|DYSKERATOSIS CONGENITA,All,"3 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Boston, Boston, Massachusetts, United States",C07J71/0063,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,0,DB01406,__DANAZOL,4055562,Terminated,NCT00953771,THROMBOTIC THROMBOCYTOPENIC PURPURA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai St. Luke's-Roosevelt, New York, New York, United States",C07J71/0063,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,0,DB01607,__TICARCILLIN,4127649,Withdrawn,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,934.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.99,384.42699999999996,124.01,6.0,3.0,3.0,36.14,87.93,5.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,DB02424,__GELDANAMYCIN,4261989,Terminated,,"MALIGNANCIES, HEMATOLOGIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D225/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,15.3432308671635,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,560.6359,163.48,8.0,3.0,2.0,58.64,152.68,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT02419755,MIXED LINEAGE ACUTE LEUKEMIA|ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOID LEUKEMIA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01116154,ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTROM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00972842,PERIPHERAL T-CELL NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|Krankenhaus der Stadt Linz, Linz, Austria|Universitaetsklinik f. Innere Medizin III, Salzburg, Austria|Hanusch Krankenhaus, Vienna, Austria",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT02589145,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00882206,LEUKEMIA|LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00744354,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Medical Center, New York, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01483690,ACUTE LYMPHOBLASTIC LEUKEMIA|PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA|PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA,All,"1 Year to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|CHOC, Orange, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota Children's Hospital, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|New York University Medical Center, New York, New York, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude, Memphis, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Medical Center, Forth Worth, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Royal Children's Hospital, Brisbane, Queensland, Australia|Sydney Children's Hospital, Sydney, Australia|Children's Hospital at Westmead, Westmead, NSW, Australia",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01312818,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"2 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University if Minnesota, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01578343,MANTLE CELL LYMPHOMA,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00785798,RELAPSED LYMPHOMAS|REFRACTORY LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University School of Medicine, New Haven, Connecticut, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01187446,CUTANEOUS LYMPHOMA|CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00109109,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00486720,MYELODYSPLASTIC SYNDROMES|BLOOD DISEASE|BONE MARROW DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00673153,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01748240,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU d'Angers, Angers, France|CH Annecy, Annecy, France|Hôpital Avignon, Avignon, France|Centre hospitalier de la côte Basque, Bayonne, France|Hôpital Avicenne, Bobigny, France|CHU de Grenoble, Grenoble, France|CH Le mans, Le mans, France|CH Lyon Sud, Lyon, France|IPC-Unité d'Hématologie 3, Marseille, France|CHU Nantes, Nantes, France|Hôpital Archet1, Nice, France|GHU Caremeau, Nimes, France|Hôpital Saint Louis, Paris, France|Hopital Saint Louis - AP-HP, Hematology Dpt, Paris, France|Hôpital Saint-Louis, Paris, France|Hopital Cochin-Hematology, Paris, France|Centre Hospitalier Joffre, Perpignan, France|CHU de Haut-Lévèque, Pessac, France|Centre Henri Becquerel, Rouen, France|Hopital Purpan-Medecine interne, Toulouse, France|Hôpital PURPAN, Service d'Hématologie Clinique, Toulouse, France|CHU Bretonneau, Tours, France|CH de Valence, Valence, France|CHU Brabois, Vandœuvre-lès-Nancy, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01000155,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00818649,LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01500538,FOLLICULAR LYMPHOMA|MARGINAL ZONE LYMPHOMA|MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00958074,CUTANEOUS T-CELL LYMPHOMA STAGE I|CUTANEOUS T-CELL LYMPHOMA STAGE II|CUTANEOUS T-CELL LYMPHOMA STAGE III|CUTANEOUS T-CELL LYMPHOMA STAGE IV,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Withdrawn,NCT00837174,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,0,DB02901,__STANOLONE,4071623,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,20.5014476683299,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,290.4403,37.3,2.0,1.0,4.0,34.69,83.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC(=O)O,0,DB03166,__ACETIC_ACID,,Terminated,NCT01003769,RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Florida, Jacksonville, Florida, United States|Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,60.052,37.3,2.0,1.0,0.0,5.34,12.64,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00070239,"HEMATOPOIETIC/LYMPHOID CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT01076556,CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00112723,ADULT LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA|ADULT LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA|ADULT MIXED CELLULARITY HODGKIN LYMPHOMA|ADULT NODULAR SCLEROSIS HODGKIN LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY MULTIPLE MYELOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00101231,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA,All,"1 Year and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00377104,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA|NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00098371,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CC1=C(N2CC2)C(=O)C(CO)=C(N2CC2)C1=O,0,DB04090,__RH-1,6156744,Terminated,NCT00558727,ADVANCED SOLID TUMORS|NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Health Science Center, Aurora, Colorado, United States|Hudson-Webber Cancer Research Center, Detroit, Michigan, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States",C07D203/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,18.431589971046602,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.22,234.2512,60.39,5.0,1.0,3.0,23.64,64.97,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O[As](O)O,0,DB04456,__ARSENOUS_ACID,,Terminated,,ESSENTIAL THROMBOCYTHEMIA (ET),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.86,125.9436,60.69,3.0,3.0,0.0,6.27,7.69,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Oc1c(I)cc(Cl)c2cccnc12,0,DB04815,__CLIOQUINOL,4485091,Terminated,NCT00963495,"ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|MYELODYSPLASIA|LYMPHOMA, NON-HODGKIN|HODGKIN'S LYMPHOMA|MULTIPLE MYELOMA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Princess Margaret Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,28.5508942688761,484.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.66,305.5,33.12,2.0,1.0,2.0,22.63,60.13,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,0,DB04835,__MARAVIROC,6586430,Terminated,NCT02134717,SARCOIDOSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4,0,DB04865,__OMACETAXINE_MEPESUCCINATE,6987103,Terminated,NCT02029417,ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA FOLLOWING MYELODYSPLASTIC SYNDROME|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|SECONDARY ACUTE MYELOID LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,65 Years and older   (Older Adult),Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,33.7419659541263,2.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,545.6213,123.99,8.0,2.0,5.0,57.62,142.07,11.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,0
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4,0,DB04865,__OMACETAXINE_MEPESUCCINATE,6987103,Terminated,NCT02078960,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Teva Investigational Site 12545, Jacksonville, Florida, United States|Teva Investigational Site 12550, Atlanta, Georgia, United States|Teva Investigational Site 12543, Indianapolis, Indiana, United States|Teva Investigational Site 12547, Buffalo, New York, United States|Teva Investigational Site 12546, Cincinnati, Ohio, United States|Teva Investigational Site 12544, Houston, Texas, United States|Teva Investigational Site 37048, Gent, Belgium|Teva Investigational Site 37047, Leuven, Belgium|Teva Investigational Site 35157, Pierre Benite Cedex, France|Teva Investigational Site 87026, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,33.7419659541263,2.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,545.6213,123.99,8.0,2.0,5.0,57.62,142.07,11.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,0
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1,0,DB04918,__CEFTOBIPROLE,5981519,Terminated,NCT00529282,FEVER|NEUTROPENIA|GRAM-POSITIVE BACTERIAL INFECTIONS|PSEUDOMONAS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07F9/572,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,65.0,23.0312737427873,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,534.57,203.44,11.0,5.0,5.0,51.22,131.04,6.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,0,DB04960,__TIPIFARNIB,6545020,Terminated,NCT00243035,REFRACTORY MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",A61K41/0038,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,0,DB04960,__TIPIFARNIB,6545020,Terminated,NCT02779777,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States",A61K41/0038,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,0,DB04960,__TIPIFARNIB,6545020,Terminated,NCT00360776,STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",A61K41/0038,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Terminated,NCT03699475,ACUTE MYELOID LEUKEMIA|MYELODYSPLASTIC SYNDROMES,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TriStar Bone Marrow Transplant, LLC, Nashville, Tennessee, United States|Methodist Healthcare System of San Antonio Clinical Trials Office, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Withdrawn,NCT02786485,LEUKEMIA|MYELODYSPLASTIC SYNDROMES|LYMPHOMAS|MULTIPLE MYELOMA|OTHER HIGH-RISK HEMATOLOGICAL MALIGNANCIES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Withdrawn,NCT03807063,"ACUTE BILINEAL LEUKEMIA|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE|MYELOPROLIFERATIVE NEOPLASM|RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA|RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ACUTE MYELOID LEUKEMIA|RECURRENT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA|RECURRENT MYELODYSPLASTIC SYNDROME",All,"12 Months and older   (Child, Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,NCT03117361,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHRU de Lille - Hôpital Claude Huriez, Lille, France|Institut Gustave Roussy, Villejuif, France|Policlinico Vittorio Emanuele Hospital, Catania, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Institut Català d´Oncologia Girona, Girona, Spain|Institut Català d´Oncologia L´Hospitalet, Hospitalet de Llobregat, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Complejo Hospitalario Regional Virgen Del Rocio, Sevilla, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,NCT03070964,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University Medical School, Chicago, Illinois, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Faculty Hospital Ostrava, Ostrava, Czechia|Fakultni Nemocnice Praha, Praha, Czechia|Ospedale Clinico Aviano, Aviano, Pordenone, Italy|Instituto di Ematologia ""Seragnoli"", Bologna, Italy|Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Centro Oncológico MD Anderson International España, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Virgen del Rocío, Sevilla, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)OC3CC(n4cnc5c(O)nc(=N)[nH]c54)OC3CO)O2)c(=O)nc1O,0,DB04998,__AGRO100,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-6.3,8272.338,3617.47,190.0,87.0,69.0,735.41,1931.71,152.0,1.0,0.0,0.0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT02679131,RELAPSED/REFRACTORY SOLID TUMORS/HEMATOLOGICAL MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Innovative Clinical Research Institute, Whittier, California, United States|Gabrail Cancer Center Research, Canton, Ohio, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT02381548,"ACUTE MYELOID LEUKEMIA|BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|MYELODYSPLASTIC SYNDROME|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|REFRACTORY ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|SECONDARY ACUTE MYELOID LEUKEMIA|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT00274651,CUTANEOUS T-CELL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Leland Stanford Junior University, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Kansas City Cancer Center, Lenexa, Kansas, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|NYU Medical Center, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Hopitaux du Haut Leveque, Pessac, France|Hospital Purpan, Toulouse, France|Universitatsklinikum Essen, Essen, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, Thailand",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Withdrawn,NCT02701673,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Withdrawn,NCT02875002,RELAPSED AND REFRACTORY AGGRESSIVE B- AND T-CELL LYMPHOMAS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States|Massey Cancer Center, Richmond, Virginia, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,0,DB05016,__ATALUREN,US-20040204461-A1,Terminated,NCT00947193,HEMOPHILIA A|HEMOPHILIA B,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|New England Hemophilia Center, Worcester, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt Hemostatis and Thrombosis Clinic, Nashville, Tennessee, United States|Puget Sound Blood Center, Seattle, Washington, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|Hôpital Cardiologique, Lille Cedex, France|Hôpital Edouard Herriot, Lyon Cedex, France|Hôpital Necker Enfants Malades, Paris, France|Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni, Firenze, Italy|A.Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,21.7499332635167,46.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.96,284.242,76.22,4.0,1.0,3.0,27.66,94.66,3.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,0,DB05076,__FENRETINIDE,4190594,Terminated,NCT00288067,ADULT NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA|B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|CONTIGUOUS STAGE II ADULT LYMPHOBLASTIC LYMPHOMA|CONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA|CONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA|CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|STAGE II MARGINAL ZONE LYMPHOMA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT LYMPHOBLASTIC LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I ADULT BURKITT LYMPHOMA|STAGE I ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE I ADULT HODGKIN LYMPHOMA|STAGE I ADULT LYMPHOBLASTIC LYMPHOMA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I GRADE 1 FOLLICULAR LYMPHOMA|STAGE I GRADE 2 FOLLICULAR LYMPHOMA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II ADULT HODGKIN LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Medical Center, Seattle, Washington, United States",C07D213/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,DB05109,__TRABECTEDIN,8895557,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00096005,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00103272,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00019708,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NON-HODGKIN LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00098488,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT02700022,DIFFUSE LARGE B-CELL LYMPHOMA|FOLLICULAR LYMPHOMA|BURKITT LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT01812005,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University, Atlanta, Georgia, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,0,DB05239,__COBIMETINIB,7803839,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,0,DB05255,__RONACALERET,7514473,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C217/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,64.3955728043697,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,447.523,78.79,5.0,3.0,3.0,47.78,118.36,11.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,0,DB05294,__VANDETANIB,RE42353,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Lu+3],0,DB05296,__MOTEXAFIN_LUTETIUM,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,1166.136,178.75,15.0,2.0,5.0,106.08,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Ga+3],0,DB05420,__GALLIUM_MALTOLATE,,Terminated,NCT00050687,PROSTATIC NEOPLASMS|MULTIPLE MYELOMA|BLADDER NEOPLASMS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, PA, Springdale, Arkansas, United States|California Cancer Care, Greenbrae, California, United States|Stanford University, Palo Alto, California, United States|Southfield Oncology Institute, Southfield, Michigan, United States|New York Presbyterian Hospital, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,445.032,49.36,3.0,0.0,3.0,11.26,44.27,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00100711,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|The Mayo Clinic, Rochester, Minnesota, United States|The Ohio State University, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00076401,"LEUKEMIA|LEUKEMIA, LYMPHOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00089284,NON-HODGKIN'S LYMPHOMA (NHL),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Jesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,0,DB05460,__EZATIOSTAT,,Terminated,NCT00909584,SEVERE CHRONIC NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.39,529.648,136.82,5.0,3.0,2.0,57.5,141.82,17.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,0,DB05460,__EZATIOSTAT,,Terminated,NCT01459159,MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bay Area Cancer Research Group, Concord, California, United States|University of Colorado, Aurora, Colorado, United States|SIU School of Medicine, Simmons Cancer Institute, Springfield, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Columbia University, New York, New York, United States|The West Clinic, Memphis, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.39,529.648,136.82,5.0,3.0,2.0,57.5,141.82,17.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,0,DB05460,__EZATIOSTAT,,Terminated,NCT00701870,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Central Hematology Oncology Medical Group, Alhambra, California, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|UCLA Medical Center, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Samsum Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Ormand Beach, Florida, United States|Suburban Hematology-Oncology Associates, PC, Lawrenceville, Georgia, United States|Medical & Surgical Specialists, Galesburg, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Case Medical Center-University Hospitals, Cleveland, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.39,529.648,136.82,5.0,3.0,2.0,57.5,141.82,17.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CS(=O)(=O)O.O=c1[nH]c2c(c3ccccc13)Cc1cc(S(=O)(=O)NCCCN3CCOCC3)ccc1-2,0,DB05549,__INO-1001,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.22,535.63,87.74,5.0,2.0,5.0,47.65,121.05,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
O.O.O.O.O.O.O.O.O.O=C([O-])[C@@H]1O[Sb]2([O-])(O[Sb]34(O)O[C@H]([C@H](C(=O)[O-])O3)[C@@H]([C@H](O)CO)O4)O[C@H]1[C@@H]([C@H](O)CO)O2.[Na+].[Na+].[Na+],0,DB05630,__SODIUM_STIBOGLUCONATE,,Terminated,NCT01009502,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Jesse Brown VHA Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.4,907.88,269.08,17.0,5.0,4.0,39.78,96.29,8.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1
O.O.O.O.O.O.O.O.O.O=C([O-])[C@@H]1O[Sb]2([O-])(O[Sb]34(O)O[C@H]([C@H](C(=O)[O-])O3)[C@@H]([C@H](O)CO)O4)O[C@H]1[C@@H]([C@H](O)CO)O2.[Na+].[Na+].[Na+],0,DB05630,__SODIUM_STIBOGLUCONATE,,Terminated,NCT00311558,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.4,907.88,269.08,17.0,5.0,4.0,39.78,96.29,8.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1
CNC(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O,0,DB05817,__LAROMUSTINE,7605137,Terminated,NCT00655395,ACUTE MYELOID LEUKEMIA (AML)|MYELODYSPLASTIC SYNDROME (MDS),All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,54.8676564200496,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.01,307.775,103.86,5.0,1.0,0.0,26.65,61.91,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2,0,DB05864,__PPI-2458,,Terminated,NCT00100347,"NON-HODGKIN'S LYMPHOMA,|SOLID TUMORS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universtiy of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of New Mexico, Albuquerque, New Mexico, United States|Columbia University Medical Center, New York, New York, United States|University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.07,424.531,115.71,5.0,2.0,3.0,46.28,110.43,9.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Withdrawn,NCT01680796,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,0,DB05943,__RESATORVID,US-20110184034-A1,Terminated,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,361.81,72.47,3.0,1.0,2.0,33.37,85.5,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,0,DB06070,__SNX-5422,7358370,Terminated,NCT02973399,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States|Wexner Medical Center, Ohio State University, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,25.561099817244703,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,521.5409999999998,142.33,6.0,3.0,4.0,51.66,131.81,8.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,0,DB06174,__NOSCAPINE,4029797,Terminated,NCT00912899,REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States|St. Vincent's Comprehensive Cancer Center, New York City, New York, United States|Weill Medical College of Cornell University, New York City, New York, United States|Columbia Presbyterian Hospital, New York City, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,47.8038563420193,253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,413.4205,75.69,7.0,0.0,5.0,42.19,107.08,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,0,DB06174,__NOSCAPINE,4029797,Terminated,NCT00183950,NON-HODGKIN'S LYMPHOMA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,47.8038563420193,253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,413.4205,75.69,7.0,0.0,5.0,42.19,107.08,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01445340,MYCOSIS FUNGOIDES|CUTANEOUS T-CELL LYMPHOMA|NEOPLASMS,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01738594,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IVA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IVB MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01742793,HODGKIN'S LYMPHOMA|MATURE T-CELL LYMPHOMA|MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01979276,MULTIPLE MYELOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00079443,RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT02061449,CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute, New York, New York, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00383565,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT02281279,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT03355768,"LYMPHOMA, T-CELL, PERIPHERAL",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C291/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,NCT00458744,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"1 Year to 21 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,A61K39/395,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O,0,DB06179,__DARINAPARSIN,,Withdrawn,NCT01139359,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,411.3,158.82,7.0,5.0,0.0,36.38,79.89,11.0,0.0,1.0,0.0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00646165,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Clinic I Provincial, Barcelona, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00742495,RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA|B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA|T-CELL NON-HODGKIN'S LYMPHOMA,All,"2 Years to 18 Years   (Child, Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vienna, Austria|Prague, Czech Republic|Prof Gerard Michel, Marseilles, France|Charite Universitymedicine, Berlin, Germany|Dr Giovanna Gioriani, Pavia, Italy|Sally Kinsey, Leeds, United Kingdom",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00419081,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Medical Center, Chicago, Illinois, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|New York Medical College Division of Oncology, Valhalla, New York, United States|Liberty Hematology and Oncology, Columbia, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,0,DB06188,__ISPINESIB,US-20100063073-A1,Terminated,NCT00101244,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",A61P29/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,45.996837717406905,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,517.07,79.0,4.0,1.0,4.0,56.32,151.42,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Terminated,NCT00577161,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Ventura County Hematology Oncology Specialist, Oxnard, California, United States|Capitol Comprehensive Cancer Care, Jefferson City, Missouri, United States|Heartland Hematology Oncology Associates, Kansas City, Missouri, United States|Cancer Care Center, Albany, New York, United States|Interlakes Foundation, Inc., Rochester, New York, United States|Hematology Oncology Consultants, Columbus, Ohio, United States|Utah Hematology Oncology, P.C., Ogden, Utah, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Terminated,NCT00060671,"LYMPHOMA, FOLLICULAR|LYMPHOMA, MIXED-CELL, FOLLICULAR|LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR|LYMPHOMA, LOW-GRADE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Clinical Research Center, Tucson, Arizona, United States|Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Rocky Moutain Cancer Center, Denver, Colorado, United States|Pasco, Hernando Oncology Associates, P.A., New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Orange Park Cancer Center, Orange Park, Florida, United States|University of Chicago Medical Center Hematology / Oncology, Chicago, Illinois, United States|Illinois Masonic Cancer Center, Chicago, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Hope Center, Terre Haute, Indiana, United States|Commonwealth Hematology/Oncology, Danville, Kentucky, United States|New England Hematology / Oncology Associates, Wellesley, Massachusetts, United States|St. Joseph Oncology, St Joseph, Missouri, United States|Christian Hospital, St Louis, Missouri, United States|St. Johns Mercy Medical Center, St. Louis, Missouri, United States|Hematology - Oncology Centers of N. Rockies, Billings, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|East Orange VA Medical Center, East Orange, New Jersey, United States|Hematology Oncology Associates of NJ, Paramus, New Jersey, United States|Summit Medical Group/Overlook Onc Center, Summit, New Jersey, United States|New Mexico Oncology / Hematology, Albuquerque, New Mexico, United States|HemOnCare, P.C., Brooklyn, New York, United States|Glens Falls Cancer Center, Glens Falls, New York, United States|North Shore - Long Island Jewish Health System, New Hyde Park, New York, United States|New York University, New York, New York, United States|Upstate NY Cancer Research, Rochester, New York, United States|South Shore Hematology-Oncology Associates, Rockville Centre, New York, United States|Clinworks, Inc, Charlotte, North Carolina, United States|Private Practice, Canton, Ohio, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Lancaster Cancer Center, LTD, Lancaster, Pennsylvania, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Central Utah Medical Clinic Hematology-Oncology, Provo, Utah, United States|Oncology of Wisconsin, Glendale, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Rhinelander Regional Medical Group Onc., Rhinelander, Wisconsin, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Withdrawn,NCT02800889,LYMPHOMA|SOLID TUMOR (EXCLUDING CNS),All,"6 Months to 21 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,0,DB06309,__REFAMETINIB,US-20090082457-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,19.7786402184849,30.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.11,572.337,107.89,6.0,4.0,3.0,46.34,116.29,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCNCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06333,__TRODUSQUEMINE,,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,685.07,145.94,8.0,6.0,4.0,84.8,192.01,20.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
Cc1cc(Nc2ncc(F)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc1N1CCN(C)CC1,0,DB06347,__CENISERTIB,8030483,Terminated,,HAEMATOLOGICAL MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.17,451.55,99.41,7.0,3.0,5.0,48.42,130.05,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,0,DB06365,__SAPACITABINE,US-20050014716-A1,Terminated,NCT01253460,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,0,DB06365,__SAPACITABINE,US-20050014716-A1,Terminated,NCT00476554,CUTANEOUS T-CELL LYMPHOMA (CTCL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Hospitals and Clinics, Stanford, California, United States|Timothy Kuzel, M.D., Chicago, Illinois, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,0,DB06370,__INDISULAM,6060498,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.4357379001622,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.21,385.846,122.12,4.0,3.0,3.0,35.23,90.94,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,0,DB06413,__ARMODAFINIL,4927855,Terminated,NCT01169753,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,0,DB06413,__ARMODAFINIL,4927855,Withdrawn,NCT01044004,B-CELL LYMPHOMA|FATIGUE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
C[C@@H]1O[C@@H](O[C@H]2C[C@](O)(C(=O)CO)Cc3c(O)c4c(c(O)c32)C(=O)c2ccccc2C4=O)[C@H](I)[C@H](O)[C@H]1O,0,DB06420,__ANNAMYCIN,5902604,Terminated,NCT00430443,ACUTE LYMPHOCYTIC LEUKEMIA|ACUTE MYELOGENOUS LEUKEMIA,All,"12 Months to 21 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Denver Children's Hospital, Denver, Colorado, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States",A61K9/1277,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,47.1467586603421,55.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.16,640.379,191.05,11.0,6.0,5.0,55.55,139.24,4.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,0,DB06448,__LONAFARNIB,WO-2004022559-A1,Terminated,NCT00109538,"MYELODYSPLASTIC SYNDROMES|LEUKEMIA, MYELOMONOCYTIC, CHRONIC|MYELODYSPLASIA|MYELOMONOCYTIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61P19/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.34,638.822,79.53,3.0,1.0,5.0,60.09,149.31,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/65,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT02204371,"TELANGIECTASIA, HEREDITARY HEMORRHAGIC",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Toronto, Ontario, Canada",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,0,DB06595,__MIDOSTAURIN,7973031,Terminated,NCT01846624,"ACUTE MYELOID LEUKEMIA (AML) WITH MULTILINEAGE DYSPLASIA FOLLOWING MYELODYSPLASTIC SYNDROME, IN ADULTS|AML (ADULT) WITH 11Q23 (MLL) ABNORMALITIES|AML (ADULT) WITH DEL (5Q)|AML (ADULT) WITH INV (16) (P13; Q22)|AML (ADULT) WITH T (16;16) (P13; Q22)|AML (ADULT) WITH T (8; 21) (Q22; Q22)|SECONDARY AML (ADULT)|UNTREATED AML (ADULT)",All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,104.182837429926,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.52,570.649,77.73,4.0,1.0,9.0,60.58,162.61,3.0,1.0,0.0,0.0,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1
CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,0,DB06595,__MIDOSTAURIN,7973031,Terminated,NCT00866281,ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA,All,"3 Months to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seattle Children's Hospital CPKC412A2114, Seattle, Washington, United States|Novartis Investigative Site, Paris Cedex 19, France|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Stockholm, Sweden",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,104.182837429926,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.52,570.649,77.73,4.0,1.0,9.0,60.58,162.61,3.0,1.0,0.0,0.0,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1
CN1CCC[C@H]1CCNC(=O)c1cn2c3cc4ccccc4cc3oc3c(N4CCC(c5cnccn5)C4)c(F)cc(c1=O)c32,0,DB06638,__QUARFLOXIN,,Terminated,NCT00955292,ADVANCED SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottsdale, Arizona, United States|San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.48,604.686,90.9,7.0,1.0,8.0,66.2,169.69,6.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,0,DB06641,__PERIFOSINE,EP-1135193-B1,Terminated,NCT01002248,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Verne, California, United States|San Francisco, California, United States|San Pablo, California, United States|Aurora, Colorado, United States|Boulder, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Longmont, Colorado, United States|Parker, Colorado, United States|Pueblo, Colorado, United States|Thornton, Colorado, United States|Niles, Illinois, United States|Winfield, Illinois, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Morristown, New Jersey, United States|Great Neck, New York, United States|Fargo, North Dakota, United States|Portland, Oregon, United States|Tualatin, Oregon, United States|Kingsport, Tennessee, United States|Bedford, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Kerrville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Ogden, Utah, United States|Christiansburg, Virginia, United States|Roanoke, Virginia, United States|Salem, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Vancouver, Washington, United States|Milwaukee, Wisconsin, United States|Winnipeg, Manitoba, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Brno, Czech Republic, Czechia|Prague, Czech Republic, Czechia|Dublin 24, Ireland|Keryx / AOI Pharmaceuticals Investigative Site, Dublin 7, Ireland|Dublin 8, Ireland|Dublin 9, Ireland|Galway, Ireland|Limerick, Ireland|Sligo, Ireland|Tullamore, Ireland|Waterford, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Nahariya, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Moscow, Russian Federation|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Kosice, Slovak Republic, Slovakia|Badalona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|La Laguna, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|Zaragoza, Spain",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,34.7933222448099,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.82,461.668,58.59,2.0,0.0,1.0,58.14,142.15,20.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,0,DB06663,__PASIREOTIDE,6225284,Withdrawn,NCT01234974,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,0,DB06685,__LAQUINIMOD,6077851,Withdrawn,NCT01975298,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D215/22,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,13.9633257356413,266.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,356.81,60.85,3.0,1.0,3.0,35.31,97.31,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCCCCCCC/C=C\CCCCCCCC(=O)O.NCCO,0,DB06689,__ETHANOLAMINE_OLEATE,5456693,Withdrawn,,CHRONIC MYELOPROLIFERATIVE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",A61B17/12022,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,13.5033573584673,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.78,343.5444,37.3,2.0,1.0,0.0,37.09,87.4,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
[I-].[K+],0,DB06715,__POTASSIUM_IODIDE,,Terminated,NCT00490490,"LYMPHOMA, NON-HODGKIN",All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.2,166.0028,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,0,DB06817,__RALTEGRAVIR,7169780,Withdrawn,NCT01620736,HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,0,DB08079,__AMG-208,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,383.4027,74.43,6.0,0.0,5.0,40.72,119.54,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
NCCc1c[nH]c2ccccc12,0,DB08653,__TRYPTAMINE,3930948,Terminated,,QUALITY OF LIFE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.21,160.2157,41.81,1.0,2.0,2.0,18.34,50.37,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,0,DB08689,__UBIQUINONE_Q1,,Withdrawn,NCT00247026,MYELODYSPLASTIC SYNDROME,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Organization, Jerusalem, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Terminated,NCT01880437,"MYELODYSPLASTIC SYNDROMES, MYELOGENOUS LEUKEMIA, ACUTE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford, California, United States|Ann Arbor, Michigan, United States|Kansas City, Missouri, United States|New York, New York, United States|Houston, Texas, United States|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Braunschweig, Germany|Essen, Germany|Hamburg, Germany|Heidelberg, Germany|Münster, Germany",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Terminated,NCT01944943,DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN LYMPHOMA|PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Henri MONDOR, Creteil, France|CHU Dijon _ Hôpital d'Enfants, Dijon, France|CHRU de Lille _ Hôpital Huriez, Lille, France|CHU de Nantes _ Hôtel Dieu, Nantes, France|Hôpital Saint-Louis, Paris, France|CHU Haut Lévèque, Pessac, France|CH Lyon Sud, Pierre-Bénite, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Hôpital René Huguenin _ Institut Curie, Saint-Cloud, France",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB08867,__ULIPRISTAL,8512745,Withdrawn,NCT01553123,LEIOMYOMAS,Female,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Women's Health Research, Phoenix, Arizona, United States|Visions Clinical Research, Tucson, Arizona, United States|Benchmark Research, Sacramento, California, United States|Sharp Rees-Stealy Medical Group, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Downtown Women's Health Care, Denver, Colorado, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Altus Research, Lake Worth, Florida, United States|Healthcare Clinical Data, Inc., North Miami, Florida, United States|All Women's Healthcare of West Broward, Plantation, Florida, United States|Physician Care Clinical Research, LLC, Sarasota, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|Atlanta Women's Research Institute, Inc, Atlanta, Georgia, United States|Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Fellows Research Alliance, Savannah, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|Advanced Gynecologic Surgery Institute, Naperville, Illinois, United States|Center for Women's Research, Palos Heights, Illinois, United States|South Bend Clinical, Granger, Indiana, United States|Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States|Women Under Study, LLC, New Orleans, Louisiana, United States|Hutzel Womens Health Specialists, Detroit, Michigan, United States|Women's Clinic of Lincoln, P.C., Lincoln, Nebraska, United States|Office of Annette Mayes, MD, PC, Las Vegas, Nevada, United States|Office of Edmond Pack, MD, Las Vegas, Nevada, United States|Office of R. Garn Mabey, Jr, Las Vegas, Nevada, United States|Lawrence Obstetrics-Gynecology Clinical Research, Lawrenceville, New Jersey, United States|Southwest Clinical Research, Albuquerque, New Mexico, United States|New York Center for Women's Health Research, New York City, New York, United States|Carolina Women's Research and Wellness Center, Durham, North Carolina, United States|Physicians for Women of Greensboro, Greensboro, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Hawthorne Medical Research, Winston-Salem, North Carolina, United States|Columbus Center for Women's Health Research, Columbus, Ohio, United States|Advanced Clinical Concepts, West Reading, Pennsylvania, United States|Southeast Regional Research Group, Aiken, South Carolina, United States|South Carolina Clinical Research Center, LLC, Columbia, South Carolina, United States|Discovery Clinical Trials - Genesis Health Central Women's Care, Dallas, Texas, United States|Advances in Health Inc, Houston, Texas, United States|Willowbend Health and Wellness Associates, Plano, Texas, United States|Clinical Trials of Texas Incorporated Laboratory, San Antonio, Texas, United States|Riverside Regional Medical Center, Newport News, Virginia, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,56.378981087907285,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.45,433.592,57.61,4.0,1.0,5.0,49.66,129.29,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=C1C[C@@H]2CC[C@@]34C[C@@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,DB08871,__ERIBULIN,6214865,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",C07D493/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.8156430316844,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,729.908,146.39,12.0,2.0,9.0,82.15,186.0,4.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Terminated,NCT01650805,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"US Oncology - Providence Health System, Site #167, Burbank, California, United States|UCLA Department of Medicine, Site #027, Los Angeles, California, United States|Bay Area Cancer Research Group, Site #156, Pleasant Hill, California, United States|Bay Area Cancer Research Group, Site #157, Pleasant Hill, California, United States|Rocky Mountain Cancer Centers, Site #191, Boulder, Colorado, United States|Cancer Center of Central Connecticut, Site #147, Southington, Connecticut, United States|Christiana Care Health Services, Site #155, Newark, Delaware, United States|University Cancer Institute, Site #149, Boynton Beach, Florida, United States|Florida Cancer Specialists, Site #180, Fort Meyers, Florida, United States|Florida Cancer Specialists, Site #179, St. Petersburg, Florida, United States|Emory University, Site #058, Atlanta, Georgia, United States|John H. Stroger, Jr. Hospital of Cook County, Site #192, Chicago, Illinois, United States|University of Chicago, Site #001, Chicago, Illinois, United States|Loyola University Chicago, Site #054, Maywood, Illinois, United States|Franciscan St. Francis Health, Site #138, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Site #050, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Associates, Site #198, Sioux City, Iowa, United States|US Oncology - Cancer Center of Kansas, Site #168, Wichita, Kansas, United States|Willis-Knighton Cancer Center, Site #196, Shreveport, Louisiana, United States|University of Maryland, Greenebaum Cancer Center, Site #040, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Site #140, Baltimore, Maryland, United States|St. Agnes Healthcare, Site #185, Baltimore, Maryland, United States|Massachusetts General Hospital, Site #047, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Site #008, Boston, Massachusetts, United States|University of Massachusetts Worcester, Site #152, Worcester, Massachusetts, United States|University of Michigan Medical Center, Site #011, Ann Arbor, Michigan, United States|Providence Cancer Institute, Site #197, Southfield, Michigan, United States|Mayo Clinic, Site #044, Rochester, Minnesota, United States|Oncology Research Park Nicollet Institute, Site #195, St. Louis Park, Minnesota, United States|Saint Luke's Hospital, Site #162, Kansas City, Missouri, United States|Mercy Clinic - Cancer & Hematology, Site #151, Springfield, Missouri, United States|Nebraska Hematology-Oncology, P.C., Site # 133, Lincoln, Nebraska, United States|US Oncology - Comprehensive Cancer Center of Nevada, Site #169, Las Vegas, Nevada, United States|John Theurer Cancer Center, Site #128, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Site #166, Albuquerque, New Mexico, United States|Maimonides Cancer Center, Site #177, Brooklyn, New York, United States|Winthrop University Hospital, Site #153, Mineola, New York, United States|Beth Israel Medical Center, Site #145, New York, New York, United States|Mount Sinai School of Medicine, Site #189, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, Site #078, New York, New York, United States|Weill Cornell Medical College, Site #006, New York, New York, United States|New York Medical College, Site #146, Valhalla, New York, United States|Southeastern Medical Oncology Center, Site #188, Goldsboro, North Carolina, United States|Signal Point Clinical Research Center, Site #139, Middletown, Ohio, United States|University of Oklahoma, Site #028, Oklahoma City, Oklahoma, United States|Providence Cancer Center Oncology and Hematology Care Eastside, Site #194, Portland, Oregon, United States|Kaiser Permanente Northwest, Site #200, Portland, Oregon, United States|Oregon Health & Science University, Site #048, Portland, Oregon, United States|Gettysburg Cancer Center, Site #160, Gettysburg, Pennsylvania, United States|Western Pennsylvania Hospital, Site #159, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Site #148, Charleston, South Carolina, United States|Carolina Hematology Oncology, Site #143, Sumter, South Carolina, United States|Associates in Oncology & Hematology, Site #186, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Site #076, Nashville, Tennessee, United States|US Oncology - Texas Oncology Austin, Site #172, Austin, Texas, United States|US Oncology - Texas Oncology Dallas, Site #171, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Site #178, Dallas, Texas, United States|Baylor College of Medicine, Site #063, Houston, Texas, United States|US Oncology - Texas Oncology Midland, Site #173, Midland, Texas, United States|US Oncology - Cancer Care Center of South Texas, Site #170, San Antonio, Texas, United States|Huntsman Cancer Institute, Site #043, Salt Lake City, Utah, United States|VCU Massey Cancer Center, Dalton Oncology Clinic, Site #069, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Site #100, Seattle, Washington, United States|US Oncology - Northwest Cancer Specialists, Site #174, Vancouver, Washington, United States|West Virginia University, Site #154, Morgantown, West Virginia, United States|Green Bay Oncology, Ltd. / St. Mary's Hospital Medical Center, Site #193, Green Bay, Wisconsin, United States|University of Wisconsin, Site #030, Madison, Wisconsin, United States|Canberra Hospital, Site #971, Garran, Australian Capital Territory, Australia|Royal North Shore Hospital, Site #941, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Site #951, Adelaide, South Australia, Australia|The Peter MacCallum Cancer Center, Site #950, East Melbourne, Victoria, Australia|Box Hill Hospital, Site #940, Melbourne, Victoria, Australia|Royal Perth Hospital, Site #972, Perth, Western Australia, Australia|Medizinische Universitat Wien / AKH, Universitatsklinik fur Inniere Medizin I, Site #561, Wien, Austria|UZ Brussel - Department Hematology, Site #544, Brussel, Belgium|Clinique Universitaire de Saint-Luc, Department of Haematology, Site #508, Bruxelles, Belgium|UZ Gent - Department Hematology, Site #756, Gent, Belgium|UZ Gasthuisberg - Department of Hematology, Site #700, Leuven, Belgium|University Health Network, Princess Margaret Hospital, Site #083, Toronto, Ontario, Canada|Jewish General Hospital, Site #129, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Site #514, Brno, Czech Republic|FN Hradec Kralove, Site #517, Hradec Kralove, Czech Republic|Fakultni nemocnice Olomouc, Hematoonkologicka klinika, Site #515, Olomouc, Czech Republic|Ustav hematologie a krevni transfuse, Site #516, Praha, Czech Republic|Helsinki University Central Hospital, Site #542, Helsinki, Finland|Institut Bergonie, Site #772, Bordeaux, France|CHRU de Brest, Hopital Morvan, Site #523, Brest, France|CHU Henri Mondor, Site #520, Creteil Cedex, France|Centre Hospitalier de Versailles, Site #958, Le Chesnay Cedex, France|Hospital Claude Huriez, Site #952, Lille Cedex, France|Institut Paoli Calmette, Site #519, Marseille, France|CHU de Brabois, Site #953, Nancy Cedex, France|CHU de Nantes, Site #521, Nantes Cedex, France|Service Hematologie - Hospital Archet I, Site #509, Nice Cedex, France|Hopital Saint-Louis, Site #957, Paris, France|Hospital Saint Antoine, Site #518, Paris, France|Centre Hospitalier Lyon Sud, Site #956, Pierre Benite, France|CHU de Poitiers, Site #954, Poitiers, France|CHU Purpan, Site #955, Toulouse Cedex, France|Universitätsklinikum Aachen, AÖR, Site #513, Aachen, Germany|Charite - Universitatsmedizin Berlin, Site #701, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526, Dresden, Germany|Universitatsklinikum Freiburg, Site #527, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Site #524, Hamburg, Germany|Universitatsklinikum Jena, Site #946, Jena, Germany|Universitatsklinikum Koln-AOR, Site #525, Koln, Germany|Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947, Mannheim, Germany|Klinikum rechts der Isar, Site #949, Munchen, Germany|Prince of Wales Hospital, Site #974, Hong Kong, Hong Kong|Queen Mary Hospital, Site #973, Hong Kong, Hong Kong|Unita Operativa di Ematologia con Trapianto, Site #529, Bari, Italy|Istituto di Ematologia ""L. & A. Seragnoli"", Site #959, Bologna, Italy|A.O. Universitaria Policlinico Vittorio Emanuele di Catania, Site #530, Catania, Italy|Clinica Ematologica, Site #528, Genova, Italy|Ospedale Niguarda Ca' Granda di Milano, Site #531, Milan, Italy|S.C. Ematologia, Site #960, Modena, Italy|San Gerardo Hospital, Site #961, Monza, Italy|U.O.C Ematologia con trapianto di midollo osseo, Site #560, Napoli, Italy|Universita Federico II, Site #510, Napoli, Italy|SCDU Medicina Interna II - Indirizzo Ematologico, Site #785, Orbassano, Italy|Dipartimento di Biotecnologie Cellulari ed Ematologia Universita La Sapienza - Policlinico Umberto I, Site #511, Rome, Italy|U.O. di Ematologia - Ospedale S. Eugenio, Site #962, Rome, Italy|The Catholic University of Korea, Site #938, Seocho-gu, Seoul, Korea, Republic of|VU Medical Centre - Department Haematology, Site #948, Amsterdam, Netherlands|Auckland City Hospital, Site #921, Grafton, Auckland, New Zealand|Christchurch Hospital, Site #922, Christchurch, New Zealand|Waikato Hospital, Site #977, Hamilton, New Zealand|North Shore Hospital, Site #976, Takapuna, New Zealand|Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Medyczne, Site #548, Gdansk, Poland|Malopolskie Centrum Medyczne, Site #546, Krakow, Poland|Klinika Hematologii Wojewodzkiego Szpitala Specjalistycznego, Site #550, Lodz, Poland|Oddzial Hematologii, Site #551, Rzeszow, Poland|Katedra i Klinika Hematologii, Site #547, Wroclaw, Poland|Instituto Portugues de Oncologia, Site #545, Lisboa, Portugal|Fundacion de Investigacion de Diego, Site #199, San Juan, Puerto Rico|Singapore General Hospital, Site #939, Singapore, Singapore|Narodny onkologicky ustav, Site #532, Bratislava, Slovakia|Univerzitna nemocnica Martin, Site #533, Martin, Slovakia|Complejo Hospitalario Universitario A Coruna, Hospital ""Teresa Herrera,"" Site #554, A Coruna, Spain|Hospital Universitari Germans Trias i Pujol, Site #512, Badalona, Spain|Hospital Clinic, Site #963, Barcelona, Spain|Institut Catala d' Oncologia de Girona, S. de Hematologia Clinica, Site #734, Girona, Spain|Hospital Universitari Son Espases, Site #553, Islas Baleares, Spain|Hospital Universitario La Princesa, Site #555, Madrid, Spain|Hospital Gregorio Maranon, Site #536, Madrid, Spain|H.U. Ramon y Cajal, Site #538, Madrid, Spain|Hospital Universitario 12 de Octubre, Site #537, Madrid, Spain|Hospital La Paz, Site #966, Madrid, Spain|Hospital Universitario Central de Asturias, Site #535, Oviedo, Spain|Hospital Universitario de Salamanca, Site #965, Salamanca, Spain|Hospital Clinico Universitario de Valencia, Site #964, Valencia, Spain|Skane University Hospital, Site #944, Lund, Sweden|Karolinska University Hospital Huddinge, Site #534, Stockholm, Sweden|Karolinska University Hospital Solna, Site #763, Stockholm, Sweden|Uppsala University Hospital, Site #945, Uppsala, Sweden|Kantonsspital Aarau, Site #541, Aarau, Switzerland|Kantonsspital St. Gallen, Site #707, St Gallen, Switzerland|Kaohsiung Chang Gung Memorial Hospital, Site #980, Kaohsiung, Taiwan|China Medical University Hospital, Site #978, Taiching, Taiwan|National Taiwan University Hospital, Site #979, Taipei, Taiwan|Western General Hospital, Site #556, Edinburgh, United Kingdom|Kent and Medway Cancer Research Network, Site #558, Gillingham, United Kingdom|University of Glasgow, Site #797, Glasgow, United Kingdom|St. James University Hospital, Site #540, Leeds, United Kingdom|Royal Liverpool University Hospital, Site #969, Liverpool, United Kingdom|Hammersmith Hospital, Site #967, London, United Kingdom|Newcastle University, Site #970, Newcastle, United Kingdom|Norfolk & Norwich University Hospital Foundation Trust, Site #557, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust, Site #968, Nottingham, United Kingdom|Oxford University Hospitals NHS Trust, Site #543, Oxford, United Kingdom",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Terminated,NCT01570868,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Withdrawn,NCT02829840,LEUKEMIA|FLT3-MUTATED ACUTE MYELOID LEUKEMIA|FLT3-MUTATED HIGH-RISK MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
COC(=O)/C=C/C(=O)OC,0,DB08908,__DIMETHYL_FUMARATE,6509376,Terminated,NCT02784834,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Suspended,NCT02569320,RECURRENT PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT01979276,MULTIPLE MYELOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT01078974,WALDENSTROM'S MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT01946152,MULTIPLE MYELOMA-LIGHT CHAIN ONLY|RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT01807286,MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Withdrawn,NCT02228512,LARGE CELL LYMPHOMA ARISING IN KSHV-ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE|PRIMARY EFFUSION LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Withdrawn,NCT04392648,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Withdrawn,NCT04355039,REFRACTORY MULTIPLE MYELOMA|RELAPSE MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01980875,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sansum Clinic, Santa Barbara, California, United States|UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|St Vincent Hospital, Sydney, Darlinghurst, New South Wales, Australia|UZ Ghent- hematology, Ghent, Belgium|Royal Victoria Regional Health Centre - Simcoe Musk, Barrie, Ontario, Canada|Centre Hospitalier du Mans, Le Mans, France|Centre Hospitalier de Perpignan, Perpignan Cedex 9, France|Szpital Specjalistyczny w Brzozowie, Oddzial Hematologii Onkologicznej, Brzozow, Podkarpackie, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|Wojewódzki Szpital Specjalistyczny w Legnicy, Legnica, Poland|Wojewodzki Szpital Specjalistyczny, im. M. Kopernika Klinika Hematologii Uniwersytetu Medycznego, Lodz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii, Olsztyn, Poland|Hospital Universitario de Salamanca, Salamanca, Spain|East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01732926,INDOLENT NON-HODGKIN'S LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Clearview Cancer Institute, Huntsville, Alabama, United States|Ironwood Cancer and Research Center, Chandler, Arizona, United States|Comprehensive Blood and Cancer Center (Bakersfield), Bakersfield, California, United States|Saint Jude Heritage Healthcare (TORI), Fullerton, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Cancer Care Associates, Redondo Beach, California, United States|San Luis Obispo Oncology and Hematology, San Luis Obispo, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|St Joseph Heritage Healthcare System, Santa Rosa, California, United States|Kaiser Permanente Vallejo Medical Center, Vallejo, California, United States|Sylvester Comprehensive Cancer Center/UMHC, Deerfield Beach, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Joliet Oncology Hematology Associates Ltd., Joliet, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|North Shore Hematology/Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Greenville, South Carolina, United States|Texas Oncology, P.A., Bedford, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Texas Oncology, P.A., Harlingen, Texas, United States|Texas Oncology, P.A., Weslaco, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Haematology and Oncology Clinics of Australia Gold Coast, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Saint Vincent's Hospital, Fitzroy, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Fraser Clinical Trials, Inc., New Westminster, British Columbia, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Centre for Clinical Research, Halifax, Nova Scotia, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hôpital Charles Lemoyne, Greenfield Park, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Quebec, Canada|CancerCare Manitoba, Winnipeg, Canada|Fakultní Nemocnice Ostrava, Ostrava - Poruba, Severomoravsky KRAJ, Czechia|Fakultní nemocnice Brno, Brno, Czechia|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|CHR Metz, Metz Cedex 03, Alsace, France|Centre Hospitalier Universitaire de Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Alsace, France|Institut Bergonié, Bordeaux Cedex, Aquitaine, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Hôpital Necker-Enfants Malades, Paris, Ile-de-france, France|Centre Jean Bernard, Le Mans, PAYS DE LA Loire, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, Rhone-alpes, France|Centre Hospitalier Universitaire Brest, Brest Cedex, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Centre Hospitalier Départmental La Roche sur Yon, La Roche sur Yon, France|Centre Léon Bérard, Lyon Cedex 08, France|Institut Paoli Calmettes, Marseille, France|Hôpital Hôtel-Dieu, Nantes cedex 1, France|Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France|Centre Hospitalier Régional et Universitaire - Hôpital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Baden-wuerttemberg, Germany|Gemeinschaftspraxis Dres. Söling Und Siehl, Kassel, Hessen, Germany|Vivantes Klinikum am Urban, Berlin, Germany|Charite - Campus Virchow, Berlin, Germany|Klinikum der Ludwig-Maximilians-Universität München, München, Germany|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Corp., Haifa, Israel|Hadassah Medical Organization, Ein Kerem, Jerusalem, Israel|Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Spedali Civili Di Brescia Azienda Ospedaliera, Brescia, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale San Raffaele-IRCCS, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Azienda Ospedaliero Universitaria (AOU) ""Maggiore della Carita"" di Novara, Novara, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Dong-A University Medical Center, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Szpital Kliniczny nr 1, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Lublin, Poland|Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi, Lódz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim, Olsztyn, Poland|Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku, Slupsk, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii i Hipertermii, Warszawa, Poland|Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Central City Hospital # 7, Ekaterinburg, Russian Federation|N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation|FSI ""V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies"", Saint Petersburg, Russian Federation|Saint Petersburg I.P. Pavlov State Medical University, Saint-Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|State Budgetary Healthcare Institution ""Volgograd Regional Clinical Oncology Dispensary #1"", Volgograd, Russian Federation|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Länssjukhuset Ryhov, Jönköping, Sweden|Changhua Christian Hospital, Changhua city, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Kent and Canterbury Hospital, Canterbury, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|Royal Bournemouth General Hospital, Dorset, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Barts and The London NHS Trust, London, England, United Kingdom|University College London Hospitals National Health Society Foundation Trust, London, England, United Kingdom|Guys and Saint Thomas NHS Foundation Trust, London, England, United Kingdom|Imperial College Healthcare NHS Trust, London, England, United Kingdom|Maidstone Hospital, Maidstone, England, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, England, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02436135,MYELOFIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Hospital and Clinics, Stanford, California, United States|University of Michigan Health System, Ann Arbor, Michigan, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01796470,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Collaborative Research Group LLC, Boynton Beach, Florida, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01090414,"CHRONIC LYMPHOCYTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clearview Cancer Institute, Huntsville, Alabama, United States|UCLA, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Center for Cancer & Blood Disorders, PC, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Long Island Jewish medical Center, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer and Research Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Yakima Regional Cancer Care, Yakima, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02928510,ABSENCE OF SIGNS OR SYMPTOMS|B-CELL NON-HODGKIN LYMPHOMA|DIGESTIVE SYSTEM SIGNS AND SYMPTOMS|INDOLENT ADULT NON-HODGKIN LYMPHOMA|RECURRENT B-CELL NON-HODGKIN LYMPHOMA|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02538614,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University, Columbus, Ohio, United States|University of Utah, Salt Lake City, Utah, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02258529,FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Shores Medical Group, Long Beach, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02044822,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|GHS Cancer Institute, Greenville, North Carolina, United States|Compass Oncology, Portland, Oregon, United States|Willamette Valley Cancer Center and Research Institute, Springfield, Oregon, United States|Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|St Vincent's Hospital, Sydney, Darlinghurst, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|St Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia|Liverpool Hospital, Liverpool, Australia|Innsbruck University Hospital, Inner Medicine,, Innsbruck, Austria|Univ. Klinik für Innere Medizin III LKH, Salzburg, Austria|Medizinische Universität Wien, Univ. Klinik f. Innere Med. I, Abteilung für Hämatologie und Hämostaseologie, Vienna, Austria|AZ Sint-Jan AV Brugge-Oostende, Brugge, Belgium|University Hospital Leuven, Leuven, Belgium|University Hospital, Brno, Czechia|Faculty Hospital Hradec Kralove, Hradec Kralove, Czechia|Hemato-Onkologicka Klinika Fn, Olomuc, Czechia|Faculty hospital Ostrava, Ostrava-Poruba, Czechia|Faculty Hospital Kralovske Vinohrady, Prague 10, Czechia|Vseobecna Fakultim Nemocnice, Praha, Czechia|Aalborg University Hospital, Aalborg, Denmark|Centre Hospitalier Universitaire Hôpital Avicenne, Bobigny, France|CHRU de Lille, Hopital Claude Huriez, Lille, France|Centre Hospitalier Universitaire Nancy, Nancy, France|Hopital Pitie-Salpetriere, Paris cedex 13, France|University of Debrecen HSC Institute of internal Medicine, Department of Hematology, Debrecen, Hungary|Institute of Hematology ""L. e A. Seràgnoli"", Bologna, Italy|A.O.Spedali Civili Brescia, Brescia, Italy|A.O.Niguarda Ca' Granda, Milan, Italy|Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy|SCDU Medicina II ed Ematologia, A.O.U. San Luigi Gonzaga, Orbassano, Italy|Uniwersyteckie Centrum Kliniczne, Gdańsk, Pomorskie, Poland|Szpital Specjalistyczny w Brzozowie, Brzozow, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|Wojewodzki Szpital Specjalistyczny, Lodz, Poland|Centrum Onkologii-Instytut Marii Sklodowskiej -Curie klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny, Wroclaw, Poland|Centro Hospitalar De Lisboa Norte, E.P.E. - Hospital Santa Maria, Lisbon, Portugal|IPO Porto Francisco Gentil, E.P.E, Porto, Portugal|Emergency County Clinical Hospital Brasov, Brasov, Romania|Spitalul Clinic Colentina, Bucharest, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Puerta De Hierro, Madrid, Spain|Hospital Clinico Universitario De Valencia (Chuv), Valencia, Spain|Saint James's University Hospital, Leeds, United Kingdom|Royal Liverpool & Broadgreen Univ. Hospitals, Liverpool, United Kingdom|University Hospital Southampton NHS Trust, Southampton, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01203930,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|SMALL LYMPHOCYTIC LYMPHOMA (SLL),All,65 Years and older   (Older Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, Moores Cancer Center, La Jolla, California, United States|Stanford University School of Medicine, Stanford, California, United States|Columbia University - Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The Universtity of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Withdrawn,NCT02662296,PROLYMPHOCYTIC LEUKEMIA|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Withdrawn,NCT03349346,DIFFUSE LARGE B-CELL LYMPHOMA|MEDIASTINAL B-CELL LYMPHOMA,All,"1 Year to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier Régional Universitaire de Lille, Lille, France|Istituto Giannina Gaslini, Genova, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|Infantile Regina Margherita Hospital, Torino, Italy|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wrocław, Poland|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario HM Monteprincipe, Madrid, Spain",C07D473/38,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Terminated,NCT02465528,TUMORS WITH ABERRATIONS IN ALK|ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMOR|GLIOBLASTOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",C07D239/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Withdrawn,NCT02729961,"ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE|CD30-POSITIVE NEOPLASTIC CELLS PRESENT|SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA",All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D239/48,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Withdrawn,NCT02343679,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",C07D239/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,DB09073,__PALBOCICLIB,6936612,Terminated,NCT02030483,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,DB09073,__PALBOCICLIB,6936612,Terminated,NCT03515200,"ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE|ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,0,DB09074,__OLAPARIB,7151102,Withdrawn,NCT03575078,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,0,DB09102,__DACLATASVIR,8329159,Withdrawn,NCT02762448,HEPATITIS C INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,64.1327337316987,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.67,738.89,174.64,6.0,4.0,6.0,83.91,201.82,13.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1
CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2cc(S(=O)(=O)O)ccc2S(=O)(=O)O)cc1,0,DB09136,__ISOSULFAN_BLUE,US-20080281127-A1,Terminated,NCT00932035,BREAST CANCER,Female,"Child, Adult, Older Adult",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope Medical Center, Duarte, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|University of North Carolina, Chapel Hill, North Carolina, United States",C07C303/02 ,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,23.0,32.7488,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,545.69,114.99,7.0,2.0,3.0,58.06,171.81,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1
[K+].[O-][Cl+3]([O-])([O-])[O-],0,DB09418,__POTASSIUM_PERCHLORATE,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.97,138.549,74.27,4.0,0.0,0.0,5.23,11.91,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,0,DB09459,__L-TARTARIC_ACID,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],0,DB11246,__COPPER_GLUCONATE,4112066,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61Q11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C,0,DB11431,__MOXIDECTIN,,Withdrawn,NCT01035619,ONCHOCERCIASIS,All,4 Years to 11 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.3,639.83,116.04,8.0,2.0,5.0,71.02,179.22,3.0,1.0,0.0,0.0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,0,DB11526,__MASITINIB,EP-1525200-B1,Terminated,NCT01470131,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical and Surgical Specialists, Galesburg, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Froedtert & Medical College of Wisconsin-CLCC, Milwaukee, Wisconsin, United States|CHU Estaing, Clermont Ferrand, France|Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France|CH Le Mans, Le Mans, France|Hôpital Universitaire Dupuytren, Limoges, France|Hôpital Ambroise Paré, Marseille, France|Hôpital de l'Hôtel Dieu, Nantes, France|Hôpital Saint Louis, Paris, France|Centre Hospitalier Saint Jean, Perpignan, France", A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,50.333682416476705,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,498.65,73.39,6.0,2.0,5.0,55.33,147.0,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03399539,RECURRENT PLASMA CELL MYELOMA|T(11;14),All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT02992522,"B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA|GRADE 1 FOLLICULAR LYMPHOMA|GRADE 2 FOLLICULAR LYMPHOMA|GRADE 3A FOLLICULAR LYMPHOMA|RECURRENT BURKITT LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|REFRACTORY BURKITT LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY FOLLICULAR LYMPHOMA|TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University, Atlanta, Georgia, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT02755597,RELAPSED/REFRACTORY MULTIPLE MYELOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Univ of Colorado Cancer Center /ID# 149130, Aurora, Colorado, United States|VA Eastern Colorado Healthcare System /ID# 156524, Aurora, Colorado, United States|Duke University Medical Center /ID# 149099, Durham, North Carolina, United States|Gabrail Cancer Center Research /ID# 149098, Canton, Ohio, United States|Royal Prince Alfred Hospital /ID# 149108, Camperdown, New South Wales, Australia|Concord Repatriation & Gen Hos /ID# 149106, Concord, New South Wales, Australia|Liverpool Hospital /ID# 149110, Liverpool, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 149105, Herston, Queensland, Australia|The Queen Elizabeth Hospital /ID# 149104, Woodville, South Australia, Australia|Royal Hobart Hospital /ID# 149111, Hobart, Tasmania, Australia|Peter MacCallum Cancer Ctr /ID# 149107, Melbourne, Victoria, Australia|Alfred Health /ID# 150085, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 149112, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 148967, Murdoch, Western Australia, Australia|Perth Blood Institute Ltd /ID# 148966, Nedlands, Western Australia, Australia|Universidade Federal de Goias /ID# 149290, Goiania, Goias, Brazil|Liga Norte Rigrandese Contra o /ID# 149023, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 149027, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 149025, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 149020, Rio de Janeiro, Brazil|Clinica Sao Germano /ID# 149851, Sao Paulo, Brazil|Victoria Hospital /ID# 149846, London, Ontario, Canada|CISSS de la Monteregie /ID# 149844, Greenfield Park, Quebec, Canada|CHU Dupuytren /ID# 149292, Limoges CEDEX 1, Franche-Comte, France|Centre Hospitalier Lyon Sud /ID# 149300, Pierre Benite CEDEX, Rhone, France|CHRU de Brest - Hopital Morvan /ID# 149299, Brest, France|CHU de Grenoble - Albet Michal /ID# 149301, Grenoble, France|CHU de Nantes, Hotel Dieu -HME /ID# 149294, Nantes, France|Charité Universitätsmedizin Campus Mitte /ID# 148949, Berlin, Germany|Universitaetsklinikum Dresden /ID# 148948, Dresden, Germany|Asklepios Klinik Altona /ID# 150116, Hamburg, Germany|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 152518, Budapest IX, Budapest, Hungary|Semmelweis Egyetem /ID# 152519, Budapest, Hungary|Semmelweis Egyetem /ID# 152520, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 152517, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 152516, Kaposvár, Hungary|Galway University Hospital /ID# 149061, Galway, Ireland|A.O.U. Policlinico S.Orsola-Malpighi /ID# 148936, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 148939, Rome, Lazio, Italy|A.O. Univ. Ospedali Riuniti /ID# 148942, Ancona, Marche, Italy|Ospedale S.Eugenio /ID# 148938, Rome, Italy|Ospedale Molinette /ID# 148943, Turin, Italy|Nagoya City University Hospital /ID# 150943, Nagoya-shi, Aichi, Japan|Kyushu University Hospital /ID# 150896, Fukuoka-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 150783, Ogaki-shi, Gifu, Japan|Gunma University Hospital /ID# 150275, Maebashi-shi, Gunma, Japan|National Hospital Organization Shibukawa Medical Center /ID# 150281, Shibukawa-shi, Gunma, Japan|Hiroshima Red Cross Hospital /ID# 150242, Hiroshima-shi, Hiroshima, Japan|Kobe City Med Ctr General Hosp /ID# 150944, Kobe-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 151051, Higashi Ibaraki-gun, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 150719, Kyoto-shi, Kyoto, Japan|JCHO Kyoto Kuramaguchi Medical /ID# 150781, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 150945, Sendai-shi, Miyagi, Japan|Okayama Medical Center /ID# 150717, Okayama-shi, Okayama, Japan|Japanese Red Cross Osaka Hospi /ID# 150716, Osaka-shi, Osaka, Japan|Saitama Medical Center Saitama Medical University /ID# 151044, Kawagoe shi, Saitama, Japan|Tochigi Cancer Center /ID# 150192, Utsunomiya-shi, Tochigi, Japan|National Cancer Center Hospital /ID# 151039, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 150780, Koto-ku, Tokyo, Japan|Japanese Red Cross Medical Center /ID# 149902, Shibuya-ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center /ID# 150784, Tachikawa-shi, Tokyo, Japan|National Cancer Center /ID# 150889, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 150888, Seongnam, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center /ID# 150893, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 150894, Gwangju, Jeonranamdo, Korea, Republic of|Severance Hospital /ID# 150891, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 150892, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 150895, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 150890, Seoul, Korea, Republic of|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 148955, Kemerovo, Kemerovskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 148956, Ryazan, Ryazanskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 148974, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Central Clinical Hosp 2 /ID# 148954, Moscow, Russian Federation|Clinical Onco Dispensary /ID# 148953, Omsk, Russian Federation|Samara State Medical Universit /ID# 148952, Samara, Russian Federation|Medical Clinica of Bashkir /ID# 151206, UFA, Russian Federation|Hospital Duran i Reynals /ID# 148989, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ de la Princesa /ID# 148980, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 148981, Madrid, Spain|Hospital Universitario Dr. Peset /ID# 148986, Valencia, Spain|China Medical University Hosp /ID# 154446, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 154444, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 154447, Changhua County, Taiwan|Taipei Veterans General Hosp /ID# 154445, Taipei City, Taiwan|Cherkassy Regional Onc Ctr /ID# 152414, Cherkasy, Ukraine|Communal Non-profit Enterprise City Clinical Hospital No.4 /ID# 152411, Dnipro, Ukraine|National Cancer Institute /ID# 152413, Kiev, Ukraine|Leicester Royal Infirmary /ID# 149057, Leicester, England, United Kingdom|Blackpool Teaching Hosp NHS /ID# 149058, Blackpool, United Kingdom|East Kent Hosp Univ NHS Trust /ID# 149059, Canterbury, United Kingdom|St Bartholomew's Hospital, Bar /ID# 149050, London, United Kingdom|University College Hospitals /ID# 149044, London, United Kingdom|King's College Hospital NHS /ID# 149045, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 149046, Manchester, United Kingdom|Nottingham Univ Hospitals NHS /ID# 149047, Nottingham, United Kingdom|Queens Hospital /ID# 149055, Romford, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 149043, Wolverhampton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03797261,ACUTE MYELOID LEUKEMIA|NON-HODGKIN'S LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope /ID# 207393, Duarte, California, United States|USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States|Miami Cancer Institute - Baptist Health South Florida /ID# 209825, Miami, Florida, United States|University of Iowa Hospitals and Clinics /ID# 207459, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 207480, Kansas City, Kansas, United States|Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 206995, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 207390, New York, New York, United States|Unc /Id# 207388, Chapel Hill, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh, Pennsylvania, United States|Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia|Royal Adelaide Hospital /ID# 210602, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210601, Fitzroy, Victoria, Australia|Alfred Hospital /ID# 210350, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 210599, Melbourne, Victoria, Australia|Universitaetsklinikum Leipzig /ID# 209824, Leipzig, Sachsen, Germany|Charite Universitatsmedizin B- /ID# 207987, Berlin, Germany|Universitaetklinikum Dresden /ID# 207803, Dresden, Germany|Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt, Germany|Univ Klinik Eppendorf Hamburg /ID# 207788, Hamburg, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03713580,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Terminated,NCT03000660,AL AMYLOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Terminated,NCT03135262,"FOLLICULAR LYMPHOMA|LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Norton Cancer Institute - Dutchmans, Louisville, Kentucky, United States|Mount Sinai Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Swedish Cancer Inst., Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Klinikum Augsburg, Augsburg, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Kassel; Klinik für Onkologie und Hämatologie, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03856112,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA|T(11;14) NEGATIVE,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03785184,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope /ID# 212211, Duarte, California, United States|Marin Cancer Care /ID# 208476, Greenbrae, California, United States|University of California, Los Angeles /ID# 208516, Los Angeles, California, United States|Karmanos Cancer Institute /ID# 208805, Detroit, Michigan, United States|Henry Ford Hospital /ID# 208481, Detroit, Michigan, United States|Duke University Hospital /ID# 208306, Durham, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208121, Pittsburgh, Pennsylvania, United States|Westmead Hospital /ID# 210267, Westmead, New South Wales, Australia|Flinders Centre for Innovation /ID# 210697, Bedford Park, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia|Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia|Monash Medical Centre /ID# 210269, Melbourne, Victoria, Australia|Tom Baker Cancer Centre /ID# 208549, Calgary, Alberta, Canada|Princess Margaret Cancer Centr /ID# 208923, Toronto, Ontario, Canada|Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada|McGill Univ HC /ID# 208486, Montreal, Quebec, Canada|Clinica Universitar de Navarra - Pamplona /ID# 209883, Pamplona, Navarra, Comunidad, Spain|Hospital Clinic de Barcelona /ID# 209888, Barcelona, Spain|Hspital Universitario Gregorio Maranon /ID# 209926, Madrid, Spain|Clinica Universitar de Navarra - Madrid /ID# 210131, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 209887, Madrid, Spain|Hospital Univ Dr. Peset /ID# 209884, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03701321,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT04285268,"HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED|RECURRENT BURKITT LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS|REFRACTORY BURKITT LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03343678,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,0,DB11586,__ASUNAPREVIR,,Withdrawn,NCT02762448,HEPATITIS C INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.12,748.2860000000003,182.33,9.0,3.0,5.0,76.14,186.82,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,1
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F,0,DB11633,__ISAVUCONAZOLE,EP-1757609-A1,Terminated,NCT03327727,INVASIVE ASPERGILLOSIS|INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States|Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|DMC Harper University Hospital, Detroit, Michigan, United States|University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Infectious Disease, Saint Louis, Missouri, United States|The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium|General Hospital Saint-Jan, Department of Hematology, Brugge, Belgium|Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium|UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir, Belgium|Hamilton Health Sciences, Infectious Disease Research, Hamilton, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Division of Infectios Diseases, Montréal, Quebec, Canada|Grenoble University Hospital Center, Department of Hematology, Grenoble, France|South Lyon Hospital Center, Pierre-Bénite, France|Hautepierre Hospital, Strasbourg, France|University Hospital Jena, Jena, Germany|Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich, Germany|Chonnam National University, Hwasun, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,102.277254153062,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.46,437.47,87.62,5.0,1.0,4.0,42.74,123.94,6.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,0,DB11648,__AFURESERTIB,US-20090209607-A1,Terminated,NCT02235740,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Cary, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,0,DB11648,__AFURESERTIB,US-20090209607-A1,Terminated,NCT02177682,"NEOPLASMS, HAEMATOLOGIC",All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Tokyo, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,NCT02614508,RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,DB11682,__DAPRODUSTAT,,Suspended,NCT03457701,ANAEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Lufkin, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.48,393.44,124.09,6.0,2.0,3.0,40.18,96.89,5.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,DB11682,__DAPRODUSTAT,,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.48,393.44,124.09,6.0,2.0,3.0,40.18,96.89,5.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O,0,DB11687,__E-6201,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.09,389.44800000000004,116.09,6.0,4.0,2.0,41.34,109.72,2.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Suspended,NCT03213691,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III CHILDHOOD NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT CHILDHOOD CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT NEUROBLASTOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM,All,"12 Months to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Terminated,NCT01278615,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,NCT02469415,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,NCT02410551,MYELOPROLIFERATIVE DISEASES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,NCT02055781,PRIMARY MYELOFIBROSIS|POST-POLYCYTHEMIA VERA MYELOFIBROSIS|POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Arizona, Scottsdale, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Moores Cancer Centre, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Center, Boulder, Colorado, United States|George Washington University- Medical Faculty Associates, Washington, District of Columbia, United States|SCRI- Florida Cancer Specialists South Region, Fort Myers, Florida, United States|SCRI - Florida Cancer Specialists North Region, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Goshen Cancer Centre, Goshen, Indiana, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Associates, L.L.P (SHOA), Sioux City, Iowa, United States|Norton Cancer Institute, Suburban, Louisville, Kentucky, United States|St Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Washington University School of Medicine Division of Oncology, Saint Louis, Missouri, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Hackensack University, Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern Jersey, Morristown, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|SCRI-Oncology Hematology Care, Cincinnati, Ohio, United States|Cleveland Clinic-Taussig Cancer Center, Cleveland, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Upstate Oncology Associates, Greenville, South Carolina, United States|Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Texas Onocolgy-Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Leesburg, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Green Bay Oncology, Green Bay, Wisconsin, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St George Hospital, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Health - Monash Medical Centre, Clayton, Victoria, Australia|Perth Blood Institute, Nedlands, Western Australia, Australia|Haematology and Oncology Clinics of Australia, Chermside, Australia|Prince of Wales Hospital, Randwick, Australia|Centre Hospitalier de Jolimont-Lobbes, Haine-Saint-Paul, Hainaut, Belgium|ZNA - Stuivenberg, Antwerpen, Belgium|AZ Sint Jan Brugge-Oostende AV, Brugge, Belgium|Hopital Brugmann, Brussels, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|St Augustinus, Wilrijk, Belgium|UC Louvain, Yvoir, Belgium|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Fakultní nemocnice Brno, Brno, NAP, Czechia|Faculty Hospital Olomouc, Olomouc, NAP, Czechia|Fakultní nemocnice Plzeň, Plzeň, NAP, Czechia|University Hospital Hradec Kralove, Králová, Czechia|Chu d'Amiens Hopital Sud, Amiens, Cedex 1, France|Hôpital Caremeau, Nimes, Cedex 9, France|CHU Rennes, Rennes, Cedex 9, France|CHU Purpan, Toulouse, Cedex 9, France|CH de Mulhouse, Mulhouse, Cedex, France|CHU de CAEN, Caen, France|Centre Hospitalier de Lens, Lens, France|Hopital l'Archet, CHU de Nice, Nice, France|Saint Antoine Hospital, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif Cedex, France|Charite-Medical University, Berlin, Germany|Gemeinschaftspraxis Hämatologie/Onkologie, Dresden, Germany|University Hospital Essen, Essen, Germany|Uniklinik Freiburg, Freiburg, Germany|Universitatsklinikum Halle (Saale), Halle (Saale), Germany|Klinik I fur Innere Medizin, Universitat Koln, Koln, Germany|University Hospital Leipzig, Leipzig, Germany|Städtisches Klinikum München GmbH, Munchen, Germany|University of Munster, Munster, Germany|University Hospital Ulm, Ulm, Germany|Semmelweis Egyetem AOK, Budapest, Hungary|University of Debrecen, Belgyogyaszati Intezet, Debrecen, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Kaposi Mór Oktató Kórház, Kaposvár, Hungary|SZTE II. sz Belgyogyoszati Klinika es Kardiologiai Kozpont, Szeged, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőint, Szolnok, Hungary|University Hospital Maastricht, Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland District Health Board, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Canterbury District Health Board, Christchurch, New Zealand|North Shore Hospital, Takapuna, New Zealand|CCDHB - Wellington Hospital, Wellington, New Zealand|Bashkir State Medical University, Ufa, Republic Of Bashkortostan, Russian Federation|Saratov State Medical University, Saratov, Saratov Region, Russian Federation|National Haematology Research Center, Moscow, Russian Federation|Republican Hopsital n.a. V.A. Baranov, Petrozavodsk, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russian Federation|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Belfast Health and Social Care Trust, Belfast, N. Ireland, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's Hospital, London, United Kingdom|Hammersmith Hosp - ICH NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Withdrawn,NCT02677948,"CHRONIC LYMPHOCYTIC LEUKEMIA|LYMPHOMA, SMALL LYMPHOCYTIC",All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Withdrawn,NCT02564536,CHRONIC MYELOMONOCYTIC LEUKEMIA|JUVENILE MYELOMONOCYTIC LEUKEMIA|ATYPICAL CHRONIC MYELOID LEUKEMIA|MYELOPROLIFERATIVE NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELOFIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Withdrawn,NCT02584777,PRIMARY MYELOFIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61P35/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,NCT00003505,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Burzynski Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,NCT00003502,CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Burzynski Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,0,DB11703,__ACALABRUTINIB,7459554,Withdrawn,NCT02735876,MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,0,DB11703,__ACALABRUTINIB,7459554,Withdrawn,,MANTLE CELL LYMPHOMA (MCL),,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Terminated,NCT01362036,MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MD Anderson Leukemia Department, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Withdrawn,NCT01554254,CORD BLOOD TRANSPLANT|HEMATOLOGIC MALIGNANCY|INHERITED METABOLIC DISEASE,All,"6 Months to 20 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pediatric Bone and Cord Blood, Duke Univ. Med. Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Withdrawn,NCT01882387,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Siteman Cancer Center, St Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Withdrawn,,"MALIGNANCIES, HEMATOLOGIC",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)C(C)C)C(N)=O,0,DB11724,__BOMBESIN,,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,1619.87,686.13,22.0,23.0,4.0,166.6,418.43,51.0,1.0,0.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,0,DB11730,__RIBOCICLIB,8324225,Terminated,NCT02414724,LYMPHOMA|SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,1,1
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,0,DB11763,__MOMELOTINIB,WO-2008109943-A1,Terminated,NCT01998828,POLYCYTHEMIA VERA|ESSENTIAL THROMBOCYTHEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottsdale, Arizona, United States|Whittier, California, United States|Tupelo, Mississippi, United States|Saint Louis, Missouri, United States|Houston, Texas, United States|Frankston, Victoria, Australia|Parkville, Victoria, Australia|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|La Tronche, France|Nantes Cedex 1, France|Paris, France|Dresden, Germany|Minden, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,414.469,103.17,7.0,2.0,4.0,44.23,118.46,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0
CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,0,DB11781,__TOSEDOSTAT,,Terminated,NCT01636609,ACUTE MYELOID LEUKEMIA|HIGH RISK MYELODYSPLASTIC SYNDROME,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.9,406.47900000000004,124.96,5.0,4.0,2.0,42.88,105.13,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,0,DB11782,__BIRINAPANT,,Terminated,NCT01486784,ACUTE MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.21,806.957,194.92,8.0,8.0,6.0,86.23,214.65,15.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,0,DB11782,__BIRINAPANT,,Terminated,NCT02147873,MYELODYSPLASTIC SYNDROME (MDS)|CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML),All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Palo Verde Hematology Oncology, Glendale, Arizona, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|North County Oncology, Oceanside, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Wellness Oncology & Hematology, West Hills, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Bond Clinic PA, Winter Haven, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville Hospital/James Graham Brown Cancer Center, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|New Jersey Hematology Oncology Associates, Brick, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Monter Cancer Center, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Blood and Cancer Care Associates, P.A., Rock Hill, South Carolina, United States|Tennessee Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Tyler Hematology Oncology PA, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Metro South Health, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|The Alfred, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Perth Blood Institute, Nedlands, Western Australia, Australia|Klinikum Rechts der Isar, Technischen Universitat Munchen, Munchen, Bayern, Germany|Klinikum der Ludwig-Maximilians-Universitat Munchen, Munich, Bayern, Germany|Marien Hospital Dusseldorf, Dusseldorf, Nordrhein-Westfalen, Germany|University Hospital of Cologne, Cologne, North Rhine Westphalia, Germany|University Hospital Halle, Halle (Saale), Saxony-Anhalt, Germany|Universitatsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Medizinische Universitatsklinik Heidelberg, Heidelberg, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, La Laguna, S/C Tenerife, Spain|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital University Reina Sofia, Cordoba, Spain|Hospital Universitario Gregorio Maranon, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.21,806.957,194.92,8.0,8.0,6.0,86.23,214.65,15.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,0,DB11805,__SARACATINIB,WO-2003045395-A1,Terminated,NCT02737202,PULMONARY LYMPHANGIOLEIOMYOMATOSIS,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States|Loyola Medical Center, Chicago, Illinois, United States|Laboratory of Translational Research NHLBI, Bethesda, Maryland, United States|University of Cincinnati, Cincinnati, Ohio, United States|Baylor College of Medicine - Ben Taub General Hospital, Houston, Texas, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,32.7488,21.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,542.026,90.44,10.0,1.0,6.0,57.31,143.64,8.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,0,DB11805,__SARACATINIB,WO-2003045395-A1,Terminated,NCT00718809,INVASIVE THYMOMA AND THYMIC CARCINOMA|RECURRENT THYMOMA AND THYMIC CARCINOMA|STAGE III THYMOMA|STAGE IVA THYMOMA|STAGE IVB THYMOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Hospitals and Clinics, Stanford, California, United States|Indiana University Medical Center, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,32.7488,21.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,542.026,90.44,10.0,1.0,6.0,57.31,143.64,8.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C[C@](C)(OC(C)=O)[C@H]2[C@@H]1OC(=O)CCCCCCC,0,DB11813,__MIPSAGARGIN,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,1409.5410000000006,529.98,23.0,13.0,3.0,148.12,339.89,50.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,DB11816,__OMECAMTIV_MECARBIL,US-20060014761-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01383447,PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University, Baltimore, Maryland, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01159301,"ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT00866333,HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tower Cancer Research Foundation, Beverly Hills, California, United States|University of Colorado, Denver, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,NCT01668173,MYELOPROLIFERATIVE NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,NCT01485536,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,0,DB11886,__INFIGRATINIB,EP-1761505-B1,Terminated,,"MALIGNANCIES, HEMATOLOGIC",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,43.0,73.7920696523542,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.68,560.475,95.09,8.0,2.0,4.0,58.51,152.71,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1
CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,0,DB11890,__CILENGITIDE,WO-2003032961-A2,Terminated,NCT00089388,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B),All,"50 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.96,588.6659999999998,235.91,10.0,8.0,2.0,59.8,159.97,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,1,1
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,0,DB11899,__MK-8776,,Terminated,NCT00907517,"MYELOGENOUS LEUKEMIA, ACUTE|LEUKEMIA, LYMPHOCYTIC, ACUTE|LEUKEMIA, LYMPHOBLASTIC, ACUTE, PHILADELPHIA-POSITIVE|MYELOGENOUS LEUKEMIA, CHRONIC, AGGRESSIVE PHASE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,376.26199999999994,86.06,5.0,2.0,4.0,35.95,114.26,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,0,DB11899,__MK-8776,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,376.26199999999994,86.06,5.0,2.0,4.0,35.95,114.26,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,0,DB11901,__APALUTAMIDE,8445507,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,73.82492453643809,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,477.44,89.33,4.0,1.0,4.0,43.44,113.6,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1
CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1,0,DB11909,__VARESPLADIB,5155118,Terminated,NCT01522196,SICKLE CELL DISEASE|VASO-OCCLUSIVE CRISIS,All,"5 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Investigator Site 101, Atlanta, Georgia, United States",C07D403/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,54.0,34.9904515493131,46.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.4,380.4,111.62,5.0,2.0,3.0,39.03,102.9,8.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,0,DB11941,__TASISULAM,WO-2003035629-A1,Terminated,NCT01185548,LYMPHOMA|ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Trent, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,415.1,63.24,3.0,1.0,2.0,33.94,81.11,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,0,DB11941,__TASISULAM,WO-2003035629-A1,Terminated,NCT01209832,ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France",A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,415.1,63.24,3.0,1.0,2.0,33.94,81.11,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Suspended,NCT02303392,PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Terminated,NCT02314247,PERIPHERAL T-CELL LYMPHOMA (PTCL)|CUTANEOUS T-CELL LYMPHOMA (CTCL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Concord Repatriation General Hospital (CRGH), Concord, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Cabrini Hospital, Malvern, Victoria, Australia|National Cancer Centre, Singapore, Singapore",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Terminated,NCT03071276,ACUTE MYELOID LEUKEMIA,All,"up to 24 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of Chicago, Chicago, Illinois, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02389543,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02431351,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Suspended,NCT03370185,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tempe, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|QUEST Research Institute, Royal Oak, Michigan, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Morristown, New Jersey, United States|Medical Oncology Associates PS, WA, Spokane, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Terminated,NCT02391545,CD20+ FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Palo Alto, California, United States|Hackensack, New Jersey, United States|Rochester, New York, United States|Dallas, Texas, United States|Kortrijk, Belgium|Leuven, Belgium|Wilrijk, Belgium|Clermont-Ferrand, France|Marseille Cedex 05, France|Pessac, France|Rouen Cedex 1, France|Tours Cedex 01, France|Bologna, Italy|Varese, Italy|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Leeds, United Kingdom|London, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Terminated,NCT02204982,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Frankston, Victoria, Australia|Bordeaux, France|Bologna, Italy|Terni, Italy|Gdynia, Poland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02576275,INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA|MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Plainville, Connecticut, United States|Plantation, Florida, United States|Thomasville, Georgia, United States|East Setauket, New York, United States|Cookeville, Tennessee, United States|Knoxville, Tennessee, United States|Spokane, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02605694,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1,0,DB11965,__SJG-136,,Terminated,NCT00301769,ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|DE NOVO MYELODYSPLASTIC SYNDROMES|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|SECONDARY MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,556.619,102.26,8.0,0.0,6.0,61.87,157.22,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0
Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,0,DB11968,__MK-7145,US-20100286123-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,46.686790283168,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.33,466.534,99.54,6.0,2.0,5.0,49.95,128.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1,0,DB11970,__BURIXAFOR,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,566.732,151.9,11.0,6.0,4.0,65.83,161.18,14.0,1.0,0.0,0.0,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,0,DB11977,__GOLVATINIB,EP-1889836-A1,Terminated,,ADVANCED OR METASTATIC SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61P35/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,81.710096716565,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.19,633.701,119.14,6.0,3.0,6.0,64.23,172.48,8.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,0,DB11978,__GLASDEGIB,8148401,Terminated,NCT02226172,PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States|UCSD Medical Center Clinical Laboratory - La Jolla, La Jolla, California, United States|University of California San Diego (UCSD) Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center- Hillcrest, San Diego, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Huntsman Cancer Institute-University of Utah, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Kobe University Hospital, Kobe, Hyogo, Japan|Osaka University Hopsital, Suita-Shi, Osaka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,45.471159572065105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,374.44800000000004,96.84,4.0,3.0,4.0,40.98,108.26,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,0,DB11979,__ELAGOLIX,6872728,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,86.0,25.692519353580106,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.68,631.6,99.18,6.0,2.0,4.0,59.44,156.06,12.0,1.0,0.0,0.0,1,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0
COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,0,DB11991,__OPROZOMIB,,Terminated,NCT01832727,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Division of Hematology/ Oncology, UNC at Chapel Hill, Chapel Hill, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France|CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France|CHU de NANCY - Hopital de BRABOlS, Vandoeuvre Les Nancy, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,532.61,148.25,8.0,3.0,3.0,53.03,134.34,14.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,0,DB12008,__PREXASERTIB,WO-2010077758-A1,Terminated,NCT03735446,ACUTE MYELOID LEUKEMIA|MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States",A61P1/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.77,365.397,134.76,8.0,3.0,3.0,37.99,100.65,8.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1,0,DB12060,__RRX-001,,Terminated,NCT02096341,MALIGNANT SOLID TUMOR|LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sarah Cannon Research Institute, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,268.02299999999997,106.59,5.0,0.0,1.0,18.33,44.1,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Terminated,NCT02198482,ACUTE MYELOID LEUKEMIA (AML)|HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Aschaffenburg, Aschaffenburg, Germany|Helios Hospital Bad Saarow, Bad Saarow, Germany|Vivantes Hospital Am Urban, Berlin, Germany|Vivantes Hospital Neukölln, Berlin, Germany|Charite Berlin Campus Virchow Hospital, Berlin, Germany|Knappschaftskrankenhaus Bochum-Langendeer, Bochum, Germany|University Hospital Bonn, Bonn, Germany|Community Hospital Braunschweig, Braunschweig, Germany|Hospital Darmstadt, Darmstadt, Germany|University Hospital Düsseldorf, Düsseldorf, Germany|Hospital Essen, Protestant Hospital Essen-Werden, Essen, Germany|Hospital Esslingen, Esslingen, Germany|Malteser Hospital St. Franziskus, Flensburg, Germany|Hospital Frankfurt-Höchst, Frankfurt, Germany|Medical Care Unit Osthessen, Fulda, Germany|University Hospital Gießen, Gießen, Germany|Wilhelm-Anton-Hospital Goch, Goch, Germany|University Hospital Göttingen, Göttingen, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Asklepios Hospital Altona, Hamburg, Germany|Hospital Hanau, Hanau, Germany|KRH Hospital Siloah-Oststadt-Heidehaus, Hannover, Germany|Hannover Medical School, Hannover, Germany|SLK-Hospital Heilbronn, Heilbronn, Germany|Marienhospital Herne, Herne, Germany|University Hospital des Saarlandes, Homburg/Saar, Germany|Community Hospital Karlsruhe, Karlsruhe, Germany|University Hospital Schleswig-Holstein, Kiel, Germany|Caritas Hospital Lebach, Lebach, Germany|Hospital Lippe-Lemgo, Lemgo, Germany|University Hospital Magdeburg, Magdeburg, Germany|University Hospital Johannes Gutenberg Mainz, Mainz, Germany|Johannes Wesling Hospital Minden, Minden, Germany|Stauferklinikum Schwäbisch-Gmünd, Mutlangen, Germany|Hospital Schwabing, München, Germany|Hospital rechts der Isar München, München, Germany|Hospital Oldenburg, Oldenburg, Germany|Hospital Passau, Passau, Germany|Hospital Stuttgart, Stuttgart, Germany|Diakonie Hospital Stuttgart, Stuttgart, Germany|Hospital Traunstein, Traunstein, Germany|Mutterhaus der Borromäerinnen, Trier, Germany|Hospital Barmherzige Brüder Trier, Trier, Germany|University Hospital Tübingen, Tübingen, Germany|University Hospital Ulm, Ulm, Germany",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Terminated,NCT02721875,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Fukui Hospital, Fukui, Yoshida-gun, Japan",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Terminated,NCT01957644,"MYELODYSPLASTIC SYNDROMES|LEUKEMIA, MYELOMONOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1230.33.33002 Boehringer Ingelheim Investigational Site, Marseille, France|1230.33.33001 Boehringer Ingelheim Investigational Site, Paris, France|1230.33.49011 Boehringer Ingelheim Investigational Site, Berlin, Germany|1230.33.49002 Boehringer Ingelheim Investigational Site, Dresden, Germany|1230.33.49001 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|1230.33.49005 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|1230.33.49004 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1230.33.49010 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1230.33.49008 Boehringer Ingelheim Investigational Site, Hannover, Germany|1230.33.49012 Boehringer Ingelheim Investigational Site, Kassel, Germany|1230.33.49014 Boehringer Ingelheim Investigational Site, Leipzig, Germany|1230.33.49009 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1230.33.49006 Boehringer Ingelheim Investigational Site, München, Germany|1230.33.49003 Boehringer Ingelheim Investigational Site, Ulm, Germany",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02527174,"LEUKEMIA, MYELOID, ACUTE|LEUKEMIA, MONOCYTIC, ACUTE|LEUKEMIA, MYELOMONOCYTIC, ACUTE|LEUKEMIA, ERYTHROBLASTIC, ACUTE|LEUKEMIA, MEGAKARYOBLASTIC, ACUTE",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02861040,RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02875002,RELAPSED AND REFRACTORY AGGRESSIVE B- AND T-CELL LYMPHOMAS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States|Massey Cancer Center, Richmond, Virginia, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,0,DB12064,__BMS-777607,,Withdrawn,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,512.893,106.78,5.0,2.0,4.0,49.23,132.8,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,0,DB12101,__CC-220,WO-2014025958-A2,Withdrawn,NCT02192489,SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,449.50699999999995,88.18,6.0,1.0,5.0,47.73,122.29,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,DB12109,__CPI-613,US-20100190858-A1,Withdrawn,NCT01520805,ACUTE MYELOID LEUKEMIA (AML)|MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cornerstone Pharmaceuticals, Inc, Cranbury, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,34.629047824390604,2.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.59,388.58,37.3,2.0,1.0,2.0,45.88,114.56,13.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT03135028,HEMATOLOGIC MALIGNANCY|ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Fukui Hospital, Fukui, Japan|Kyushu University Hospital, Fukuoka, Japan|Tokai University Hospital, Kanagawa, Japan|Tohoku University Hospital, Miyagi, Japan|NTT Medical Center Tokyo, Tokyo, Japan|Kindai University Hospital, Ōsaka, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT02404220,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|UCLA, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|University of California San Diego (UCSD), San Diego, California, United States|University of Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Bon Secour St. Francis Hospital, Greenville, South Carolina, United States|University of WA, Seattle, Washington, United States|Princess Margaret, Toronto, Ontario, Canada|Medizinische Klinik mit Schwerpunkt Hepatologie & Gastroenterology, Berlin, Germany|Medizinische Klinik und Poliklinik I, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT02568683,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Forrest General Hospital, Hattiesburg, Mississippi, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France|Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, NORD Pas-de-calais, France|Institut Paoli Calmettes, Marseille, Provence Alpes COTE D'azur, France|Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France|Centre Hospital Lyon Sud, Pierre Benite, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT03225924,DLBCL,All,"60 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Jules Bordet, Bruxelles, Belgium|Clinique Universite Catholique de Louvain Saint-Luc, Bruxelles, Belgium|University Hospital Gent, Gent, Belgium|Hopital Joliment, Haine-Saint-Paul, Belgium|Az Groeninge, Kortrijk, Belgium|UCL Namur, Yvoir, Belgium|Ch de Bourg En Bresse, Bourg-en-Bresse, France|CHU Côte de Nacre, Caen, France|CHU Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|Ch de Versailles - Hopital Andre Mignot, Le Chesnay, France|Clinique Victor Hugo, Le Mans, France|Chu de Limoges - Hopital Dupuytren, Limoges, France|Clinique de La Sauvegarde, Lyon, France|CHU Lyon Sud, Lyon, France|CHU Montpellier, Montpellier, France|Ch Region Mulhouse Et Sud Alsace, Mulhouse, France|Hopital Necker Paris, Paris, France|Chu de Bordeaux, Pessac, France|Ch Annecy Genevois, Pringy, France|Chu de Reims - Hopital Robert Debre, Reims, France|Chu de Rennes - Pontchaillou, Rennes, France|Ch de Roubaix-Hopital Victor Provo, Roubaix, France|Iuct Oncopole de Toulouse, Toulouse, France|Hôpital Bretonneau- Centre H. Kaplan, Tours, France|Ch de Valenciennes, Valenciennes, France|Chru de Nancy, Vandœuvre-lès-Nancy, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT01796470,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Collaborative Research Group LLC, Boynton Beach, Florida, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT01799889,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|NON-FL INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Rocky Mountain Cancer Centers, LLP, Boulder, Colorado, United States|Kaiser Permanente of Colorado, Denver, Colorado, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer - Colonial, Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Gwinnett Hospital System Dba The Center for Cancer Care, Lawrenceville, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Hematology Oncology Clinic, PLLC, Baton Rouge, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|One Medical Center Drive, Lebanon, New Hampshire, United States|Summit Medical Group, P.A., Florham Park, New Jersey, United States|Clinical Research Alliance, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Williamette Valley Cancer Center and Research Institute, Springfield, Oregon, United States|Prairie Lakes Health Care System, Inc., Watertown, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Cancer Care Network of South Texas, San Antonio, Texas, United States|Cancer Care Center of South Texas, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|University of Washington, Seattle, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Yakima Valley Memorial Hospital North Star Lodge, Yakima, Washington, United States|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,0,DB12146,__RIGOSERTIB,WO-2003072062-A2,Terminated,NCT02730884,LEUKEMIA|MYELOFIBROSIS|ANEMIA|SPLENOMEGALY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61P17/12 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,86.0,32.7488,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.64,451.49,120.39,9.0,2.0,2.0,46.32,116.5,11.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,0,DB12146,__RIGOSERTIB,WO-2003072062-A2,Withdrawn,NCT02075034,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",A61P17/12 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,86.0,32.7488,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.64,451.49,120.39,9.0,2.0,2.0,46.32,116.5,11.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Terminated,NCT02456675,REFRACTORY HODGKIN LYMPHOMA|RECURRENT ADULT HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Withdrawn,NCT02355431,SOLID TUMORS AND HEMATOLOGIC MALIGNANCY|NSCLC (NON-SMALL CELL LUNG CARCINOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ogden, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",C07D335/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00612612,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00538187,ADULT NON-HODGKIN LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00719901,REFRACTORY MULTIPLE MYELOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,0,DB12226,__TERAMEPROCOL,US-20060135461-A1,Terminated,NCT00664677,LEUKEMIAS|ACUTE MYELOID LEUKEMIA (AML)|ACUTE LYMPHOCYTIC LEUKEMIA (ALL)|ADULT T CELL LEUKEMIA (ATL)|CHRONIC MYELOID LEUKEMIA (CML-BP)|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|MYELODYSPLASTIC SYNDROME (MDS)|CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.77,358.478,36.92,4.0,0.0,2.0,41.9,104.55,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,0,DB12226,__TERAMEPROCOL,US-20060135461-A1,Terminated,NCT00664586,REFRACTORY SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Sarah Cannon Cancer Center, Nashville, Tennessee, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.77,358.478,36.92,4.0,0.0,2.0,41.9,104.55,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,0,DB12254,__ABT-751,5250549,Terminated,NCT00439296,RECURRENT PEDIATRIC ALL|RELAPSED PEDIATRIC ALL|ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY PEDIATRIC ALL,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSF School of Medicine, San Francisco, California, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Seattle Children's Hospital, Seattle, Washington, United States",C07H15/26,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,25.9225035421671,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.4,371.41,100.55,6.0,3.0,3.0,38.29,97.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,0,DB12255,__VADADUSTAT,US-20070299086-A1,Terminated,NCT03140722,ANEMIA|DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Bakersfield, California, United States|Research Site, Elk Grove, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Lynwood, California, United States|Research Site, San Diego, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Statesboro, Georgia, United States|Research Site, Detroit, Michigan, United States|Research Site, Bronx, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Norfolk, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,39.5572804369699,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.53,306.7,99.52,5.0,3.0,2.0,29.63,75.51,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,0,DB12255,__VADADUSTAT,US-20070299086-A1,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,39.5572804369699,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.53,306.7,99.52,5.0,3.0,2.0,29.63,75.51,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,0,DB12267,__BRIGATINIB,9012462,Withdrawn,NCT04260009,ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK +) ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMORS|SOLID TUMORS,All,"1 Year to 25 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65717,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,72.0,70.99940450522591,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,584.1,85.86,9.0,2.0,5.0,64.1,164.77,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1
CC(C)OP(=O)(OC(C)C)C(Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OC(C)C)OC(C)C,0,DB12276,__APOMINE,6048995,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/404,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,19.7129304503172,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.53,562.665,91.29,3.0,1.0,1.0,61.56,151.23,14.0,1.0,0.0,0.0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,0,DB12323,__RADOTINIB,US-20080096899-A1,Withdrawn,NCT02421926,"LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE",All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Seoul National University Bundang Hospital, Seongnam, Gyong-gi Province, Korea, Republic of|Korea University Ansan Hospital, Ansan, Korea, Republic of|Busan National University Hospital, Busan, Korea, Republic of|Haeundae Paik Hospital, Busan, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soonchyunhyang University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",A61P35/00 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,42.0542516273434,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,530.515,110.51,7.0,2.0,5.0,52.47,150.32,7.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,NCT03287245,POLYCYTHEMIA VERA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cleveland Clinic Cancer Center, Independence, Ohio, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, Australia|Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, Canada|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, Italy|Az. Ospedaliero-Universitaria Careggi; CRIMM, Firenze, Toscana, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,NCT03135262,"FOLLICULAR LYMPHOMA|LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Norton Cancer Institute - Dutchmans, Louisville, Kentucky, United States|Mount Sinai Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Swedish Cancer Inst., Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Klinikum Augsburg, Augsburg, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Kassel; Klinik für Onkologie und Hämatologie, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,NCT02624986,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Arizona, Phoenix, Arizona, United States|University of Colorado, Aurora, Colorado, United States|Norton Medical Plaza II, Louisville, Kentucky, United States|Swedish Cancer Institute, Cary, North Carolina, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Zentralklinikum Augsburg, Augsburg, Germany|Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Wurzburg, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|North Shore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,,POLYCYTHEMIA VERA (PV),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,0,DB12332,__RUCAPARIB,6495541,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Withdrawn,NCT01423539,DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fountain Valley, California, United States|Hudson, Florida, United States|Lawrenceville, Georgia, United States|Centralia, Illinois, United States|Harvey, Illinois, United States|Terre Haute, Indiana, United States|Hazard, Kentucky, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Jefferson City, Missouri, United States|Great Falls, Montana, United States|Newark, Ohio, United States|Nashville, Tennessee, United States",C07D487/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Withdrawn,,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,0,DB12369,__SOTRASTAURIN,WO-2005039549-A1,Withdrawn,NCT02285244,PROLYMPHOCYTIC LEUKEMIA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,20.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.12,438.4812,94.22,6.0,2.0,6.0,46.82,126.14,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,0,DB12381,__MERESTINIB,US-20100022529-A1,Terminated,NCT03292536,BONE METASTASES|BREAST CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,26.6453109920121,7.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.75,552.5309,105.14,4.0,2.0,6.0,55.09,163.62,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1
Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,0,DB12405,__TRICIRIBINE,5633235,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,34.7276124766422,177.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,320.309,144.47,8.0,4.0,4.0,31.22,90.56,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,0,DB12415,__GALETERONE,WO-2008154382-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,0,DB12442,__ALVESPIMYCIN,,Terminated,NCT01126502,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,616.7455,169.52,9.0,4.0,2.0,66.39,172.38,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0
COc1c(C)cc2c(c1O)[C@@H]1[C@@H]3Cc4c(OC(C)=O)c(C)c5c(c4[C@H](CNC(=O)/C=C/c4cccc(C(F)(F)F)c4)N3[C@@H](O)[C@H](C2)N1C)OCO5,0,DB12454,__ZALYPSIS,,Terminated,NCT00359294,SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,709.7189999999997,130.03,9.0,3.0,7.0,70.93,180.8,8.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,1,1,0
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,0,DB12483,__COPANLISIB,7511041,Terminated,NCT02455297,"LYMPHOMA, MANTLE-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baltimore, Maryland, United States|Hackensack, New Jersey, United States|New York, New York, United States|New York, New York, United States|Burlington, Vermont, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,0,DB12483,__COPANLISIB,7511041,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1
CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,0,DB12494,__SGI-1776,WO-2008058126-A2,Terminated,NCT00848601,PROSTATE CANCER|NON-HODGKINS LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"UCLA, Los Angeles, California, United States|Cancer Therapy Research Center, San Antonio, Texas, United States|Royal Marsden Hospital, Sutton, England, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,405.425,54.69,5.0,1.0,4.0,39.98,112.63,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,1
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNCc1ccc([123I])cc1)C(=O)O)C(=O)O,0,DB12514,__IOFOLASTAT_I-123,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,531.337,165.06,8.0,6.0,1.0,46.59,114.95,14.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,0,DB12522,__TOREFORANT,WO-2007117399-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,392.551,69.73,5.0,2.0,4.0,48.0,131.1,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1
O=N[O-],0,DB12529,__NITRITE,,Terminated,NCT01033227,SICKLE CELL DISEASE,All,"8 Years to 23 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,46.0055,52.49,3.0,0.0,0.0,2.44,7.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,0,DB12591,__BMS-911543,,Terminated,NCT01236352,CANCER,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States|The Mount Sinai School Of Medicine, New York, New York, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,432.532,85.8,5.0,1.0,6.0,48.82,134.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,0,DB12594,__AZD-9056,WO-2001044170-A1,Withdrawn,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61P1/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.33,419.01,61.36,3.0,3.0,4.0,47.83,118.78,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,DB12602,__PENTETREOTIDE,6180082,Terminated,NCT00002947,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD LANGERHANS CELL HISTIOCYTOSIS|GASTROINTESTINAL CARCINOID TUMOR|HEAD AND NECK CANCER|INTRAOCULAR MELANOMA|ISLET CELL TUMOR|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|NEOPLASTIC SYNDROME|NEUROENDOCRINE CARCINOMA OF THE SKIN|PHEOCHROMOCYTOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Yale Comprehensive Cancer Center, New Haven, Connecticut, United States",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,57.0,26.2510523830058,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1394.58,494.22,23.0,17.0,5.0,140.9,353.02,34.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0
CC(C)NCCCn1c(Sc2cc3c(cc2I)OCO3)nc2c(N)ncnc21,0,DB12638,__PU-H71,WO-2014018862-A1,Terminated,NCT01581541,SOLID TUMORS|LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.61,512.368,100.11,7.0,2.0,4.0,46.94,119.54,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0
S=C=NCCc1ccccc1,0,DB12695,__PHENETHYL_ISOTHIOCYANATE,6348220,Withdrawn,NCT00968461,LEUKEMIA|LYMPHOPROLIFERATIVE DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,34.3990636358036,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.41,163.239,12.36,1.0,0.0,1.0,18.1,50.7,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)[C@H](C(=O)Nc1ccc(C(=O)NO)cc1)c1ccccc1,0,DB12707,__AR-42,,Suspended,NCT02569320,RECURRENT PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,312.369,78.43,3.0,3.0,2.0,32.81,90.21,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCOC(=O)[C@H](C)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc21)N[C@@H](C)C(=O)OCC,0,DB12762,__RABACFOSADINE,,Terminated,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,526.535,184.61,9.0,4.0,3.0,52.56,133.52,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Terminated,,MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Withdrawn,,DIFFUSE LARGE B-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](NC(=O)c3cc(=O)[nH]c(=O)[nH]3)C[C@@H](C(=O)NCCNC(=O)COCCOCC(=O)Nc3cc(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(S(=O)(=O)O)c34)C[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2OC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O,0,DB12778,__RIVIPANSEL,,Terminated,NCT02433158,SICKLE CELL ANEMIA|SICKLE CELL DISEASE|SICKLE CELL DISORDERS|PAIN CRISIS|VASO-OCCLUSIVE CRISIS,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Non-Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama Women's and Children's Hospital, Mobile, Alabama, United States|Arkansas Children's Hospital Research Pharmacy, Little Rock, Arkansas, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|UC Davis Medical Center Main Hospital, Sacramento, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Howard University Center for Sickle Cell disease, Washington, District of Columbia, United States|MedStar Health Research Institute, Washington, District of Columbia, United States|Howard University Hospital, Washington, District of Columbia, United States|Golisano Childrens Hospital of Southwest Florida, Fort Myers, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|University of Miami, Miami, Florida, United States|St. Mary's Medical Center, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center:, Atlanta, Georgia, United States|Grady Health System, Atlanta, Georgia, United States|Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center:, Atlanta, Georgia, United States|Emory Children's Center, Atlanta, Georgia, United States|Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center/, Atlanta, Georgia, United States|Children's Healthcare of Atlanta: Scottish Rite Campus, Atlanta, Georgia, United States|Memorial Family Medicine Center, Savannah, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|The University of Chicago/Comer Children's Hospital, Chicago, Illinois, United States|University of Chicago, Investigational Drug Service Pharmacy, Chicago, Illinois, United States|University of Maryland Medical System Investigational Pharmacy, Baltimore, Maryland, United States|University of Maryland Medical System, Baltimore, Maryland, United States|Johns Hopkins Department of Medicine Clinical Trials Unit, Baltimore, Maryland, United States|The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|The Johns Hopkins Hospital Department of Pharmacy Services, Baltimore, Maryland, United States|Johns Hopkins Medicine, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Center for Clinical Investigation, Brigham and Women's Hospital, Boston, Massachusetts, United States|Investigational Drug Services, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center - Outpatient Clinical Research Unit, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Center for Outpatient Health, Saint Louis, Missouri, United States|Barnes-Jewish Hospital Department of Pharmacy, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Center for Advanced Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Bristol Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|SUNY Downstate Medical Center University Hospital of Brooklyn, Brooklyn, New York, United States|Columbia University Medical Center Research Pharmacy, New York, New York, United States|MS CHONY Pediatric Emergency Department, New York, New York, United States|MS CHONY Pediatric Hematology/Oncology Unit, New York, New York, United States|Duke University Hospital, Investigational Drug Service, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University Brody School of Medicine, Greenville, North Carolina, United States|East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States|Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|University of Cincinnati - Hoxworth Building, Cincinnati, Ohio, United States|University of Cincinnati Medical Center / Investigational Pharmacy, Cincinnati, Ohio, United States|University of Cincinnati Medical Center / Research Office, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University of Cincinnati Physicians Company LLC, Cincinnati, Ohio, United States|UC Health Ridgeway Hospital, Cincinnati, Ohio, United States|The Ohio State University Investigational Drug Services, Columbus, Ohio, United States|The Ohio State University Wexner Center East, Columbus, Ohio, United States|The Ohio State University James Comprehensive Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Rhode Island Hospital-Pharmacy Service, Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Lifespan Comprehensive Sickle Cell Center, Charleston, South Carolina, United States|Medical University of South Carolina-Hospital, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MUSC Investigational Drug Services, Charleston, South Carolina, United States|Cook Children's Hematology and Oncology Center, Fort Worth, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Cook Children's Hematology and Oncology Center-Grapevine, Grapevine, Texas, United States|University of Texas Medical School, Houston, Texas, United States|Primary Children's Hospital Laboratory, Salt Lake City, Utah, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Main Hospital-VCU, Richmond, Virginia, United States|Virginia Commonwealth University - Investigational Drug Services, Richmond, Virginia, United States|Virginia Commonwealth University- Clinical Research Services Unit, Richmond, Virginia, United States|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Miseracordia Community Hospital, Edmonton, Alberta, Canada|Kaye Edmonton Clinic 3C, Edmonton, Alberta, Canada|University of Alberta Hospital, Pharmacy Services, Edmonton, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Research transition Facility, Edmonton, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|The Montreal Children's Hospital / McGill University Health Centre, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1447.42,567.07,30.0,15.0,8.0,140.15,328.37,30.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](NC(=O)c3cc(=O)[nH]c(=O)[nH]3)C[C@@H](C(=O)NCCNC(=O)COCCOCC(=O)Nc3cc(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(S(=O)(=O)O)c34)C[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2OC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O,0,DB12778,__RIVIPANSEL,,Terminated,,PAIN CRISIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1447.42,567.07,30.0,15.0,8.0,140.15,328.37,30.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
O[C@H]([C@@H]1CO1)[C@@H](O)[C@H]1CO1,0,DB12873,__DIANHYDROGALACTITOL,US-20020037328-A1,Withdrawn,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,11.663483849771,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,146.142,62.22,4.0,2.0,2.0,13.67,31.38,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT02889523,"LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"60 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHRU Lille - Hôpital Claude Huriez, Lille Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|CHU Lyon Sud, Pierre-Bénite Cedex, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT03213665,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III HODGKIN LYMPHOMA|ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV HODGKIN LYMPHOMA|ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA|EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|LOW GRADE GLIOMA|RECURRENT EPENDYMOMA|RECURRENT EWING SARCOMA|RECURRENT GLIOMA|RECURRENT HEPATOBLASTOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT LANGERHANS CELL HISTIOCYTOSIS|RECURRENT MALIGNANT GERM CELL TUMOR|RECURRENT MALIGNANT GLIOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT MEDULLOBLASTOMA|RECURRENT NEUROBLASTOMA|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT OSTEOSARCOMA|RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT RHABDOID TUMOR|RECURRENT RHABDOMYOSARCOMA|RECURRENT SOFT TISSUE SARCOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY LANGERHANS CELL HISTIOCYTOSIS|REFRACTORY MALIGNANT GERM CELL TUMOR|REFRACTORY MALIGNANT GLIOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY MEDULLOBLASTOMA|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY OSTEOSARCOMA|REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|REFRACTORY RHABDOID TUMOR|REFRACTORY SOFT TISSUE SARCOMA|RHABDOID TUMOR|STAGE III SOFT TISSUE SARCOMA AJCC V7|STAGE IV SOFT TISSUE SARCOMA AJCC V7|WILMS TUMOR,All,"12 Months to 21 Years   (Child, Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Withdrawn,NCT03217253,ANN ARBOR STAGE III B-CELL NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA|METASTATIC MALIGNANT SOLID NEOPLASM|STAGE III HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIB HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIC HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IV HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IVA HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IVB HEPATOCELLULAR CARCINOMA AJCC V7|UNRESECTABLE SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,DB12907,__MANNOSE,3932678,Withdrawn,NCT00886496,"FEVER, SWEATS, AND HOT FLASHES|INFECTION|LEUKEMIA|LYMPHOMA|MYELODYSPLASTIC SYNDROMES|NEUTROPENIA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,2 Years to 17 Years   (Child),Industry|NIH,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Children's Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A23L27/30,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,18.628719275549802,11245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.24,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,DB12907,__MANNOSE,3932678,Withdrawn,NCT00520325,CANCER|HEMATOLOGIC DISEASES|FEVER|NEUTROPENIA,All,2 Years to 17 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A23L27/30,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,18.628719275549802,11245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.24,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
CC(/C=N/N=C(N)N)=N\N=C(N)N,0,DB12967,__MITOGUAZONE,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,184.2024,153.52,8.0,4.0,0.0,18.58,48.85,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,DB12978,__PEXIDARTINIB,7893075,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,39.064457175712,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.64,417.82,66.49,4.0,2.0,4.0,39.33,105.89,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,0,DB12986,__VS-5584,,Terminated,NCT01991938,NON HEMATOLOGIC CANCERS|METASTATIC CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The Royal Marsden, Sutton, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.96,354.418,107.87,8.0,1.0,4.0,38.53,99.61,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(N)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,0,DB13023,__IPI-493,,Terminated,NCT01193491,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Weill Cornell Cancer Center, New York, New York, United States|M.D. Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.97,545.633,180.27,8.0,4.0,2.0,56.28,149.59,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,0,DB13053,__CP-195543,WO-2001034134-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.41,428.407,66.76,4.0,2.0,4.0,41.92,109.38,5.0,0.0,1.0,0.0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,,ADVANCED MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,0,DB13994,__AZD-7325,US-20070142328-A1,Suspended,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=P(O)(O)OP(=O)(O)O.O=P(O)(O)OP(=O)(O)O.O=P([O-])([O-])OP(=O)([O-])O.[Fe+3].[Fe+3].[Fe+3].[Fe+3],0,DB13995,__FERRIC_PYROPHOSPHATE_CITRATE,6689275,Terminated,,IRON-REFRACTORY IRON-DEFICIENCY ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K33/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,85.3241339657898,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.72,1321.5710000000001,140.62,7.0,1.0,0.0,14.23,68.14,21.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1
O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ca+2].[Na+].[Na+],0,DB14598,__EDETATE_CALCIUM_DISODIUM_ANHYDROUS,,Withdrawn,NCT01101412,"CHRONIC MYELOPROLIFERATIVE DISORDERS|INFECTION|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.03,374.26800000000003,167.0,10.0,0.0,0.0,24.74,105.69,11.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB14649,__DEXAMETHASONE_ACETATE,WO-2003030823-A2,Terminated,NCT02419469,LEUKEMIA|PRECURSOR-B ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOBLASTIC LYMPHOMA|LYMPHOMA,All,"12 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,32.7488,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.6,434.4977,100.9,5.0,2.0,4.0,45.02,111.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1
CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB14649,__DEXAMETHASONE_ACETATE,WO-2003030823-A2,Terminated,NCT01878708,T-CELL LYMPHOMA|RELAPSED T-CELL LYMPHOMA|REFRACTORY T-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,32.7488,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.6,434.4977,100.9,5.0,2.0,4.0,45.02,111.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N\O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1,0,DB14733,__CEFTOBIPROLE_MEDOCARIL,6232306,Terminated,NCT00529282,FEVER|NEUTROPENIA|GRAM-POSITIVE BACTERIAL INFECTIONS|PSEUDOMONAS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D501/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.0312737427873,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.16,690.66,256.48,13.0,4.0,6.0,64.88,163.59,9.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,1
CC(C)C[C@@H](NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](N)Cc1c[nH]c2ccccc12)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)O,0,DB14786,__NEROFE,,Withdrawn,NCT03059615,ACUTE MYELOGENOUS LEUKEMIA|MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Reẖovot, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.76,1897.215,666.11,25.0,25.0,9.0,199.41,511.75,54.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,0
CC(C)C[C@@H](NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](N)Cc1c[nH]c2ccccc12)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)O,0,DB14786,__NEROFE,,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.76,1897.215,666.11,25.0,25.0,9.0,199.41,511.75,54.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,0
O=[N+]([O-])c1nccn1CC(O)C[18F],0,DB14830,__FLUOROMISONIDAZOLE_F-18,,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,188.149,81.19,4.0,1.0,1.0,15.65,40.27,4.0,0.0,1.0,0.0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB14846,__BIMIRALISIB,WO-2010052569-A2,Withdrawn,,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.16,411.389,102.52,9.0,1.0,4.0,38.5,113.66,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,0,DB14904,__PIMASERTIB,WO-2013059320-A1,Terminated,NCT00957580,"LEUKEMIA, MYELOID, ACUTE|HEMATOLOGIC NEOPLASMS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Hospital Hotel Dieu, Service D'Hematologie, Nantes, Cedex, France|Hospital Edouard Herriot, Service d'Hematologie Clinique, Lyon Cedex, France|Hospital Saint Louis, Service des Maladies du Sang, Paris, France|CHU du Haut-Leveque, Service des Maladies du Sang Unite de Recherche Clinique, Pessac, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.17,431.20599999999996,94.48,5.0,4.0,2.0,36.39,92.2,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,1
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,0,DB14909,__IMETELSTAT,,Withdrawn,NCT01568632,SOLID TUMORS|LYMPHOMA,All,"1 Year to 21 Years   (Child, Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.2,4610.18,1587.05,74.0,45.0,35.0,442.86,1045.35,95.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,0
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,0,DB14969,__GTX-758,US-20070265296-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,181.0,60.0587281052999,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.09,341.314,60.77,3.0,2.0,3.0,32.11,88.88,3.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,0,DB14989,__UMBRALISIB,US-20140011819-A1,Suspended,NCT03776864,HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,27.13813425327001,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,571.56,105.15,7.0,1.0,6.0,56.6,163.22,6.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@@H]1CSSC[C@H](C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCCN)C(O)=N[C@H](CC(=N)O)C(=O)O)N=C(O)[C@@H](CCC(=N)O)N=C1O,0,DB15008,__GO-203-2C,,Withdrawn,NCT02658396,MULTIPLE MYELOMA|MULTIPLE MYELOMA IN RELAPSE|REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,2352.8,1353.82,72.0,55.0,1.0,242.72,738.97,81.0,1.0,0.0,0.0,1,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0
CC(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@@H]1CSSC[C@H](C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCCN)C(O)=N[C@H](CC(=N)O)C(=O)O)N=C(O)[C@@H](CCC(=N)O)N=C1O,0,DB15008,__GO-203-2C,,Withdrawn,,MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,2352.8,1353.82,72.0,55.0,1.0,242.72,738.97,81.0,1.0,0.0,0.0,1,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0
Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F,0,DB15011,__AVACOPAN,,Terminated,,ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.82,581.656,61.44,3.0,2.0,5.0,58.26,158.6,7.0,1.0,0.0,0.0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H]1[C@H]2N(C(=O)CN(C)N2C(=O)NCc2ccccc2)[C@@H](Cc2ccc(OP(=O)(O)O)cc2)C(=O)N1Cc1cccc2cccnc12,0,DB15034,__PRI-724,WO-2014061828-A1,Terminated,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.09,658.6519999999998,155.85,8.0,3.0,6.0,65.6,171.76,8.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,0,DB15057,__NUC-1031,,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.43,580.482,162.01,7.0,3.0,4.0,53.24,134.78,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1
C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]2N)[C@H](O)[C@@H]1O,0,DB15080,__ELX-02,,Terminated,NCT04069260,GENETIC DISEASE|NONSENSE MUTATION|CYSTINOSIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McGill University Health Center, Montréal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,482.531,262.38,14.0,10.0,3.0,48.09,109.01,6.0,1.0,0.0,0.0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0
Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21,0,DB15147,__TINOSTAMUSTINE,,Terminated,NCT03687125,MULTIPLE MYELOMA IN RELAPSE|MULTIPLE MYELOMA PROGRESSION|MULTIPLE MYELOMA WITH FAILED REMISSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of Kansas Medical Center Kansas City, Kansas City, Kansas, United States|Memorial Sloan Kettering Cancer Centre, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin, United States|Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway|Universitatsspital Basel, Basel, Switzerland|Universitatsspital Bern, Bern, Switzerland|Department of Clinical Research Oncology/Hematology, Kantonsspital St. Gallen, Saint Gallen, Switzerland|University Hospital Zurich, Zürich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,415.36,70.39,4.0,2.0,2.0,46.02,110.31,12.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0
Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21,0,DB15147,__TINOSTAMUSTINE,,Withdrawn,NCT04279938,RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,415.36,70.39,4.0,2.0,2.0,46.02,110.31,12.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0
CN1CCN(Cc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2)CC1,0,DB15187,__DUBERMATINIB,,Terminated,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.57,516.06,93.7,8.0,2.0,4.0,55.45,141.3,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,0,DB15189,__BIRABRESIB,EP-0989131-A1,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61P1/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.08137744101521,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.04,491.99,92.4,5.0,2.0,5.0,50.88,146.03,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1
CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2,0,DB15195,__MIBENRATIDE,,Withdrawn,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,2097.27,940.67,37.0,32.0,5.0,203.7,528.21,32.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,1,1
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,0,DB15205,__CAPROMORELIN,6107306,Terminated,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0202,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,17.7416374052855,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,505.619,117.33,6.0,2.0,4.0,54.59,140.17,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,0,DB15219,__TOMIVOSERTIB,,Terminated,NCT02937675,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Florida Cancer Specialist, Sarasota, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Rochester, Rochester, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C,0,DB15245,__OLOROFIM,,Withdrawn,,INVASIVE ASPERGILLOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,498.56199999999995,83.36,6.0,1.0,5.0,52.99,144.16,6.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1
Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C,0,DB15245,__OLOROFIM,,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,498.56199999999995,83.36,6.0,1.0,5.0,52.99,144.16,6.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,0,DB15250,__VERCIRNON,US-20130059893-A1,Withdrawn,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,37.848826464609104,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.15,444.93,90.18,4.0,1.0,3.0,45.01,118.09,5.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,0,DB15266,__TAK-580,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,506.29,135.78,7.0,3.0,3.0,43.95,114.04,6.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,0,DB15273,__VS-4718,,Withdrawn,NCT02215629,RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA|RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.55,501.51,87.75,7.0,3.0,4.0,50.39,131.1,8.0,1.0,0.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,0,DB15295,__TENALISIB,US-20140364447-A1,Terminated,NCT03471351,CLASSICAL HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States|Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,, Detroit, Michigan, United States|University of Washington, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.31,415.42800000000005,92.79,6.0,2.0,5.0,41.59,116.09,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(=O)C3CCCC3)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)C)c4cccs4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB15384,__SIMOTAXEL,,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,896.01,230.52,10.0,4.0,7.0,91.58,221.91,16.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,0,DB15418,__AZD-9977,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,399.37800000000004,96.97,5.0,2.0,4.0,38.12,101.36,3.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,0,DB15440,__GSK-3117391,,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,403.523,100.55,5.0,3.0,3.0,45.52,108.98,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1
CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,0,DB15499,__CERDULATINIB,WO-2012045020-A1,Withdrawn,NCT04021082,"PERIPHERAL T-CELL LYMPHOMA (PTCL NOS)|NODAL LYMPHOMAS OF T FOLLICULAR HELPER (TFH)|FOLLICULAR T-CELL LYMPHOMA (FTCL)|AITL|ALCL|HSTCL|EATL I,II|MEITL, EATL TYPE II|NASAL LYMPHOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.08,445.54,133.55,8.0,3.0,4.0,47.74,121.17,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,1
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01445340,MYCOSIS FUNGOIDES|CUTANEOUS T-CELL LYMPHOMA|NEOPLASMS,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01738594,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IVA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IVB MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01742793,HODGKIN'S LYMPHOMA|MATURE T-CELL LYMPHOMA|MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01979276,MULTIPLE MYELOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00079443,RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT02061449,CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00383565,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT02281279,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT03355768,"LYMPHOMA, T-CELL, PERIPHERAL",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00268242,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00060112,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT02414724,LYMPHOMA|SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21.O=S(=O)(O)O,0,,_SELUMETINIB_SULFATE,,Suspended,NCT03213691,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III CHILDHOOD NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT CHILDHOOD CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT NEUROBLASTOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM,All,"12 Months to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Suspended,NCT03399539,RECURRENT PLASMA CELL MYELOMA|T(11;14),All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Suspended,NCT01864018,AMYLOIDOSIS|PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Withdrawn,NCT03856112,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA|T(11;14) NEGATIVE,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
O=C1/C(=C2\Nc3ccccc3C2=O)Nc2ccccc21,0,,_INDIGO,4167422,Suspended,NCT01755325,CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China|The NO.1 People's Hospital of Huaian, Huaian, Jiangsu, China|The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|First Hospital Affiliated to Suzhou University, Suzhou, Jiangsu, China|The FIrst Affiliated Hospital, College of Medicine, Nanchang University, Nanchang, Jiangxi, China|The Second Affiliated Hospital, College of Medicine, Nanchang University, Nanchang, Jiangxi, China|The Tumor Hospital of Jiangxi, Nanchang, Jiangxi, China|The NO.1 Hospital of Nanchang, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Xijing Hospital-Fourth Military Medical University, Xi'an, Shanxi, China|The FIrst Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The People's Hospital of Peking University, Peking, China|Ruijin Hospital, Shanghai, China",C09B69/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,60.3872769461385,87.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],0,,_PYRIDOSTIGMINE_BROMIDE,5298504,Suspended,NCT03312244,HIV-1-INFECTION|CD4+ T LYMPHOCYTOPENIA|IMMUNE DEFICIENCY|IMMUNO-SENESCENCE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Suspended,NCT03370185,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tempe, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|QUEST Research Institute, Royal Oak, Michigan, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Morristown, New Jersey, United States|Medical Oncology Associates PS, WA, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Terminated,NCT02391545,CD20+ FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Palo Alto, California, United States|Hackensack, New Jersey, United States|Rochester, New York, United States|Dallas, Texas, United States|Kortrijk, Belgium|Leuven, Belgium|Wilrijk, Belgium|Clermont-Ferrand, France|Marseille Cedex 05, France|Pessac, France|Rouen Cedex 1, France|Tours Cedex 01, France|Bologna, Italy|Varese, Italy|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Leeds, United Kingdom|London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Terminated,NCT02204982,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Frankston, Victoria, Australia|Bordeaux, France|Bologna, Italy|Terni, Italy|Gdynia, Poland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02576275,INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA|MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Plainville, Connecticut, United States|Plantation, Florida, United States|Thomasville, Georgia, United States|East Setauket, New York, United States|Cookeville, Tennessee, United States|Knoxville, Tennessee, United States|Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02605694,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Miami, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
COc1ccc(C2=CN3C(=O)c4cc(OC)c(OCCCOc5cc6c(cc5OC)C(=O)N5C=C(c7ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN8C(=O)C=CC8=O)C(C)C)cc7)C[C@H]5C=N6)cc4N=C[C@@H]3C2)cc1,0,,_TALIRINE,,Terminated,NCT02706899,MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Colorado Hospital, Denver, Colorado, United States|Cancer Specialisits of North Florida, Fleming Island, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Georgia Regents University Hospital, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|Bozeman Deaconess Health Group, Bozeman, Montana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Weill Cornell, Brooklyn, New York, United States|Westchester Medical Center, Hawthorne, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Case Western Reserve University (CWRU) - University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Research Center, Portland, Oregon, United States|Oregon Health & Science, Portland, Oregon, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Froedtert & Medical College of Wisconson Clinical Cancer Center, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
O=C([O-])[C@@H]1CCC(O)=N1.O=C([O-])[C@@H]1CCC(O)=N1.[Mg+2],0,,_MAGNESIUM_PIDOLATE,WO-1997038701-A1,Terminated,NCT00532883,HEMOGLOBIN SC DISEASE,All,"5 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hospital and Research Center, Oakland, California, United States|University of California Davis, Sacramento, California, United States|University of Colorado, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Saint Christopher's Hospital, Philadelphia, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Medical Center, Dallas, Texas, United States",A61K33/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl,0,,_EZATIOSTAT_HYDROCHLORIDE,,Terminated,NCT00909584,SEVERE CHRONIC NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl,0,,_EZATIOSTAT_HYDROCHLORIDE,,Terminated,NCT01459159,MYELODYSPLASTIC SYNDROME (MDS),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bay Area Cancer Research Group, Concord, California, United States|University of Colorado, Aurora, Colorado, United States|SIU School of Medicine, Simmons Cancer Institute, Springfield, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Columbia University, New York, New York, United States|The West Clinic, Memphis, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl,0,,_EZATIOSTAT_HYDROCHLORIDE,,Terminated,NCT00701870,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Central Hematology Oncology Medical Group, Alhambra, California, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|UCLA Medical Center, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Samsum Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Ormand Beach, Florida, United States|Suburban Hematology-Oncology Associates, PC, Lawrenceville, Georgia, United States|Medical & Surgical Specialists, Galesburg, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Case Medical Center-University Hospitals, Cleveland, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,0,,_BMS-833923,US-20090105211-A1,Terminated,NCT01357655,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"John Theurer Cancer Center, Hackensack, New Jersey, United States|Tennessee Oncology Pllc, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Antwerpen, Belgium|Local Institution, Brugge, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Helsinki, Finland|Local Institution, Nantes, Cedex, France|Local Institution, Bordeaux, France|Local Institution, Le Chesnay, France|Local Institution, Lille, France|Local Institution, Paris Cedex 10, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Chorzow, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Wroc#aw, Poland|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Oviedo, Spain|Local Institution, Pamplona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,52.10784615700521,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1
CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2cc(S(=O)(=O)[O-])ccc2S(=O)(=O)[O-])cc1.[Na+],0,,_ISOSULFAN_BLUE,EP-0743523-B1,Terminated,NCT00932035,BREAST CANCER,Female,"Child, Adult, Older Adult",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope Medical Center, Duarte, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|University of North Carolina, Chapel Hill, North Carolina, United States",C07D335/02,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,75.4019589724635,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C,0,,_MAFODOTIN,,Terminated,NCT02855359,"DIFFUSE, LARGE B-CELL, LYMPHOMA|FOLLICULAR LYMPHOMA, GRADE 3B|TRANSFORMED LYMPHOMA / DLBCL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Saint Bernards Cancer Center, Jonesboro, Arkansas, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States|Poudre Valley Hospital Harmony Campus, Fort Collins, Colorado, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hattiesburg Clinic (Forrest General Hospital), Hattiesburg, Mississippi, United States|Research Medical Center, Kansas City, Missouri, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Montefiore Medical Center - Bronx, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Regional Medical Oncology Center, Wilson, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Health - Baylor University Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Scott and White Memorial Hospital - Temple, Temple, Texas, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Vista Oncology INC PS, Olympia, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Ponce Medical School Foundation, Ponce, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C,0,,_MAFODOTIN,,Terminated,NCT02592876,"LYMPHOMA, B-CELL|LYMPHOMA, LARGE B-CELL, DIFFUSE|LYMPHOMA, FOLLICULAR, GRADE 3B|FOLLICULAR LYMPHOMA, GRADE 3B",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Mercy Cancer Center, San Diego, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Shands Cancer Center / University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin (Milwaukee), Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1.O=S(=O)(O)O,0,,_BLEOMYCIN_SULFATE,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT03488225,"ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|B ACUTE LYMPHOBLASTIC LEUKEMIA|B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE",All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT01005914,LEUKEMIA,All,18 Years to 60 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",C07D519/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00882206,LEUKEMIA|LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00365274,ANAPLASTIC LARGE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00736450,CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE I ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA,All,"19 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Saint Francis Medical Center, Grand Island, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00080847,CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA,All,19 Years to 59 Years   (Adult),NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southwest Oncology Group, San Antonio, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT01439347,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA, Los Angeles, California, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University Fienberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cornell, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT01670084,"B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT00900445,ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA,All,"10 Years to 19 Years   (Child, Adult)",Other|NIH,,"Childrens Oncology Group, Philadelphia, Pennsylvania, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT02538926,B ACUTE LYMPHOBLASTIC LEUKEMIA|B LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT B LYMPHOBLASTIC LYMPHOMA|RECURRENT T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA|REFRACTORY B LYMPHOBLASTIC LYMPHOMA|REFRACTORY T LYMPHOBLASTIC LYMPHOMA|T ACUTE LYMPHOBLASTIC LEUKEMIA|T LYMPHOBLASTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT02861040,RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00135499,"LYMPHOMA, LARGE-CELL, DIFFUSE",All,"60 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT01659099,DIFFUSE LARGE B CELL LYMPHOMA CD20 POSITIVE,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|RHMS Baudour, Baudour, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Hôpital Erasme, Bruxelles, Belgium|Clinique universitaire Saint LUC, Bruxelles, Belgium|CHU de Charleroi, Charleroi, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Ch Jolimont, Haine Saint Paul, Belgium|AZ GROENINGE - Oncology Centre - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liège, Belgium|CHU de Liège - Clinique Saint Joseph, Liège, Belgium|CHU de Liège -Domaine Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Saint Joseph -Hôpital de Warquignies, Mons, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|Centre Hospitalier de Wallonie Picarde - CHwapi, Tournai, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CHU d'Amiens - Hôpital Sud, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|Hôpital de Bayonne - CHU de la Côte Basque, Bayonne, France|CH de Beauvais, Beauvais, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CH de Blois, Blois, France|APHP - Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH Dr Duchenne, Boulogne sur Mer, France|CH Fleyriat, Bourg en Bresse, France|CHU de Brest - Hôpital de Morvan, Brest, France|CH Brive la Gaillarde, Brive la Gaillarde, France|CHU de Caen, Caen, France|Centre François Baclesse, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau Le Lez, France|CH de Chambéry, Chambéry, France|CHU de Châlon sur Saône, Châlon sur Saône, France|APHP - Hôpital Antoine Béclère, Clamart, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU d'Estaing, Clermont Ferrand, France|Pôle Santé Publique, Clermont Ferrand, France|CH de Compiègne, Compiègne, France|CH Sud Francilien, Corbeil Essonnes, France|APHP - Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH de Dunkerque, Dunkerque, France|Institut Daniel Hollard, Grenoble, France|CHU de Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|CH La Rochelle, La Rochelle, France|APHP - Hôpital Bicêtre, Le Kremlin Bicêtre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CH de Lens, Lens, France|CH Saint Vincent de Paul, Lille, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Dupruytren - Limoges, Limoges, France|CH Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|CH Mantes La Jolie, Mantes La Jolie, France|Hôpital de la Conception, Marseille, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CH Marc Jacquet, Melun, France|Hôpital Notre Dame Bon Secours, Metz, France|CHI de Meulan, Meulan en Yvelines, France|CHU de Montpellier - Saint Eloi, Montpellier, France|Centre Val d'Aurélie - Paul Lamarque, Montpellier, France|Centre Auréen de Cancérologie, Mougins, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Centre Catherine de Sienne, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Clinique Valdegour, Nîmes, France|CHR d'Orléans, Orléans, France|APHP - Hôpital Saint Louis, Paris Cedex 10, France|APHP - Hôpital Saint Antoine, Paris Cedex 12, France|Institut Curie, Paris, France|APHP - Hôpital de la Pitié Salpetrière, Paris, France|Hôpital Cochin, Paris, France|APHP - Hôpital Necker, Paris, France|CH Saint Jean, Perpignan, France|CHU de Haut Lévèque, Pessac, France|Hospices Civils de Lyon - CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH d'Annecy, Pringy, France|CHU Robert Debré, Reims, France|Institut du Cancer de Courlancy, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Clinique Mathilde, Rouen, France|CH Yves Le Foll - St Brieuc, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|CHI de Poissy St Germain, Saint germain en laye, France|CHU de Saint Malo, Saint Malo, France|CH de Saint Quentin, Saint Quentin, France|Institut de Cancérologie, St Priest en Jarez, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Hopital Saint Husse, Toulon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU de Tours, Tours, France|CHU de Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CHU de Brabois, Vandœuvre-lès-Nancy, France|CH Bretagne Atlantique, Vannes, France|CH de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif, France",A61K9/1075,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,0,,_VINORELBINE_TARTRATE,5994409,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,23.688371424464503,559.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],0,,_SODIUM_THIOSULFATE,,Terminated,NCT00074165,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|DRUG/AGENT TOXICITY BY TISSUE/ORGAN|LYMPHOMA|THROMBOCYTOPENIA,All,"18 Months to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O.Cl,0,,_ALVESPIMYCIN_HYDROCHLORIDE,,Terminated,NCT01126502,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00100711,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|The Mayo Clinic, Rochester, Minnesota, United States|The Ohio State University, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00076401,"LEUKEMIA|LEUKEMIA, LYMPHOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00089284,NON-HODGKIN'S LYMPHOMA (NHL),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Jesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT02168907,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT00947388,RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT02420210,DIFFUSE LARGE B-CELL LYMPHOMA,All,70 Years and older   (Older Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Withdrawn,NCT00939328,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Withdrawn,NCT00041171,ADULT SOLID TUMOR|BREAST CANCER|HEAD AND NECK CANCER|KIDNEY AND URINARY CANCER|MALE REPRODUCTIVE CANCER|THORAX AND RESPIRATORY CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT01904643,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|RECURRENT ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, School of Medicine, Stanford, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT01801046,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|CHILDHOOD ACUTE ERYTHROLEUKEMIA (M6)|CHILDHOOD ACUTE MEGAKARYOCYTIC LEUKEMIA (M7)|CHILDHOOD ACUTE MONOBLASTIC LEUKEMIA (M5A)|CHILDHOOD ACUTE MONOCYTIC LEUKEMIA (M5B)|CHILDHOOD ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|CHILDHOOD ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|CHILDHOOD ACUTE MYELOID LEUKEMIA IN REMISSION|CHILDHOOD ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA|UNTREATED CHILDHOOD ACUTE MYELOID LEUKEMIA AND OTHER MYELOID MALIGNANCIES,All,"Child, Adult, Older Adult",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Comprehensive Cancer Center, Los Angeles, California, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT01260714,ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME|ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA|ADULT ACUTE MONOBLASTIC LEUKEMIA|ADULT ACUTE MONOCYTIC LEUKEMIA|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13.1Q22); CBFB-MYH11|ADULT ACUTE MYELOID LEUKEMIA WITH MATURATION|ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22); RUNX1-RUNX1T1|ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22;Q23); MLLT3-MLL|ADULT ACUTE MYELOID LEUKEMIA WITHOUT MATURATION|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA|ADULT ERYTHROLEUKEMIA|ADULT PURE ERYTHROID LEUKEMIA|ALKYLATING AGENT-RELATED ACUTE MYELOID LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,"60 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT00609739,LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT00005987,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Withdrawn,NCT00005998,LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],0,,_PRAVASTATIN_SODIUM,5151360,Terminated,NCT01342887,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|RECURRENT ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07C215/40,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.948972258157198,597.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,0
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT03488225,"ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|B ACUTE LYMPHOBLASTIC LEUKEMIA|B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE",All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT00262925,RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush - Copley Medical Center, Aurora, Illinois, United States|Mercy Hospital and Medical Center, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Edward H Kaplan MD and Associates, Skokie, Illinois, United States|Carle Clinic-Urbana Main, Urbana, Illinois, United States|Saint Anthony Memorial Health Center, Michigan City, Indiana, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazelton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT00275106,LYMPHOMA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"Kinderklinik, Giessen, Germany|Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children, London, England, United Kingdom|Royal Manchester Children's Hospital, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT00000723,"LYMPHOMA, NON-HODGKIN|HIV INFECTIONS",All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Primary Purpose: Treatment,"Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT00005641,CHRONIC MYELOPROLIFERATIVE DISORDERS|GRAFT VERSUS HOST DISEASE|LEUKEMIA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"15 Years to 60 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Withdrawn,NCT01670084,"B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
CC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,,_DEXAMETHASONE_ACETATE,3962430,Terminated,NCT02419469,LEUKEMIA|PRECURSOR-B ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOBLASTIC LYMPHOMA|LYMPHOMA,All,"12 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,10.842111747674403,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,,_DEXAMETHASONE_ACETATE,3962430,Terminated,NCT01878708,T-CELL LYMPHOMA|RELAPSED T-CELL LYMPHOMA|REFRACTORY T-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,10.842111747674403,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Terminated,NCT00275106,LYMPHOMA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"Kinderklinik, Giessen, Germany|Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children, London, England, United Kingdom|Royal Manchester Children's Hospital, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom",A61K47/6889,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Terminated,NCT00814164,LEUKEMIA,All,"60 Years to 120 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",A61K47/6889,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Withdrawn,NCT00900445,ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA,All,"10 Years to 19 Years   (Child, Adult)",Other|NIH,,"Childrens Oncology Group, Philadelphia, Pennsylvania, United States",A61K47/6889,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00687674,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT01159301,"ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00303966,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
O=c1ncnc2[nH][nH]cc1-2,0,,_ALLOPURINOL,,Terminated,NCT00899431,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,0,,_ALLOPURINOL,,Terminated,NCT01564277,ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|DE NOVO MYELODYSPLASTIC SYNDROMES|NONCONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|STAGE I ADULT BURKITT LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,0,,_ALLOPURINOL,,Terminated,NCT00607152,HYPERURICEMIA,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Shanghai, China",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00369629,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT01445392,MESOTHELIOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Withdrawn,NCT00712062,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,0,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Terminated,NCT00062231,"CHRONIC MYELOPROLIFERATIVE DISORDERS|FEVER, SWEATS, AND HOT FLASHES|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUTROPENIA|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,"Hopital Universitaire Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Institut Bergonie, Bordeaux, France|Institut Curie Hopital, Paris, France|Charite - Campus Charite Mitte, Berlin, Germany|Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Klinikum der Albert - Ludwigs - Universitaet Freiburg, Freiburg, Germany|Ruprecht - Karls - Universitaet Heidelberg, Heidelberg, Germany|Klinikum der Stadt Mannheim, Mannheim, Germany|Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt, Rostock, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Wolfson Medical Center, Holon, Israel|Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Universita Degli Studi di Udine, Udine, Italy|National Cancer Institute - Bratislava, Bratislava, Slovakia|St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Hopital D'Yverdon, Yverdon, Switzerland|Hacettepe University - Faculty of Medicine, Ankara, Turkey|Ibn-i Sina Hospital, Ankara, Turkey|Marmara University Hospital, Istanbul, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,0,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Terminated,NCT00324324,BREAST CANCER|CHRONIC MYELOPROLIFERATIVE DISORDERS|GESTATIONAL TROPHOBLASTIC TUMOR|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUROBLASTOMA|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
CNNCc1ccc(C(=O)NC(C)C)cc1.Cl,0,,_PROCARBAZINE_HYDROCHLORIDE,4978332,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,38.6701985667056,42.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
CNNCc1ccc(C(=O)NC(C)C)cc1.Cl,0,,_PROCARBAZINE_HYDROCHLORIDE,4978332,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,38.6701985667056,42.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,0,,_OXYCODONE_HYDROCHLORIDE,4126684,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.425532351793603,207.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,0,,_METHADONE_HYDROCHLORIDE,4126684,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.425532351793603,2832.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl,0,,_DOXEPIN_HYDROCHLORIDE,4370324,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,28.2552003121213,135.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1,0,,_CEFTOBIPROLE_MEDOCARIL,,Terminated,NCT00529282,FEVER|NEUTROPENIA|GRAM-POSITIVE BACTERIAL INFECTIONS|PSEUDOMONAS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,1
CN(C)C(=N)N=C(N)N.Cl,0,,_METFORMIN_HYDROCHLORIDE,,Terminated,NCT01849276,ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q)|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl,0,,_DEXRAZOXANE_HYDROCHLORIDE,6308714,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",A61N7/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,35.64754923099029,86.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",A61K38/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00612612,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00538187,ADULT NON-HODGKIN LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00719901,REFRACTORY MULTIPLE MYELOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K49/0021,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,,_CHLORHEXIDINE_GLUCONATE,4199567,Terminated,NCT00528008,WOUND INFECTION,Female,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Women' s Health Centre, Eastern Health, St. John's, Newfoundland and Labrador, Canada",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
O=C1N=C(O)NC1(c1ccccc1)c1ccccc1,0,,_PHENYTOIN,3962430,Terminated,NCT00801931,LEUKEMIA|LYMPHOMA|NEUROBLASTOMA|IMMUNODEFICIENCIES|ANEMIA,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia Presbyterian Medical Center, New York, New York, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
O=c1ccc2cc3ccoc3cc2o1,0,,_PSORALEN,4169840,Terminated,NCT00724061,LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,22.5713053656132,1003.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
Cl.O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,,_FORODESINE_HYDROCHLORIDE,,Terminated,NCT00419081,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Medical Center, Chicago, Illinois, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|New York Medical College Division of Oncology, Valhalla, New York, United States|Liberty Hematology and Oncology, Columbia, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Terminated,NCT02465528,TUMORS WITH ABERRATIONS IN ALK|ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMOR|GLIOBLASTOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Withdrawn,NCT02729961,"ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE|CD30-POSITIVE NEOPLASTIC CELLS PRESENT|SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA",All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Withdrawn,NCT02343679,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,0,,_CYPROHEPTADINE_HYDROCHLORIDE,4913865,Terminated,NCT00949117,"LEUKEMIA|LYMPHOMA|MALNUTRITION|MYELODYSPLASTIC SYNDROMES|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC|WEIGHT CHANGES",All,2 Years to 17 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.39109632641321,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,0,,_CYPROHEPTADINE_HYDROCHLORIDE,4913865,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.39109632641321,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,0,,_LOSARTAN,,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,0,,_CATECHIN,4094969,Terminated,NCT00942422,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|PRECANCEROUS CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",A01N25/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,35.9103883036612,1741.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1.Cl,0,,_ALVOCIDIB_HYDROCHLORIDE,WO-2014083132-A1,Terminated,NCT01076556,CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",C12N5/067 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,88.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,0,,_SDX-101,4420476,Terminated,NCT00293111,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,18.661574159633602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
O=C(O)O,0,,_BICARBONATE,,Terminated,NCT01894594,SICKLE CELL ANEMIA|CHRONIC KIDNEY DISEASE|METABOLIC ACIDOSIS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University hospitals Case Medical Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)O,0,,_BICARBONATE,,Terminated,NCT01846429,TUMOR|CANCER|PAIN|MALIGNANT SOLID TUMOR|UNRESECTABLE MALIGNANT NEOPLASM|HEMATOLOGIC MALIGNANCY|MULTIPLE MYELOMA|LYMPHOMA|NEOPLASM METASTASIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,,_ERIBULIN,,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC.CS(=O)(=O)O,0,,_ERIBULIN_MESYLATE,,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00096005,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00103272,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00019708,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NON-HODGKIN LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00098488,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
CCc1c(C)c2cc3nc(cc4nc(cc5cc(C)c(cc1[nH]2)[nH]5)C(C)=C4CCC(=O)O)C(CCC(=O)O)=C3C,0,,_PHOTOFRIN,,Terminated,NCT01966809,"BRAIN TUMOR, RECURRENT",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,0,,_TETRAXETAN,4508625,Terminated,NCT01147393,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",B03C1/01,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,34.0,17.8730569416209,1632.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=N[O-].[Na+],0,,_SODIUM_NITRITE,,Terminated,NCT01033227,SICKLE CELL DISEASE,All,"8 Years to 23 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,,_LEUPROLIDE_ACETATE,4851211,Terminated,NCT00275262,"HODGKIN DISEASE|LYMPHOMA, NON-HODGKIN|MULTIPLE MYELOMA|MANTLE CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Saint Louis, Missouri, United States|New York, New York, United States|Durham, North Carolina, United States|Houston, Texas, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00387426,"ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA|ACUTE UNDIFFERENTIATED LEUKEMIA|ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOMONOCYTIC LEUKEMIA|CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|MAST CELL LEUKEMIA|MENINGEAL CHRONIC MYELOGENOUS LEUKEMIA|PRIMARY MYELOFIBROSIS|PROGRESSIVE HAIRY CELL LEUKEMIA, INITIAL TREATMENT|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA|UNTREATED HAIRY CELL LEUKEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,0,,_DAPTOMYCIN,4874843,Terminated,NCT01216241,FEBRILE NEUTROPENIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Rochester Medical Center, Rochester, New York, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,0,,_DAPTOMYCIN,4874843,Withdrawn,NCT00296049,"INFECTION|NEUTROPENIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21,0,,_VS-5584,,Terminated,NCT01991938,NON HEMATOLOGIC CANCERS|METASTATIC CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The Royal Marsden, Sutton, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,0,,_MILCICLIB,US-20090017025-A1,Terminated,NCT01301391,MALIGNANT THYMOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MedStar Georgetown University Hospital, Washington, District of Columbia, United States|NIH, Center for Cancer Research, Medical Oncology, Bethesda, Maryland, United States|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, (mi), Italy",A61K39/395,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,58.7773876260292,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,0,,_MILCICLIB,US-20090017025-A1,Terminated,NCT01011439,THYMIC CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|NIH, Center for Cancer Research, Medical Oncology, Bethesda, Maryland, United States|Hopital Larrey, Toulouse Cedex, France|Institut de cancerologie Gustave Roussy, Villejuif Cedex, France|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, (mi), Italy|Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy",A61K39/395,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,58.7773876260292,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1
O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,0,,_KW-2449,7470717,Terminated,NCT00346632,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA|MYELODYSPLASTIC SYNDROMES|CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Contact Kyowa, Princeton, New Jersey, United States|Weill Cornell/New York Presbyterian Hospital, New York, New York, United States|M.D. Anderson Cancer Center, Houston, Texas, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,53.0277829113534,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0
CC(C)[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,0,,_CILENGITIDE,WO-2003032961-A2,Terminated,NCT00089388,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B),All,"50 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21,0,,_PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,0,,_ARMODAFINIL,,Terminated,NCT01169753,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,0,,_ARMODAFINIL,,Withdrawn,NCT01044004,B-CELL LYMPHOMA|FATIGUE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,0,,_UCN-01,,Terminated,NCT00082017,"LYMPHOMA, LARGE-CELL, KI-1|LYMPHOMA, T-CELL",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0
O.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ca+2].[Na+].[Na+],0,,_EDETATE_CALCIUM_DISODIUM,,Withdrawn,NCT01101412,"CHRONIC MYELOPROLIFERATIVE DISORDERS|INFECTION|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O,0,,_TENOFOVIR_DISOPROXIL_FUMARATE,WO-2002085358-A2,Withdrawn,NCT01528865,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,38.0,32.7488,159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,0,,_RUXOLITINIB_PHOSPHATE,US-20080312259-A1,Withdrawn,NCT02528877,"ACUTE MYELOID LEUKEMIA IN REMISSION|PRIMARY MYELOFIBROSIS|PRIMARY MYELOFIBROSIS, PREFIBROTIC STAGE|SECONDARY ACUTE MYELOID LEUKEMIA|SECONDARY MYELOFIBROSIS",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"City of Hope Medical Center, Duarte, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,60.0,32.7488,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC(=O)O.CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,0,,_SOTRASTAURIN_ACETATE,,Withdrawn,NCT02285244,PROLYMPHOCYTIC LEUKEMIA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0
N=C(N)NCCC[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCCOCCOCCOCCNC(=O)COCC(N)=O)CSCC(=O)N[C@@H](CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C/c1ccc(F)cc1)C(=O)N2,0,,_FLUCICLATIDE,,Withdrawn,NCT01571726,MULTIPLE MYELOMA|SMOLDERING MULTIPLE MYELOMA|MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,0,,_PASIREOTIDE,,Withdrawn,NCT01234974,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,0,,_RGB-286638,,Withdrawn,NCT01168882,HEMATOLOGICAL MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1
COc1cc2c(cc1O)CCN[C@]21CS[C@H]2c3c(OC(C)=O)c(C)c4c(c3[C@@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,,_TRABECTEDIN,,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,0,,_ESOMEPRAZOLE,,Withdrawn,NCT00567658,LARYNX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,0,,_CURCUMIN,WO-2002069910-A2,Withdrawn,NCT00969085,CUTANEOUS T-CELL LYMPHOMA,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K8/315,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,0,,_CURCUMIN,WO-2002069910-A2,Withdrawn,NCT00247026,MYELODYSPLASTIC SYNDROME,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Organization, Jerusalem, Israel",A61K8/315,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,0,,_CURCUMIN,WO-2002069910-A2,Withdrawn,NCT01269203,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,0,,_HYDROXYCHLOROQUINE_SULFATE,5318960,Withdrawn,NCT04392128,COVID19|HEMATOLOGIC MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",A61K47/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0
O=C([O-])CCCc1ccccc1.[Na+],0,,_SODIUM_PHENYLBUTYRATE,5605930,Withdrawn,NCT00387530,GASTRIC CANCER|HEAD AND NECK CANCER|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,35.680404115074204,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
Cl.N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,,_MELPHALAN_HYDROCHLORIDE,4997651,Withdrawn,NCT03328936,HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT|RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,27.4995379781925,71.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,,_ULIPRISTAL_ACETATE,WO-1989012448-A1,Withdrawn,NCT01553123,LEIOMYOMAS,Female,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Women's Health Research, Phoenix, Arizona, United States|Visions Clinical Research, Tucson, Arizona, United States|Benchmark Research, Sacramento, California, United States|Sharp Rees-Stealy Medical Group, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Downtown Women's Health Care, Denver, Colorado, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Altus Research, Lake Worth, Florida, United States|Healthcare Clinical Data, Inc., North Miami, Florida, United States|All Women's Healthcare of West Broward, Plantation, Florida, United States|Physician Care Clinical Research, LLC, Sarasota, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|Atlanta Women's Research Institute, Inc, Atlanta, Georgia, United States|Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Fellows Research Alliance, Savannah, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|Advanced Gynecologic Surgery Institute, Naperville, Illinois, United States|Center for Women's Research, Palos Heights, Illinois, United States|South Bend Clinical, Granger, Indiana, United States|Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States|Women Under Study, LLC, New Orleans, Louisiana, United States|Hutzel Womens Health Specialists, Detroit, Michigan, United States|Women's Clinic of Lincoln, P.C., Lincoln, Nebraska, United States|Office of Annette Mayes, MD, PC, Las Vegas, Nevada, United States|Office of Edmond Pack, MD, Las Vegas, Nevada, United States|Office of R. Garn Mabey, Jr, Las Vegas, Nevada, United States|Lawrence Obstetrics-Gynecology Clinical Research, Lawrenceville, New Jersey, United States|Southwest Clinical Research, Albuquerque, New Mexico, United States|New York Center for Women's Health Research, New York City, New York, United States|Carolina Women's Research and Wellness Center, Durham, North Carolina, United States|Physicians for Women of Greensboro, Greensboro, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Hawthorne Medical Research, Winston-Salem, North Carolina, United States|Columbus Center for Women's Health Research, Columbus, Ohio, United States|Advanced Clinical Concepts, West Reading, Pennsylvania, United States|Southeast Regional Research Group, Aiken, South Carolina, United States|South Carolina Clinical Research Center, LLC, Columbia, South Carolina, United States|Discovery Clinical Trials - Genesis Health Central Women's Care, Dallas, Texas, United States|Advances in Health Inc, Houston, Texas, United States|Willowbend Health and Wellness Associates, Plano, Texas, United States|Clinical Trials of Texas Incorporated Laboratory, San Antonio, Texas, United States|Riverside Regional Medical Center, Newport News, Virginia, United States",61K31/56 ,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl,0,,_ONDANSETRON_HYDROCHLORIDE,5470868,Withdrawn,NCT00499668,MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|NAUSEA AND VOMITING|SOLID TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,23.688371424464503,175.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CN(CCCl)CCCl.Cl,0,,_MECHLORETHAMINE_HYDROCHLORIDE,4198419,Withdrawn,NCT03288818,MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",C07C323/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,73.0,15.146101562660403,341.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,0,,_DEXLANSOPRAZOLE,,Withdrawn,NCT01479231,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS|DYSPHAGIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
